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1.1 Definition of G-Protein coupled r e c e p t o r  
Membrane receptors share the property of being able to respond to an 
extracellular stimulus(i) and translate it in a large variety of intracellular signaling 
cascades that modify cell behavior. Membrane receptors can be divided in three 
principal groups: 
 
- Ion channels that allow flow of ions across the cell membrane in order to 
maintain or alter the membrane potential. 
- Enzyme-coupled receptors that act as enzyme themselves or coupled to 
intracellular enzymes. 
- G-Protein coupled receptors that couple to membrane bound 
heterotrimeric GTP binding G-proteins (G-Proteins) regulating a series of 
heterogeneous intracellular signals. 
Among membrane receptors, G-Protein coupled receptors (GPCRs) form the 
largest protein family in the mammalian genome. However, an exact size of this 
protein family has yet to be determined1. 
According to the classical definition of GPCRs, a membrane protein to be 
classified as GPCR has to show the following two characteristics2: 
 
- Seven domains in the amino acid sequences formed each by 25 to 35 
consecutive residues with high hydrophobicity. 
- The ability to couple to one or several G-Proteins 
 
The presence of the seven consecutive highly hydrophobic stretches of amino 
acid residues leads to the formation in the tertiary protein structure of a strongly 
preserved topology. Seven α-helices cross the cell membrane in an anti- 
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clockwise   manner leading   to   the   N-terminus   being   exposed   to the 
extracellular side and the C-terminus exposed to the cell intracellular 
environment. Three extracellular and three intracellular loops connect the 
transmembrane domains. The overall structure can vary in length among the 
wide group of GPCRs, with the shorter receptors being around 300 amino acids 
long and the longest ones around ~1000 amino acids in length3. 
 
Figure 1.1 Topology of GPCRs: the seven transmembrane α-helices (black) connected by three intracellular loops 
(red, plus C-terminus) and three extracellular loops (green, plus N-terminus). 
 
 
The GPCRs main function is to translate extracellular stimuli presented in form 
of a large variety of ligands into activation of intracellular signaling cascades. In 
the canonical description of these receptors the translation is achieved by 
activation of the heterotrimeric G-Proteins, but also a large variety of other 
proteins such as ß- arrestins and neurochondrin. 
The activation of the G-Proteins has not yet been shown for most of GPCRs, 
especially for the ones recently discovered or predicted by genome analysis. This 
is the reason why it has been suggested to define GPCRs as seven 
transmembrane domain receptors4, considering that the presence of the seven 




Figure 1.2 Different possible ligands that can interact with GPCRs and drive intracellular responses through 
activation of G-Proteins. 
 
 
1.2 GPCRs classification 
The ability of GPCRs to sense a wide range of extracellular inputs and drive 
different intracellular signal cascades is reflected in their heterogeneous 
sequences. Sequence similarity can however still be used as criteria to classify 
this large number of receptors in different subfamilies. Two classifications are 
currently used: 
 
 The first classification divides GPCRs in different classes (from A to F) and 
clans (identified by a roman numeration) and it was proposed and 
introduced by both Atwood and Findlay5, in separate work by Kolakowsky6 
in 1994 and refined by Bockaert and Pin7 in 1999. This classification 
system spans all GPCRs in vertebrates and invertebrates, and it is based 
on the development of sequence-based fingerprints in the seven 
hydrophobic transmembrane domains common among GPCRs. 
 A more complete view of the human repertoire of GPCRs was achieved 
in 2001 when the sequencing of the entire human genome was completed. 
This led in the following years to the development of an alternative 
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classification system8. This classification system called GRAFS         has         
been         proposed         by         Fredriksson9  and divides the GPCRs 
expressed in the human genome in five main families: glutamate, 
rhodopsin, adhesion, frizzled/taste2 and secreting. The GRAFS system 
also provided a classification for the large family of rhodopsin like GPCRs. 
 
 






The main difference between the GRAFS classification systems and the formerly 
proposed system is the further division of the Class B GPCRs into secretin-like 
and adhesion GPCRs. 
 
1.2.1 Class A (rhodopsin-like) 
Class A GPCRs are the biggest and the most studied subfamily. The receptors 
belonging to this subfamily are also identified as rhodopsin-like receptors. All 
Class A GPCRs shared highly conserved common motifs with the amino acid 
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sequence of rhodopsin, although the overall homology across the entire 
subfamily can be low10. The common amino acid motifs are located in the 
transmembrane domains and in the first and second intracellular loops. 
According to the different mechanism they used for the ligand binding process, 
Class A GPCRs can be divided in three different subgroups11: 
 
- A-α that includes rhodopsin, adrenergic and dopamine receptors. The 
ligand binding mechanism in this receptor group is manly based on a core 
structure formed by the transmembrane domains. 
- A-β, in which the ligand binding process is mostly carried out by the N- 
terminus plus extracellular loops as well as the transmembrane domains 
(ligands for this group are usually small peptides). Chemokines, opioids 
and somatostain receptors belong to this subgroup. 
- A-γ, in which the ligand binding process is mostly carried out by the N- 
terminus of the receptor that in this group is longer in comparison with the 
previous two. Glycoprotein hormones such as luteinizing hormone belong 
to this subgroup. 
- A-δ, in which the ligand binding process is mostly carried out by the N- 
terminus. Belongs to this group purinoreceptors 2 (P2RYs), glycol- protein 




Figure 1.4 Classification of human Class A (rhodopsin-like) GPCR genes according to their different ligand- 





1.2.2 Class B (secretin-like) 
Class B GPCRs do not share most of the common motifs of the Class A GPCRs 
and additionally harbor a large extracellular domain that is involved mainly in the 
ligand binding process. The receptors that belong to this family are also known 
as secretin-like receptors. They are regulated by peptides belonging to the 
glucagon hormone family, involved in regulating important endocrine and 
neuroendocrine functions. 
 
1.2.3 Class C (glutamate receptor-like) 
Class C GPCRs, or the metabotropic glutamate/pheromone-like receptors, are 
characterized by an extremely long N-terminus (about 500 to 600 amino acids) 
and share a large hydrophilic extracellular agonist-binding pocket. These 
residues form a disulphide bond (the crystal structure for this ligand binding 
domain have been solved for metabolic glutamate receptors). This GPCR 
subfamily includes mostly glutamate receptors, as well as calcium and GABA 
receptors. 
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1.2.4 Adhesion GPCRs 
Adhesion GCPRs, partially belonging to the class B GPCRs, are a set of ~30 
receptors that present a hybrid structure. The peculiarity of their protein structure 
is an extremely long extracellular domain that includes different subdomains13, 
responsible for facilitating and integrating the interaction between two different 
cells and between the cell and its surrounding matrix. The huge extracellular 
domain is connected to the seven-transmembrane domain in the cell membrane 
by a GAIN domain (GPCR-Autoproteolisis Inducing), responsible for the 
expression of the receptor at the cell membrane. Despite the main propose 
function for this receptor is probably to regulate cell position in space, it has been 
proposed an active role also for cell-cell communication14 and cell migration15, as 
well as in formation and development of cancer metastasis16. 
 
1.2.5 Other GPCRs classes 
The remaining classes are formed by genes encoding for fungi GPCRs (class 
D) pheromones receptors (Class E), frizzled/smoothened receptors (class F) 
and a group of cAMP-receptors found in Dictyostelium discoideum (class G). 
Frizzled receptors present a common long N-terminus that is supposed to interact 
actively in the ligand binding process by exposing the binding pocket in the 
extracellular domain of the receptor normally masked. These receptors have a 
predominant role in embryonic development and present similarity with the class 
B GPCRs. 
 
1.3 G-Protein classification 
1.3.1 Common G-Protein activation mechanism 
Once activated, GPCRs undergo conformational changes that trigger the 
activation of internal signaling cascades17.  These internal signaling cascades 
are mediated by the interaction of GPCRs with the G- Protein gene ensemble.  
G-Proteins can be classified according to the secondary messenger they 
activate; however, a common activation mechanism for these proteins can be 
identified. Every G-protein should is composed by three different subunits, which 
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are defined as the α, ß and γ subunit. In the inactive state the α and the ß subunits 
are anchored to the plasma membrane by short lipid tails while the ß subunit is 
placed in between the α and the γ subunits, forming a tight complex18. The G-
protein α subunit contains a binding site for the guanosine 5’ diphosphate (GDP) 
that makes the G-protein idle in the inactive state. The activation of a GPCR act 
as guanine nucleotide exchange factor: the affinity of the α subunit for the GDP 
is reduced, leading to the release of the GDP from its binding site and causing 
its replacement by guanine 5’ triphosphate (GTP) that is present in a higher 
concentration in the intracellular cell matrix. The dissociation of GDP from the α 
subunit causes the dissociation of the G-protein into two separate complexes: 
one of which is made by the α subunit and one formed by the ß and γ subunit 
tighten together. In this state, both the α and the ß-γ subunits are able to trigger 
different intracellular signaling pathways, translating the activation of the GPCR 
into a cellular response. 
G-proteins can come back to their inactive state by its intrinsic GTPase activity 
that hydrolases the terminal GTP-phosphate. This brings back the α subunit to 
its inactive state in which it is bound to GDP and promotes the binding between 
the α subunit and the ß-γ complex. 
The GTP-GDP exchange completed by the GTPase activity of the α subunit is 
not the only mechanism that revert to its inactive state the G-protein.  Concurrent 
mechanisms have been proposed that involve regulators of G- protein signaling, 
or RGS proteins19,20 (GTPase activating proteins). The RGS proteins have been 
proved to interact with the α subunit-GTP complex and promote the hydrolysis 
of the GTP in a shorter time scale in comparison with the one associated to the 




Figure 1.5 G-Protein activation cycle upon agonist binding: once the agonist binds to a GPCR, the GTP-GDP 
exchange enables morphological change and dissociation of the α and βγ subunits and the initiation of the 
signaling cascade (in the case in figure, cAMP production). GTP hydrolysis brings back the heterotrimeric G- 





The previously described mechanisms control the length of activation for a G-
proteins, depending on the action of the intrinsic GTPase activity of the α subunit 
and the RGS activity. In some specific cases the activated signaling cascade has 
an intrinsic GTPase activity, like phospholipase C-ß in its C- terminus22,23 . 
 
1.3.2 G-Protein subunits and their signaling functions 
Sixteen different genes are currently identified for coding for 28 different G-
Protein α subunits. These 28 different α subunits can be grouped into four 
families according to the second messenger they activate: 
 
- Gα-s subunits activate production of cyclic AMP (cAMP) through adenylyl 
cyclase. It has been shown that Gα-s subunits can interact with potassium 
channels, Src tyrosine kinases and tubulin GTPase24,26. In the Gα-s family 
we list the Gα-s (S), the Gα-s (L) and the Gα-s (XL), s p l i c e d  products 
of the same gene (GNAS). A forth Gα-s subunit is expressed mainly in 
olfactory and some CNS ganglia and called Gα-s-olf (GNAL). 
 
- Gα-i/o subunits inhibit the production of cAMP by adenylyl cyclase and 
can be seen as having an inverse Gα-s physiological function. They can 
also activate potassium channels, inhibit calcium channels, activate 
RAP1GAPII-dependent ERK/MAP kinase and activate Src tyrosine 
kinases. There are five different versions of Gα-i/o: 
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o Gα-o1 (GNAO1) Gα-o2 (GNAO2), specifically expressed in 
neurons and neuroendocrine cells27,28. 
 
o Gα-i1-3 (GNAI1, GNAI3), ubiquitously express although it has been 
found preferential expression in neuronal system29,30. 
o Gα-z (GNAZ), found predominantly in neuronal tissues, which 
has functional roles remained largely undefined31. 
o Gα-t1/2 (GNAT1, GNAT2) stimulate cGMP phosphodiesterases 
and have a highly specific expression in the visual system (retinal 
rode and cone outer segments) although expression has been 
reporter also in taste buds32,33. 
o Gα-gust (GNAT3) has a specific taste function and it has been 
reported express in the taste buds involved in the sweet and bitter 
taste and also in chemoreceptors in the airways34. 
- Gα-q/11 subunits have all the common function of activating 
phospholipase Cbetha (PLCbetha) isoforms. PCLbetha in the active form 
hydrolase the phospholipid phosphatidylinositol 4,5 biphosphate to 1,2 
diacyclycerol (DAG) and inositol 1,4,5 triphosphate (IP3). IP3 interact with 
specific IP3 channel that are expressed in the smooth endoplasmatic 
reticulum (SER)35. The release of calcium from IP3 channels establishes 
a positive feedback that drives the release of more calcium from other IP3 
channels. Ryanodine receptors can also be activated by this positive 
feedback system, increasing the release of calcium. The initial 
concentration of calcium in the intracellular matrix is restored by the 
activation of calcium ATPases on the plasma membrane and 
endoplasmatic reticulum and by calcium and sodium channels. Five 
different α subunits belong to the Gα-q/11 family: Gα-q (GNAQ), Gα-11 
(GNA11), Gα-14 (GNA14), Gα-15 (GNA15) and Gα-16 (GNA16). Gα-q 
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and Gα-11 are widely expressed, while the rest of the members of the 
family are specifically expressed in hematopoietic cells. Also, one striking 
difference is that Gα-11, Gα-14, Gα-15 and Gα-16 are known   to 
be promiscuous Gα subunits involved in the coupling of Gα-s and Gα-i/o 
coupled GPCRs with the IP3 pathway36-38. 
- Gα-12/13 (GNA12, GNA13) are widely expressed and are associated with 
responses linked to monomeric GTP-binding G-Proteins such as RAS. 
When RAS is bound to GTP and activated, it starts a phosphorylation 
cascade that end with the activation of mitogen- activated protein kinases 
MAPK. The activation of MAPK leads to the phosphorylation of various 
effector proteins that effect gene transcription 
and influence cell behaviors such as cell proliferation, differentiation and 
morphology39,40. 
1.4 GPCRs structure 
1.4.1 Data gathering for GPCR crystal structures 




Receptor name Receptor ID PDB ref. num. GPCR class 
Muscarinic Receptor 2
41,42
 CHRM2 4MQT, 4MQS, 3UON Rhodopsin-α 
Muscarinic Receptor 3
43,44
 CHRM3 4DAJ, 4U14,4U15, 4U16 Rhodopsin-α 
Dopamine Receptor 3
45
 DRD3 3PBL Rhodopsin-α 
Serotonin 5-HT1b Receptor
46
 HTR1B 4IAQ, 4IAR Rhodopsin-α 
Serotonin 5-HT2b Receptor
47, 48
 HTR2B 41B4, 4NC3 Rhodopsin-α 
β2 Adrenergic Receptor
21
 ADRB2 4QKX, 4LDE, 4LDL, 4LDO, 4GBR, 3SN6, 
3P0G, 3PDS, 3NY8, 3NY9, 3NYA, 3KJ6, 




 ADRB1 1DEP, 2VT4, 2Y00, 2Y02, 2Y03, 2Y04, 2Y01, 
2YCW, 2YCX, 2YCZ, 2YCY, 4AMI, 4AMJ, 





 RHO 4ZWJ, 4WW3, 4BEY, 4BEZ, 4A4M, 3AYM, 
3AYN, 2X72, 3PQR, 3PXO, 3OAX, 3C9L, 
Rhodopsin-α 
12  
  3C9M, 3CAP, 2Z73, 2ZIY, 2PED, 2J4Y, 2J28, 
2I35, 2I36, 2I37, 2G87, 2HPY, 1U19, 1GZM, 




 HRH1 3RZE Rhodopsin-α 
A2A Adenosine Receptor
52,53
 ADORA2A 4UG2, 4UHR, 3UZA, 3UZC, 3VG9, 3VGA, 





 P2Y12 4PXZ, 4PY0, 4NTJ Rhodopsin-δ 
Protease-activated Receptor
56
 PAR1 3VW7 Rhodopsin-δ 
Neurotensin Receptor 1
57
 NTSR1 3ZEV, 4BUO, 4BV0, 4BWB, 4XEE, 4XES, 
4GRV 
Adhesion 




CRHR1 3EHT, 3EHU, 2L27, 4K5Y Secretin 
Glucagon Receptor
59
 GCGR 2A83, 3CZF, 4ERS, 4L6R, 4LF3, 4L6R Secretin 
Smoothened Receptor
60
 SMOH 4N4W, 4JKV , 4N4W Glutamate 
Glutamate mGluR1 Receptor
61





 CXCR4 4RWS, 3ODU, 3OE0, 3OE6, 3OE8, 3OE9, 
2K01, 2K03, 2K04, 2K05, 1VMC, 2SDF, 1SDF 
Rhodopsin-γ 
C_C Chemokine Receptor 5
63
 CCR5 4S2S, 4MBS, 2QAD Rhodopsin-γ 
Nociceptin Receptor
64
 ORL1 5DHG, 5DHH, 4EA3 Rhodopsin-γ 
Kappa-Opioid Receptor
65
 OPRK1 4DJH Rhodopsin-γ 
Opioid Receptor, Mu 1
66
 OPRM1 4DKL, 5C1M Rhodopsin-γ 
Opioid Receptor delta 1
67
 OPRD1 4EJ4, 4N6H, 4RWA, 4RWD Rhodopsin-γ 
 
Table 1.1 List of available 3D GPCR crystal structures solved by X-Ray diffraction and laser-based imaging 
techniques with relative PDB reference numbers 
 
 
In most cases the GPCR is crystalized together with an agonist or antagonist that 
has the function to stabilize the protein crystal, making the structure acquisition 
easier. Only in two cases was it possible to acquire a diffraction pattern from a 
GPCRs bound to the related G- Protein complex21,68. 
The surprisingly low amount of crystal structures can be explained by taking in 
account that the protein crystallization process is not trivial, especially in the case 
of proteins like GPCRs. The presence of loops on the intracellular and the 
extracellular side and the elasticity suggested by morphological changes upon 
activation makes even more difficult to obtain a sufficiently resolved diffraction 
spectra that allow to identify a crystal structure69,70. 
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The use of Synchrotron Radiation sources as well as improved crystallization 
protocols might increase the limited number of solved 3D GCPR crystal 
structures71. However, taking in account the topological resemblance between 
GPCRs, it is possible to use solved crystal structures to model mechanism of 
ligand binding, signal transduction and morphology changes as well as other 
common protein mechanisms. 
 
 
1.4.2 Current GPCR model based on crystal structures 
The crystal structure of bovine rhodopsin is considered as a good model for 
describing GPCRs. Indeed, the majority of the GPCRs are identified as belonging 
to the Class A subfamily. Second, the intermediate amino acid sequence length 
of rhodopsin among the GPCRs suggests that the functionally important 
sequences are included in the rhodopsin sequence, while the poorly conserved 
sequences are most likely located at protein sites responsible for the interaction 
with the G-protein (i.e. the intracellular loops or at the N-terminus level). 
The first crystal structure of the inactive state of bovine rhodopsin was the first 
GPCRs crystal structure solved by Palczewski et al. 50 in 2000. Upon the 
absorption of a photon, the 11-cis retinal linked to the Lys296 of the rhodopsin 
sequences undergoes an isomerization in all-trans state, leading to a 
conformational change of the protein structure. Hydrolization of the all-trans 
retinal leads to retinal dissociation from rhodopsin that can be regenerated by 
new 11-cis retinal produced by retinoid isomerohydrolase (RPE65) in retinal 
epithelial cells. The conformational changes upon light activation can be 
performed by rhodopsin thanks to the flexibility of its transmembrane domains 
(between 19 and 34 amino acids long and able to be tilted and kinked). 
Different features of the rhodopsin crystal structure are found to be conserved in 
many other GPCRs, not exclusively belonging to the Class A. An Asp/Glu-Arg- 
Tyr (D/ERY) motif is found at the end of the TM3 and well conserved among 
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most Class A GPCRs. It is involved in receptor stabilization in the inactive state 
and in the activation process itself. In the TM7, a highly conserved NPXXY motif 
is present in order to give to the receptor structure stability by interaction with the 
adjacent TM6. The extracellular loops contain two cysteine residues highly 
conserved among all GPCR families. These residues are supposed to increase 
the receptor structure stability by forming a disulphide bond. 
One attribute of the rhodopsin structure is the presence of the ionic lock, a salt 
bridge between the Arg residue in the (D/ERY) motif in the TM3 and a Glu residue 
in the TMVI72. The same Arg residue forms another salt bridge with the adjacent 
Asp residue that is found to be present in all other class A GPCRs in their inactive 
state. 
The presence of the salt bridge between the Arg and the Glu in TM3 and TM6 is 
the reason why rhodopsin has no basal activity and a stable ON state: upon 
interaction with a photon, the isomerization of the 11-cis retinal and consequent 
structural changes allows the break of the salt bridge that is not present in any 
active state of rhodopsin73. 
The break of the ionic lock allows the interaction of the TM3 and TM6 with the G-
Protein in the receptor active state. Mutations in the amino acid residues involved 
in the formation of the ionic lock lead to modifications in the constitute and 
agonist-binding activity. 
In 2011, Standfuss et al.74 solved the crystal structure of a mutated-constitutively 
active form of bovine rhodopsin, together with a peptide derived from the C- 
Terminus of the α-subunit of the Gα-t1/2. This crystal structure suggests that the 
rotation of the TM6 is critical in the conformational changes involved in rhodopsin 
activation, and also how the rearrangement of hydrogen bonds between the 
retinal-binding pocket and the previously cited common GPCRs motif can be 
proposed as common mechanism of agonist-related GPCRs activation. In 2011 
the crystal structure of the complex between the ß2- adrenergic receptor (B2AR) 
and the Gα-s subunit was solved by Rasmussen et 
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al.21 This was the first crystal structure ever showing a high-resolution view of 





Figure 1.6 Rhodopsin amino acid sequence represented in a structure-based model (from top to bottom: 
intracellular loops [C-I, C-II, C-III and COOH-terminal], transmembrane domains and extracellular loops [E-I, E-  
II, E-III and NH2-terminal] sequences) 
 
The additional information brought by this crystal structure describe the 
interaction between the B2AR and the Gα-s protein as mainly focused on the C- 
terminal α helices of the Gα-s protein and the nucleotide-binding pocket. Also, in 
the active state the B2AR shown a displacement of the TM6 of ~14 Å caused by 
the interaction with the Gα-s protein. 
 
1.5 Mechanisms of GPCR activation 
1.5.1 A two states model of GPCR activity 
In a simple description, a GPCR can occupy two different energetically stable 
states: a ground state (or inactive state) and an “excited” state (or active state), 
in which receptor activation and corresponding intracellular signal transduction 
are started by the ligand-receptor interaction75. This description is missing
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important aspect of GPCRs activity such as constitutive activity76 and 
intermediate states of activation, but it gives a general idea of the different 
mechanism of interaction between a GPCR and its ligands77. 
Rhodopsin and the ß2-adrenergic receptor with their corresponding crystal 
structures can be consider as standard reference model to explain ligand- binding 
mechanism for GPCRs78,79. Also, mutagenesis studies in biogenic amine 
receptors such as the α1 and ß2 adrenergic receptors, the H2 histamine receptor 
and the muscarinic acetylcholine receptor family show peculiar binding 
sites and morphological changes in the ligand binding process. 
In rhodopsin, 11-cis retinal acts as an inverse agonist, keeping the receptor 
inactivated in the dark. The 11-cis retinal is covalently bond to Lys296 in the TM7. 
The exposures to light cause the isomerization of the 11-cis retinal in all- trans 
retinal that has an agonist function in rhodopsin activation. 
In the cases of ligand-activated GPCRs, such as the bioamine receptors (Class 
A GPCRs), the ligand-binding pocket is formed by different transmembrane 
domains, where the main interaction happens at TM3, TM5 and TM6. It has been 
shown by using mutagenesis approaches that the interaction between the 
positively charged amine and the receptor is mainly controlled by a highly 
conserved aspartic acid residue in the TM3. 
This mechanism of activation that involves the interaction between the ligand and 
the transmembrane domains of GPCRs shown in rhodopsin and bioamine 
receptors is actually not common in all Class A GPCRs80,81. 
In the case of peptide activated GPCRs (Class A), such as angiotensin and 
chemokine receptors, the mechanism of ligand binding involves also the N- 
terminus and the first and second extracellular loops. The transmembrane 
domains are also involved, in particular the TM6 and TM782. 
For receptors such as adenosine receptors (Class A) the ligand binding process 
more close resembles the rhodopsin-ß2-adrenergic model, with an important role 
of the transmembrane domains together with the second extracellular loop. 
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Among Class A GPCRs, protease-activated receptors present a unique 
mechanism of activation. They have on the N-terminus a site for cleavage by 
protease such as thrombin. Once the receptor’s N-terminus is cleaved, this act 
as agonist by interacting with its own extracellular loops, in a way comparable to 
the peptide activated GPCRs83-85. 
For the other GCPRs classes previously described, there is a prominent role of 
the N-terminus in comparison with the Class A GPCRs. In the case of Class C 
metabotropic glutamate receptors, the complete ligand-binding site is made by 
the receptor N-terminus86. As shown in the metabotropic receptor 1 (mGluR1, 
Class C GPCRs) crystal structure, the formation of a disulphide-linked dimer 
allows an open-close formation in response to ligand binding87. 
The two state model is actually a very good approximation in the case of 
rhodopsin, in which the presence of the 11-cis retinal as inverse agonist brings 
close to zero the probability of receptor activation in the dark. Retinal 
isomerization (and consequently the presence of light) is necessary condition to 
allow the conformational changes necessary to induce signal transduction by 
rhodopsin. For all other GPCRs, including genes belonging to the Class A 
rhodopsin-like, it has been recorded widely spontaneous activation in the 
absence of any agonist, and this phenomenon is defined as constitutive activity. 
 
1.5.2 Beyond the two state model 
The two state model is consistent with GPCRs activation curves obtained from 
radio ligand-binding assay and it is able to explain a variety of effects, such as 
basal activity and ligand potency of adrenergic and muscarinic receptors. Also, 
constitutive activity can be explained using this model with statistical arguments: 
without the presence of activating molecules, a GPCR population would be 
mostly found in its ground or inactive state (G1). If the difference in energy 
between the ground state and the excited (activated, E1) state is low enough, it 
will be possible to observe spontaneous transitions 
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between the G1 and E1, also without the presence of an agonist. In this way the 
constitute activity of GPCRs can be described as a product of statistical 
oscillations in the receptor population, depending on the difference in energy 
levels between the ground and active states at equilibrium. The presence of an 
agonist modifies this equilibrium, moving the GPCR statistical distribution 
towards a majority of receptor being in the E1 state instead of the G1. 
Experiments such as fluorescence quenching studies on amine receptors 
suggest the presence of different agonist induced receptors conformation rather 
than an agonist dependent action in modulating the equilibrium between a single 
inactive and active state88. The activity of GPCRs might be determined by a 
series of structural switches upon activation and different agonist might have 
different abilities to modulate the activity of these switches. 
These recent results made necessary to modify also the simple model based on 
agonist-antagonist effects when talking about GPCR-ligand interactions. The 
classical definition of agonist has to be updated: a molecule can be defined as a 
full agonist when the interaction between the molecule and the GPCRs produces 
a maximal effect (i.e. signal intensity) in a specific assay. A partial agonist is a 
molecule that produces a signal detectable, submaximal and bigger than the 
constitute activity one. GPCRs antagonist can be defined as molecules that block 
the interaction between the agonist and the GPCRs, but also as compounds that 
blocks the receptor state at the ground state G1, removing constitutive activity. 
The efficiency of this blocking action makes possible to distinguishes between 
molecules that are full antagonists and partial antagonists. 
In the case of rhodopsin, the active state E1 is attained through the formation of 
multiple intermediate states. The G1 state (or dark state) is maintained by the 
action of the 11-cis retinal. Without the 11-cis retinal rhodopsin shows a basal 
activity a million time smaller than the one registered in the fully activated E1 
state. The spectral property of the 11-cis retinal allow to monitor the multiple 
intermediate states that can be trapped at low temperature and can be detected 










The structures of the dark ground state of rhodopsin show high similarity with 
respect to the transmembrane domains, while they differ the most at the level of 
the cytoplasmic loops90 (due also to the flexibility of the loops themselves). 
For three of the inactive intermediate states of rhodopsin crystal structures are 
also available. Bathorhodopsin and lumihodopsin are basically isomorphus of the 
dark state receptor structure. Although the isomerization process that lead to the 
conformational change of retinal from 11-cis to all trans is completed by the stage 
of the lumirhodopsin, this results only in minor local changes in the structure of 
the receptor. 
It has been observed that GPCRs can couple to different G-Proteins according 
to the full or partial agonist that activates them. Different agonists can promote 
distinct conformational states that dictate the class of G-protein to couple or if a 




Figure 1.8 Rhodopsin activation mechanism through different intermediated meta-states with relative absorption 
spectra maxima and estimated life-times 
 
 
Most of the available information about GPCR structures comes from X-ray 
spectroscopy techniques. One of the limit of this approach is that it gives access 
to structural information only of GPCR states that are stable enough to be 
crystalized with sufficient purity to get a readable diffraction spectrum. This limit 
makes not accessible to X-ray spectroscopy many other less stable states that 
could have however important functional roles  
This notion that different active conformational states give GPCRs the ability to 
stimulate a diverse array of signaling pathways is defined as ligand bias or 
functional selectivity91. Actually, ligand bias and functional selectivity for GPCR 
are two slightly different concepts92: 
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- Ligand bias is a system-independent concept. It reflects how different 
ligands might thermodynamically control through energy exchange 
stabilization of distinct conformations of the ligand-bound receptor, 
exposing different receptor coupling mechanisms. This implies that 
although in vivo signaling assays might be influenced by presence and 
distribution of receptor coupling properties, in vitro assays can identify 
intrinsic bias associated with specific ligand-receptor states. 
- Functional selectivity is general concept that describes differential 
pharmacological effects of ligands on specific GPCRs including 
pharmacokinetics, target receptor conformation and activation of different 
molecular targets. Unlikely ligand bias, functional selectivity is system 
dependent and it is indeed the most appropriate term to use when 
speaking about in vivo pharmacology tested on different assays in 
different systems. 
The main consequences of GPCRs functional selectivity is that the 
pharmacological properties and classification of ligands (full or partial agonist, 
antagonist etc.) will depend upon their efficacy, target and biochemical pathways 
investigated93,94. 
The search for ligands having the properties of modulating different responses of 
a specific target receptor has pushed the development of techniques for large 
compound screening. While such techniques are currently available for 
screening G-protein mediated pathways, in the last years a significant number of 
techniques have been developed to screen for ß-arrestins activation for GPCRs. 
One of the earliest techniques to monitor ß-arrestins-GPCR interaction was 
based on the use of a fluorescent-tagged ß-arrestin and the study of its 
relocalization upon GPCR activation (transfluor approach). A more recent 
approach is based on bioluminescent energy transfer (BRET): both ß-arrestins 
and the target GPCR are tagged with a fluorescent protein and Renilla luciferase 
(the GPCR is tagged on its C-terminus). When the two proteins get close enough, 
the bioluminescence emitted from the Renilla luciferase is enough to excited the 
fluorescent tag that will then emit a detectable signal at higher wavelength. 
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A similar approach, also based on proximity between GPCRs and ß-arrestins, is 
the so-called TANGO approach95, 96. The target GPCR gets tagged at the C- 
terminus with a transcription factor (Gal4) using a protease cleavage site. 
The ß-arrestin is tethered with a Tobacco Etch Virus nuclear-inclusion-an 
endopeptidase (TEV). When the two proteins are close enough, the protease on 
the ß-arrestin cleaves the linker site on the GPCR C-terminus, with consequent 
release of the transcription factor. The screening system expresses a ß-
lactamase reporter gene, which is activated by the Gal4 transcription factor. 
The previously described techniques were used to detect ligand bias properties 
for different GPCRs. Probably the most studied GPCR for ligand bias is the 
angiotensin II type 1 receptor97 (AT1R). Ligands that stimulate ß-arrestin 
mediated pathways through AT1R are proved to have anti-apoptotic and cardio 
protective functions.  Other GPCRs for which ligand bias (in vitro) and functional 
selectivity (in vivo) has been proved are H-HT4 and H-HT7 serotonin 
receptors98,99, β1 and α2 adrenergic receptors100,101, dopamine 2 receptor102, 
histamine 2 and histamine 4 receptors103-105, EDG1 receptor106 and the glucagon-
like peptide-1 receptor107. 
 
1.6 Orphan G-Protein coupled receptors ( oGPCRs) 
In the human genome around 350 genes encode for not-olfactory GPCRs, and 
for about 200 of them a candidate agonist has been determined. For the 
remaining genes, any agonists have no yet been discovered, making them 
orphan G-Protein coupled receptors108 (oGPCRs). As for the other GPCRs, also 
the oGPCRs can be divided by sequence homology in different families, placing 
most of them in the Class A rhodopsin- like family. Considering the importance 
of GPCRs in drug development, different approaches have been used in order to 
identify possible agonists109. 
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The first approach to be used was the “reverse pharmacology”: enormous 
libraries of different exogenous compounds were screened by monitoring the 
change in level of intracellular second messengers. Later on the reverse 
pharmacology approach was enhanced in the so called “orphan receptor 
strategy”, in order to increase the rate of deorphanization of o G P C R s 110. 
The orphan receptor strategy’s aim is to reduce the amount of compounds 
included in the screening process by using only extract from tissue in which the 
oGPCR was found mostly expressed. The candidate (ant)agonist in this 
technique is isolated by further titration of the tissue extract and finally identified 
using mass spectroscopy techniques111. 
These two process focus on measuring the change in the intracellular level of 
second messenger upon interaction of the receptor with a possible agonist. 
Always looking at the intracellular environment, it is possible to detect oGPCR 
activation by monitoring the level of protein connected to the internalization of the 
receptor such as ß-arrestin2 (in a modified GFP tagged version). This approach, 
called “transfluor technology”, quantify the modification in distribution of ß-
arrestin2 from broadly in the cell cytosol to a localized distribution as a 
consequence of ligand-dependent internalization112. oGPCRs can also be 
extracellular-tagged using a pH sensitive fluorescence antibody such as 
CypHer5. Cypher5 is a cyanine pH-sensitive dye not fluorescent at pH7.4 and 
brightly fluorescent at lower pH. Due to the acidic nature of the endosomal 
recycling compartments, the use of the cyanine dye Cypher5 permits to identify 
ligand-dependent internalization by measuring an intense intracellular 
fluorescence. 
Despite the availability of different approaches, the rate of deorphanization of 
oGPCRs in the last ten years has decreased in a sensitive manner113. This might 
have different explanations. For example, oGPCRs might have a not G- Protein 
mediated signaling function not possible to detect with the current screening 
methods, or the lack of accessory proteins such as ß-arrestins in the screening 
essay might as well interfere with the expression, the ligand and signaling 
coupling properties of the oGPCRs114. 
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1.6.1 Class A oGPCRs 
oGPCRs are distributed among the different GPCRs subfamilies according to 
their sequence similarity with not-orphan GPCRs belonging to the same 
subfamily. In human, most oGPCRs belong to the Class A rhodopsin-like family. 
In April 2011 the IUPHAR (International Union of Basic and Clinical 
Pharmacology) database listed 94 genes supposed to be human Class A 
oGPCRs. 
The composition of this family is heterogeneous, and it is possible to identify 
different subfamilies among the family of human Class A oGPCRs115. 
 
- 65 genes are considered as human Class A oGPCRs, but due to their lack 
of similarity with other GPCRs subfamilies they are currently identified with 
a GPRXX (where xx is a number) nomenclature. 
- Eight genes are identified as MAS related GPCRs (MRGPRD, 
MRGPRE, MRGPRF, MRGPRG, MRGPRX1-X2-X3-X4). 
- Seven genes are identified as trace amine associated receptor (TAAR2- 
3-4-5-6-8-9). 
- Three genes are classified as leucine-rich repeat containing G-protein- 
coupled receptor (LGR4, LGR5, LGR6). 
- Two genes are identified as proto-oncogenes (MAS1, MAS1L). 
 
- Two genes are identified as opsins (OPN3, OPN5). 
 
- One gene is identified as a lysophosphatidic acid receptor 6 (LPR6). 
 
- One gene is identified as an oxoglutamate receptor (OXGR1). 
 
- One gene is identified as a purinergic receptor (P2RY8). 
 
- One gene is identified as a succinate receptor (SUCNR1). 
 
Human Class A oGPCR present a wide range of expression116,117. Most of them 
are expressed ubiquitously in human tissues, while a considerable number of 
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oGPCR genes is found expressed in the brain and in the central nervous system 
(suggesting that these receptors might have a physiological relevance in 
neurological functions). Several other oGPCR genes are expressed in organs 
involved in the immune response such as bone marrow, thymus, spleen and 
lungs. 
Another hint suggesting that human Class A oGPCRs might have relevant 
physiological roles is coming from observed phenotypes in case of knockout and 
overexpression in murine models of these receptor118. 
For class A oGPCR genes there are no or few information about possible 
candidate agonists and relative G-Protein mediated signaling pathways that they 
might activate. This lack of information has driven in the past years the rise of 
alternative-signaling hypothesis for oGPCRs. 
 
1.6.2 Class C oGPCRs 
Six oGPCRs have been group in the Class C GPCR subfamily. GPR5CA-B-C-D 
all shares a similar N-terminus structure, short and containing two conserved 
cysteine residues. These four oGPCRs can be divided into two clusters based 
on sequence analogy (limited to the transmembrane domains): one formed by 
GPRC5B and 5C that are 50% identical, and one formed by GPRC5A and 5D 
that are 52% identical. The sequence identity between these two clusters can be 
measured around 40%. Both clusters contain typical conserved motifs of Class 
C GPCRs (such as the W in the TM6 and the P in the PKXY motif in the TM7) 
that are involved in the activation machinery and G-Protein signaling. Two other 
orphans were identified as belonging to Class C GPCRs, GPR158 and GPR158L 
that don’t show any conserved domain in their respective N termini. Only recently, 
GABABRL (a new proposed member of the GABABR group) was proposed to be 
added to the list of Class C oGPCRs. GABABRL shows a sequence similarity 
with GABABR1 and GABABR2 of ~30%, but cells that express GABABRL alone 
or co-localized with GABABR1 or GABABR2 were not able to respond to GABA, 




1.6.3 Adhesion oGPCRs 
Most of adhesions GPCRs are considered as orphans, including LEC receptors 
and EGF-TM7-lathophilin related protein119,120 (ETL/ELTD1). While the 
endogenous ligand for LEC receptors is still unknown, α-latroxin (a molecule 
present in the venom of the black widow spider) can bind the extracellular 
adhesion part and the first transmembrane domain with consequent activation of 
the LEC1 receptor. 
Three cadherin EGF LAG seven-pass-G-Type-receptors (CELSR1-2-3) are 
contained in the human genome. Mutations in the last cadherin domain of mouse 
CELSR1 gave rise to the spin cycle mutant, inducing a phenotype with abnormal 
head-shaking behavior and neural tube effect. 
GPR64, GPR97, GPR111 till 116, GPR123, GPR 126, GPR128, GPR133, 
GPR144, three brain angiogenesis inhibitor (BAI) and MASS1 are all considered 
as adhesion oGPCRs. In rat, GPR116 has been shown to exist as a homodimer 
that is linked by disulphide bonds and it has been shown that can undergo 
endoproteolytic cleavage. 
The MASS1 can be expressed as three different isoforms with its longest isoform 
being composed of ~6000 amino acids. Mutations in the gene are associated 
with audiogenic seizures in mice. 
 
1.7 Physiological relevance of oGPCRs in human diseases 
Information about oGPCR role in physiology can currently only be obtained in 
case of constitutive activity and by knockout studies. Also, high expression of an 
oGPCRs in a specific tissue and/or specific environmental conditions (i.e. cancer, 
inflammation, etc.) can be interpreted as a role that oGPCR in that specific 
physiological context. 
 
1.7.1 Tumorigenesis and metastatic formation 
Orphan GPCRs are physiologically relevant in different kind of cancer, such as 
triple negative breast cancer121, skin and lung cancer. In last years, attention 
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was focused on GPR161122, which is expressed in the triple negative breast 
cancer. This cancer is known to be connected with a poor diagnosis, decreasing 
the possibility of success of the usual treatment approaches. The overexpression 
of GPR161 in this cancer increases cell proliferation and migration enhancing 
cancer metastatic activity123,124. In contrast, the    knockout 
of the GPR161 gene impairs the proliferation of human breast cancer cell lines, 
making GPR161 a good candidate target for new therapeutic approaches. 
GPR19125,126 is as well considered a possible target to treat small-cell lung 
cancers (SCLC or oat cell cancer, about 10% to 15% of all lung cancers), due to 
its overexpression in tissue sample of lung cancer patients. GPCR5a127,128 in 
breast cancer and GPR34129,130 in lymphoma are supposed play a relevant role 
in the metabolism and growth of the relevant cancer cells types. 
 
1.7.2 Neurological and psychiatric disorders 
Most of the human oGPCRs are expressed in different parts of the nervous 
system, especially in the brain. Several studies proposed that oGPCRs might 
have a physiological relevant role in neurodegenerative and psychiatric diseases, 
as well as high-order functional brain activities. Among all, GPR37 and GPR37L1 
have attracted attention in the last years131,132 because they are expressed 
exclusively in the brain (both in neurons and glia) and they are both associated 
with juvenile Parkinson’s disease. Knockout of GPR37 in murine models leads to 
an underdevelopment of the dopaminergic tone in the brain and the arising of 
perturbation of dopaminergic signals. 
GPR6133,134 , GPR52135,136 and GPR88137,138,139 are in various forms connected to 
major mental illness by altering the dopaminergic system in the striatum. The 
knockout of GPR6 leads to reduction of production of cAMP in the striatopallidal 
neurons and consequent alteration of the striatal dopaminergic system. GPR6 
knockdown mice show reduced abnormal involuntary movements. In mice 
missing GPR52 a psychosis-related behavior was recorded, while GPR52 
transgenic mice show an opposite antipsychotic behave. GPR88 is highly 
expressed in Dopamine1 (D1R)-Dopamine2 (D2R) containing medium spiny 
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neurons (MSN) in the striatum of rodents. The co-localization of GPR88 with DR1 
and DR2 dopamine receptors suggest a role of GPR88 in schizophrenia. 
 
1.7.3 Metabolic disorders 
For many oGPCRs a role in metabolic disorders has been proposed. GPR21140, 
141, GPR26142, 143, GPR27144,145, GPR50146,147  and GPR82148,149  have shown  to 
be involved in diverse ways in the reduction of body weight, food intake and 
increase in insulin sensitivity and glucose tolerance in mouse models. GPR26 
has been proposed as a strong regulator of energy homeostasis through the 
control of hypothalamic AMP activated protein kinase (AMPK); GPR27 
modulates pancreatic ß-cell function, its knockdown in these cells is responsible 
for the reduction of insulin promoter activity and glucose stimulated insulin 
secretion, a phenotype similar to the one of the GPRC5B knockout. 
On the other hand, the hyper activation of GPRC5B impairs the insulin production 
in pancreatic ß-cells, resulting in a phenotype comparable to Type 2 diabetes. 
GPRC5B is therefore considered a possible target for diabetes therapy in order 
to restore a normal insulin secretory function in patients affected by Type 2 
diabetes. 
 
1.8 Ligand-independent functions of oGPCRs 
The examples of the previous section on the physiological relevant roles of 
oGPCRs are mostly obtained by studying the effect of knockdown, knockout and 
overexpression of those receptors in murine models. For other GPCRs for which 
it is not possible to identify a physiological function by these genetic methods, 
hypothesis about their physiological roles are more difficult. 
This is why it is has been theorized that some or more oGPCRs might have a 
ligand-independent function, or might be not functional at all150,151. 
 
1.8.1 Constitutive activity of oGPCRs 
In some specific cases it is possible to identify signaling properties and 
physiological importance of oGPCRs by high levels of constitute activity. 
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Constitutive activity for GPCRs is common and is due to specific sequences in 
the receptor structure that stabilize the active form, permitting the interaction with. 
Examples of oGPCRs constitutive activity are GPR3152,153, GPR6134 and 
GPR12154. These oGPCRs all couple to Gα-s subunit, increasing the amount of 
cAMP in the intracellular matrix. These receptors are also an example of the large 
amount of information that the constitutive activity bring with it: all three oGPCRs 
are shown to mediate different neurological functions, like promoting neuronal 
survival by inhibiting apoptosis in various physiological conditions, enhance 
neurite outgrow and increasing cAMP levels during neurite elongations. These 
receptors have a function in memory and learning (GPR6 
knockout mice shown locomotion and memory problems), as well as a role in 
regulating pain and analgesia induced by morphine and cocaine. GPR3 has been 
identified as a molecular target for neuropathic pain therapy and as part of the 
pro-opioid receptor system. 
The degree of constitutive activity of GPCRs and oGPCRs depends also on the 
tissue specific levels of G-Proteins and ß-arrestin2, and on the level of proteins 
such as G-Protein coupled receptor kinase 2 involved in GPCRs internalization 
and recycling. 
Taking in account the importance of the constitutive activity for deciphering 
signaling coupling and physiological relevance of oGPCRs, a more precise 
description of the mechanism has been proposed in order to predict constitutive 
activity also for other oGPCRs. 
The study of GPR61155  has demonstrated that removing the N-terminus from 
this oGPCR reduce in a sensitive way the magnitude of the signal supposed to 
be related to constitutive activity. This lead to the hypothesis of the existence of 
an N-terminus tethered ligand that might regulate receptor activation. 
The high constitute activity for the previously mentioned oGPCRs can be 
triggered by structural properties of the receptor, stabilized in its active form, or 
by the presence in the native tissue of an endogenous ligand no yet detected 
with any of the currently available approaches. This was the case for two 
oGPCRs, the GPR40 and the GPR174156,157,158. The GPR40159  is now    known 
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as FFAR1, or free- fatty acid receptor 1, because it was discovered that its 
constitutive activity was actually triggered by the permanent occupation of its 
ligand-binding pocket by the endogenous free fatty acid 1. 
 
1.8.2 Orphan GPCRs acting as co-receptors 
The struggle to identify oGPCRs ligands might also reflect that some oGPCRs 
might have a truly ligand-independent mechanism of activation of their signal 
transduction. One possible function without the need of agonists is if they act as 
co-receptors, forming heterodimeric (or higher order) complexes with other 
oGPCRs, GPCRs or other proteins. The properties of GPCRs to heterodimerize 
and form functional complex has been shown mostly for receptors belonging to 
the Class C. 
One example of this kind of interaction is the heterodimer between GABAB1 and 
GABAB2160,161: GABAB1 is responsible for ligand binding, while GABAB2 is then 
activating the G-Protein mediated signal cascade. In this case, the GABAB2 
receptor can be seen as the oGPCRs that use the ligand binding 
process and the related conformational change of his heterodimer partner to 
enhance signal transduction through G-protein. 
A similar process has been recently observed for GPR179 in the retina162, 
which can heterodimerize with the glutamate receptor mGluR6163. The functional 
heterodimer is involved in the signal transmission from photoreceptors in the 
retina to ON bipolar cells in case of dim light conditions. 
In some cases, the presence of an oGPCRs can interfere positively or negatively 
with the function and activity of an independent ligand-activated GPCRs: this is 
the case of the dimer complex between GPR50 and the melatonin receptor 
MT164,165, where the role of GPR50 after formation of the dimers is to negatively 
interfere with the melatonin-depended signal by interaction with its long C-
terminal tail. In a similar case, the ß-alanine binding mas-related receptor MRGD 
signal gets potentiated and its internalization inhibited by interacting with its 
orphan homolog MRGE166. 
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It has been shown also that oGPCRs can form heteromeric complexes also with 
proteins other than GPCRs. GPR37 can associate with the dopamine transporter 
DAT, regulating its activity negatively. In knockout GPR37 mice dopamine uptake 
and DAT surface expression in striatal membranes are both upregulated167, 168. 
For some GPCRs it has been demonstrated the formation of complexes also with 
ion channels, such as the ß2-adrenergic receptor and the calcium activated 
potassium channel169 or the calcium channel Cav1.2170 or the complex between 
dopamine receptor D5 and the GABAa ligand-activated channel. 
In the majority of these non-oGPCRs-ion channel complexes a ligand is not 
required since they are formed constitutively, suggesting that such complex might 
be also formed between oGPCRs and ion channels. 
 
1.9 Experimental approaches to study G P C R  
The modularity and shared topology of GPCRs allowed the development of 
experimental techniques that became fundamental for studying activation and 
signaling mechanisms. These techniques share the general property of improved 
temporal and spatial control of GPCR activation and signaling. This allows to 
dissect GPCR structural properties and partition common functional motifs and 
their role in physiological relevant processes. 
One pioneering approach was the design, through targeted mutations, of GPCRs 
that respond only to synthetic ligands, called RASSL171,172,173,174. This approach 
permits to activate selectively GPCRs by removing ligand dependence on the 
endogenous agonist(s) present in the tissue in which GPCRs are expressed. 
RASSL receptors were used to demonstrate that in t h e  taste signal processing 
differently activated cell populations play a fundamental role rather than the 
activation of specific GPCRs175,176. 
This approach has been further used and developed also in neuroscience with 
the creation of a class of synthetic GPCRs called DREADDs177,178 able to be 
activated only by an inactive cloazapine derivative. Collectively, these synthetic 
receptors have been used to study neurological process at the level of the CNS 
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and in the peripheral nervous system. The previously described approaches are 
based on a deep physiological and structural knowledge of the receptor studied. 
For many GPCRs a limited amount of information is available and this limitation 
reduces the use of the previously described methods. Novel methods allow to 
combine well-studied GPCRs with other GPCRs for which less information is 
available, in order to use the first as tool to study activation and signaling 
mechanisms of the latter. 
 
1.9.1 Chimeric GPCRs as their use as functional probes 
A chimeric GPCR is a synthetic protein created with DNA engineering from two 
different GPCRs that combines characteristics belonging to both parent 
receptors. 
The chimeric approach is based on the hypothesis that GPCRs consist in first 
approximation of two substructures179: 
 
- The first is formed by the N-terminus, transmembrane domains and the 
extracellular loops (responsible for ligand binding). 
- The second is formed by the intracellular loops (responsible for coupling 
with the G-Protein and activation of different intracellular signaling 
pathways). 
Also, in this hypothesis these two substructures are topologically connected but 
functionally independent. 
A direct consequence of this hypothesis is the possibility to create by DNA 
engineering a synthetic GPCR fusing ligand binding and G-Protein binding 
domains from two different GPCRs (i.e. GPRA and GPRB). This process would 
lead to the creation of a receptor that is able of being activated by GPRA- 
agonists and transduce GPRB-signal transduction. This approach has been used 
widely, with large library of synthetic receptor created and tested. Up to 2004 
more than 100 chimeric GPCRs were cloned and verified to be expressed and/or 
functional179. 
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Chimeric GPCRs have been engineered to determine which regions in the 
protein structure are responsible for the ligand binding process. Substitution of 
the N-terminus or of the extracellular loops and transmembrane domain has been 
used to modify the affinity of GPCRs to different agonists. 
Substitution of intracellular loops and intracellular portion of transmembrane 
domains has been demonstrated to be effective in switching and tuning the 
coupling of chimeric GPCRs between the different G-Protein mediated signaling 
pathways. Initially limited to GPCRs belonging to the same family or class, the 
creation of chimeric GPCRs with parents GPCRs coming from different classes 
was first achieve by creating a ß2-adrenergic receptor-Frizzled2 chimera   used 
to study the mechanism of WNT signaling, especially important in early 
development180,181. There are at the moment no theoretical, experimental or 
bioinformatics tools precise enough to predict if a chimeric GPCRs is going to 
have folding and/or expression or signaling issues. From literature, it looks 
important to preserve the two different substructures while assembling the 
chimeric receptor. There are examples in literature182 in which mixing of 
transmembrane domains belonging to the parents GPCRs leads to not functional 
chimeric GPCRs. However, it has to be taken in account that more not functional 
chimeras might have been engineered and tested, but not published. The 
concept that the preservation of the two substructures enhances 
the probability of conservation of the receptor functionality is in accordance with 
the available structural data that show how transmembrane domains are highly 
involved in the conformational changes related to GPCR and signal activation. 
Another strength of the chimeric approach is the conservation of selectivity in the 
G-Protein binding process. It has not been shown till now an example in literature 
in which the creation of a chimeric receptor leads to the activation of a G-Protein 
mediated signaling pathway not belonging to the parent GPCRs that donate the 
intracellular sequences supposed to interact with the G-protein. In comparison 
with other approaches like targeted mutagenesis, the chimeric approach has the 
advantage to give a quantitative analysis in the change in 
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properties of the GPCRs such as possibility to bind to new ligands or to signal 





Figure 1.9 Chimeric approach for creating synthetic GPCRs with combined properties of parents GPCRs 
 
 
1.9.2 Optogenetic control of GPCRs 
Experimental approaches that lead to the control of GPCRs and their related G- 
Protein mediated signaling pathway beyond the use of endogenous or 
exogenous agonist or antagonist are fundamental for the study of the 
physiological processes that are mediated by GPCRs activation. Chimeric 
GPCRs can be powerful and useful to study those processes, but they might be 
subject to constrains when based on the use of a chemicals as trigger for the 
activation of the synthetic chimeric GPCRs. In particular, (i) chemicals are 
subjected to diffusion processes that influence experimental spatial and temporal 
resolution, (ii) may have collateral side difficult to predict and (iii) oblige to control 
for possible toxic effects. 
Light is one possible stimulus that is not influenced by the previously described 
limitations (together   with   temperature183,   magnetic   fields184-187,  ultrasonic 
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radiation188-190) and it has been largely use as trigger for controlling biological 
processes. 
The advantages of using light to modulate biological processes are (i) light allows 
to precisely control in time the experimental conditions, making possible to divide 
an experiment in two different states (ON and OFF state) and facilitating the 
interpretation of the data collected. (ii) modern optical techniques make possible 
to highly control the delivery of light, with spatial resolution that permit single cells 
activation (iii) light can be tuned to reduce at the minimum the side effects and 
damages to the biological system studied (phototoxicity). 
Optogenetics is defined as a set of techniques based on the use of light to control 
biological processes. Light has been used more and more widely to modulate 
biochemical and second messenger pathways. Not all system can be naturally 
modulated by light, and that in order to make an experiment controllable with light 
both genetic engineering and special experimental set up might be needed. 
Three different approaches can be used in order to achieve optical control of a 
biological system: 
 
- Insert a light-activated protein (i.e. Channelrhodopsin) and use its 
endogenous coupling properties to modulate the system activity. 
- By using DNA engineering, modify in a light-sensitive manner one or 
more proteins involved in the process of study. 
- Create light-sensitive chimeric GPCRs with equivalent signaling 
functions to the receptor on which control need to be achieved. 
In the case of GPCRs all approaches have been used. Improved DNA cloning 
techniques are facilitating the use of the chimeric approach with several protein 
families and larger number of receptors191. 
Light-sensitive GPCRs naturally expressed in vertebrates and recently 
discovered microbial light-sensitive GPCRs represent a large ensemble of light- 
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sensitive proteins that can be use as template for the creation of light-sensitive 
chimeric GPCRs192,193. 
 
1.9.2.1 Light-sensitive GPCRs 
The process in which the absorption of a photon from a protein activates a signal 
cascade is called phototransduction. Light-sensitive GPCRs are defined as 
opsins, and they represent the universal photoreceptor molecules of all visual 
system in the animal kingdom. The phototransduction process in the opsin is G-
Protein mediated. Upon interaction with a photon (or a few photon) opsins 
undergo morphological changes that trigger the activation of G-Protein mediated 
signaling pathways194. 
The mammalian visual system is a good example to explain the mechanisms of 
phototransduction. Opsins are expressed both in cone and in rods (two different 
sets of photosensitive cells). Upon the opsin interaction with photons, the Gα 
subunit detach from the Gß-γ subunit, and binds to its effector cyclic nucleotide 
phosphodiesterase195 (PDE). The activation by the Gα subunit of the PDE causes 
a decrease in intracellular concentration of cGMP, inducing the closing of cyclic 
nucleotide gated channels. Channel closure modifies the cell membrane 
potential, bringing the photosensitive cells to a state of hyperpolarization. 
Hyperpolarized cells released neurotransmitters to downstream cells, making the 
visual signal travelling till it reaches the ganglion cells that form the optical nerve, 
and as last step the brain. 
Opsins can be divided in 6 subfamilies196,197,198: 
 
 
- Vertebrate opsins 
 
- Gα-o coupled opsins 
 
- Gα-s coupled opsins 
 
- Gα-q coupled opsins (found in invertebrates) 
 




The vertebrate opsins subfamily comprises visual and non-visual opsin with 
different spectral sensitivity, including four groups of cone opsin and one group 
of rod opsin. The four groups of cone opsins are divided according to the 
wavelength for which they are sensitive: 
 
- The S group is sensitive to UV and violet light. 
 
- The M1 group is sensitive to blue light. 
 
- The M2 group is sensitive to green light. 
 
- The L group absorbs red or green light and it can be consider strictly 
related to the opsins in the M2 group. 
In the human genome, nine different genes code for opsins: one gene for a long 
wave sensitive opsin (OPN1LW), one gene for medium wave sensitive opsin 
(OPN1MW, with two isoforms OPN1MW2 and OPN1MW3), one gene for a short 
wave sensitive opsin (OPN1SW) and one coding for rhodopsin199. The remaining 
five genes code for opsin not involved in the human vision: OPN3 (also known 
as encephalopsin), OPN4 (melanopsin), OPN5 (neuropsin), RRH (peropsin) and 
RGR (a retinal coupled GPCR). 
Several hypotheses have been made about the physiological role played by not 
visual opsins. 
Encephalopsin (OPN3) was the first not-visual opsin discovered and it has the 
interesting feature of being expressed in cells and tissues classically believed not 
to be photosensitive. It is present in the brain (mostly in the hypothalamus) in the 
heart, lung, skeletal muscles, pancreas kidney and placenta. It is supposed to 
play a role in circadian rhythms and in not photosensitive processes such as 
asthma, and presents a peak of absorption in the blue-green region200,201. 
Melanopsin (OPN4) it is considered to be a Gα-q coupled opsin according to 
sequence analysis and experiments202-204. It presents an absorption   maximum 
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around 480 nm and is mostly expressed in the photosensitive retinal ganglion 
cells (pRGCs). It also shows the interesting feature of having a bi-stable state, 
making the process of photoinduction reversible by light. pRGCs are involved in 
the stimulation of different brain regions such as the suprachiasmatic nuclei 
(SCN), the olivary pretectal nucleus (OPN) and the ventrolateral preoptic areas 
(VLPO). 
It is supposed to be involved in the visual system, but not in the image-forming 
set of responses to light, but in processes such as the suppression of melatonin 
release, pupil constriction, circadian rhythms and related induction of 
sleep205,206,207. 
Neuropsin (OPN5) in expressed in the eye, brain, testes and spinal cord in 
human. It is listed as a Class A oGPCR, although it is known to respond to light 
in the UV range. In a three-state activation system, the ground state can be 
excited with UV wavelengths (absorption peak at 380nm) to bring the protein to 
an excited state, which is stable in the dark and can be further activated by blue 
light208. Another light excitation (with wavelengths in the range of 635-690 nm) 
can bring back neuropsin to its UV sensitive ground state. It has been 
demonstrated that UV activation of neuropsin can trigger coupling of the receptor 
with the Gα-I protein in mammalian cells, lowering the level of intracellular 
cAMP209-212. 
RRH, also known as peropsin, it is localized in the apical microvilli of the Retinal 
Pigment Epithelium (RPE), in proximity with the photoreceptor of the outer 
segment of the human visual system. RRH has the property to use as 
chromophore all-trans-retinal, and to isomerize it to the 11-cis form. This is the 
opposite process that usually occur in the phototransduction process (i.e. in 
rhodopsin), where 11-cis retinal is isomerized by light to its all trans form. This 
photochemical property suggest that RRH might be involved in the machinery of 
retinal recycling, isomerizing all-trans-retinal to 11-cis retinal that can bind to 
other opsin express in the visual system213-215. 
RGR, or Retinal G-Protein coupled receptor, is expressed mostly at the RPE, like 
RRH, but also in the Mueller cells of the neural retina. RGR has been 
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isolated and purified in the bovine RPE, showing both the properties to respond 
to UV and visible light and to bind to all-trans retinal but not to the 11-cis form. 
This, like in the case of the RRH, can suggest a role in the retinal recycling 
machinery, taking in account that the all-trans retinal get enzymatically bring back 
to their 11-cis form and supplied to other opsins216,217,218. 
 
1.9.2.2 Use of light-sensitive GPCRs in Optogenetic 
There are several examples in literature of the use of endogenous or chimeric 
light-sensitive GPCRs. 
The Korana group opened to the use of chimeric light-activated GPCR to control 
biological process, although their work does not contain any in vivo application219. 
In order to prove a common activation mechanism for GPCRs (based on the 
structural information available at the time) the Korana group engineered several 
rhodopsin-ß2-adrenergic receptor chimeras. For each of the 
intracellular loops of the ß2-adrenergic receptor different candidate sequences 
to be cloned at specific sites of the rhodopsin structure were identified. In order 
to decide where to insert the intracellular loops of the ß2-adrenergic receptor in 
the rhodopsin sequence, the Korana group identified the boundaries between the 
transmembrane domain of rhodopsin and the intracellular domains of the ß2-
adrenergic receptor. Cloning single and different combination of the ß2- 
adrenergic receptor intracellular loops in the rhodopsin sequence different 
versions of the rhodopsin-ß2 chimera were created. Comparing the light- 
stimulated signal with the one of the isopropanol activated ß2-adrenergic 
receptors it was suggested that the intracellular loops might have different roles 
in the coupling the ß2-adrenergic receptor with the G-Protein. The Korana group 
identified as minimal working chimera the one in which only the third intracellular 
loop of the ß2-adrenergic receptor is present in the rhodopsin structure, with only 
one sequence suited to create a functional chimera out of the six possible 
sequences for the third intracellular loop. The full rhodopsin-ß2- chimeric 
receptor, with all four extracellular loops belonging to the ß2- adrenergic receptor, 
showed activation half in magnitude in comparison with the 
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one obtained by stimulating the endogenous ß2-adrenergic receptor with 10 uM 
Isoproterenol. 
In addition to this, the Korana group showed that the replacement of the third 
intracellular loop in rhodopsin was already sufficient to drastically reduce the 
rhodopsin-G-protein mediated signaling pathways (Gα-t1/2), while the 
replacement of other loops kept the signaling properties of rhodopsin intact. It 
has to be noticed that the results of the Korana group works have been later 
confirmed by the crystal structure of the ß2-adrenergic receptor solved by 
Rasmussen in 201121. 
The work of the Korana group on the rhodopsin-ß2-adrenergic receptor chimera 
is extremely important for several reasons. First, they used for the first time the 
chimeric approach to prove a common activation mechanism between GPCRs 
and to verify their modularity based on the information available on rhodopsin. 
Second, they opened the way to the application of chimeric GPCRs in vivo by 
proving that they can trigger a response strong enough to be candidate for an in 
vivo use. 
Third, they showed how delicate is the choice of the sequences for loops 
replacement and the likelihood of getting a not-functional chimeric receptor. 
In 2009, the results achieved by the Korana group were used by the Deisseroth 
group to engineer a set of light-activated chimeric GPCRs220, termed optoXRs. 
By sequence homology, Deisseroth and co-workers identified the same cutting 
sites in the sequence of the ß2-adrenergic receptor and the α1-adrenergic 
receptor, getting a single candidate sequence for both the intracellular loops of 
rhodopsin and the other two amine receptors. 
In comparison with the work of Korana, the optoXRs of Deisseroth achieved a 
light stimulation of the same order of magnitude of their relative ligand-activated 
receptors, although a different (less potent) agonist was used (10uM of 
Norepinephrine instead of 10uM Isoproterenol). The further step proved by 
Deisseroth paper was that the signal obtained by light stimulation of optoXRs 
was strong enough to trigger reward-related behavior (in the case of the light- 
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activated α1-adrenergic chimeric receptor) and anxiety related behavior (in the 
case of the light-activated ß2-adrenergic chimeric receptor) in a mouse. 
One other example of control of neuronal activity through the use of chimeric 
GPCR is represented by the rhodopsin-5-HT1a chimera engineered by 
Herlitze221 group in 2010. The 5-HT1a is a metabotropic G-Protein coupled 
receptor linked to the Gα-i/o signaling pathway. 
In this case only the insertion of the C-terminus of the 5-HT1a in the rhodopsin 
structure it was sufficient to light activate the G-Protein related inward rectifying 
potassium channel and to cause a membrane hyperpolarization in the 
hippocampal neurons, comparable to the agonist induced response of the 
endogenous 5-HT1a. Also, the light-activated chimera is able to rescue 5-HT1a 
signals in neuronal slices of knockout mice, proving the possibility to use such 
tool in controlling serotonergic neuronal activity and behaviors in normal and 
disease-related murine models. 
The repertoire of opsin in vertebrate and human offers the possibility to explore 
different wavelength sensitivities, a property that get even more important in vivo 
where tissue light absorption plays an important role. 
Rhodopsin is not the only light-sensitive GPCRs that has been used as 
optogenetic tools. 
Among the non-visual opsins, OPN3 (encephalopsin) has been shown to 
regulate cell migration in human orbital fat stem cells trough activation of MAPK 
and to down regulate the anti-apoptotic pathway in 5-Fluorouracil sensitive 
hepatocellar Carcinoma, as well as play a role as regulator of cAMP signaling222. 
Melanopsin (OPN4) has been used to create a synthetic light- regulated 
transcription device in order to enhance blood-glucose homeostasis in mice, by 
regulating calcium release in the ER and PKC-related activation of TRPC calcium 
pump223. Neuropsin (OPN5) has been used in Neuro2a and HEK293 cells to 
regulate cAMP decrease, calcium release and MAPK210 activation upon 
illumination with UV light. In the design of optogenetic tools based on light-
sensitive GPCRs, the potency of the light-induced signal has to be taken in 
account in order to think of possible in vivo uses. Opsins that show a bleach 
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resistant property can be used to repeat and sustain in time a low 
magnitude signal in order to achieve a light stimulated signal strong enough to 
be able to trigger the same biological responses of the relative agonist activated 
receptor. This is the case of the box jellyfish opsin224 (JellyOP). This opsin shows 
the property of trigger a reversible, high magnitude and reproducible increase of 
cAMP in mammalian cells, with both a spike-like behave in the case of flashed 
illumination and a repeatable sustained level in case of repeated stimulation. This 
suggests that the JellyOP can be used as a promising optogenetic tool to regulate 
Gα-s activity in mammalian cells and as a template for design of chimeric 
optogenetic tool. 
 
1.9.3 Bioinformatics tool in GPCR functional characterization 
The properties of GPCRs described in the previous sections (modularity, 
structural homology, ligand and G-Protein coupling mechanisms) have been 
mostly studied with either in vitro or in vivo techniques. 
Modern technology actually allows us to use a third approach, an in silico 
approach, to explore the properties of GPCRs and ideally to predict specific 
characteristics of them such as candidate ligands or G-Protein coupling just by 
knowing the amino-acid sequence225. 
There is nowadays a large variety of bioinformatics tools specialized in different 
aspect connected with GPCRs: GPCRs predictors, ligand predictors, structural 
predictors and G-Protein coupling predictors. 
The sequencing of a larger number of vertebrate genomes is increasing the 
number of homologues of known human GPCRs found in these vertebrates. The 
identification of new homologues, as well as the identification of new possible 
candidate genes for GPCRs is usually done based on sequences homology. 
Multiple sequence alignments have been the base of GPCRs discovery and 
classification. Historically, Muscle and ClustalW2 have been the most used 
software to perform this kind of alignment, while now Muscle has been proven to 
be faster and more stable of other software alternatives226-228. 
In the last years the focus on using in silico tools for studying GPCRs has moved 
to the development of algorithm able to predict the coupling of GPCRs with one 
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or more G-Proteins. The in silico approach would give an estimate of the coupling 
based on sequence properties and supply a guide for experimental design to 
actually prove the coupling itself. 
The idea behind the development of such coupling-algorithms is based on the 
modularity of GPCRs. The hypothesis is that specific amino acid sequences and 
topological features both in the receptor and in the G-protein structurally 
determine the GPCRs-G-Protein coupling. These features facilitate the 
interaction with a particular Gα (in most of the cases) subunit. Crystal structures 
data and studies based on chimeric receptors suggest that the sequences 
responsible for G-Protein coupling are located in the cytoplasmic side of the 
receptor. In particular, the intracellular loops are supposed to play a major role in 
the G-Protein coupling process. The difficulty in understanding how this coupling 
might be influenced by amino acid sequences relay on different factors mostly 
concerning the description of the forces involved in the GPCR-G-protein coupling 
(i.e. chemical, electrical, quantum) and at which scale these forces acts 
(intracellular level, single loop, single amino acid etc.). 
All these factors imply that studying the GPCR-G-Protein coupling cannot be 
limited to the description of the interaction as a two bodies problem, but requires 
a statistical approach. GPCRs are classified in different families according to 
structural properties; the same structural properties may allow a classification of 
GPCRs according to their coupling properties that goes beyond the experimental 
evidences. Algorithms that can be trained on a sample of GPCRs for which the 
G-Protein coupling information is known represent the best available approach 
to guess coupling properties for GPCRs for which this information is still missing. 
The training sample is needed in order to create statistical fingerprints of known 
GPCR-G-Protein interaction based on structural properties. These fingerprints 
can be applied on GPCRs not included in the training sample and use to guess 
G-Protein coupling properties for these receptors. 
One other approach would be to consider the probability of a specific G-Protein 
coupling given some peculiar structural properties (i.e. specific amino acids in 
the intracellular loops) on a subset of GPCRs for which the coupling is known, 
and extend these probabilities to the whole ensemble of GPCRs (including the 
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ones with unknown coupling). 
These two different approaches are based on two different mathematical tools: 
hidden Markov Models to create GPCR fingerprints and Bayesian statistics to 
calculate conditional coupling properties. In its simplest description, a hidden 
Markov model is a stochastic model that assumes that future states of a system 
depend only on the present state that is partially observable. Bayesian statistics 
estimate the degree of belief in a proposition before and after accounting for 
evidence and compute a possible distribution of outcomes. 
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In section 1.9 I described how orphan GPCRs have physiological relevant 
functions in many different biological process. A large number of oGPCRs are 
involved in different diseases and this make them promising future targets for 
drug development. The lack of endogenous or exogenous ligands makes the 
development of drug targeting oGPCRs a complicate process. The standard 
deorphanization approaches uses in the past years have achieved some 
success in the deorphanization process, but the rate with which new ligands are 
discovered for oGPCR has significantly slowed down. 
The approach I proposed is based on the contemporary use of chimeric GPCRs 
and optogenetic. My aim is to find answer to three fundamental questions related 
to oGPCRs: 
 
- Are oGPCRs functional at all? 
 
- If yes, which signaling pathways do they preferentially activate? 
 
- It is possible to retrieve a possible ligand for the receptors still consider 
as orphan? 
For some of the oGPCRs these questions have been partially addresses and in 
some cases positively answered, but there is still a large number of oGPCRs for 
which this questions remain nowadays still without an answer. 
Till April 2011 IUPHAR listed 94 oGPCRs in the Class A subfamily: out of these 
94 receptors, 29 genes were either identified as opsins or insert in one GPCR 
group and named accordingly. For the remaining 65 receptors, the known 
information is gene sequences and expression pattern, while few data are 
available about other properties (putative ligands, signaling pathways and so on). 
The previously mentioned three questions lead to a forth one: is there an 
alternative method to decipher activation properties and signaling pathway of 
oGPCRs and use this information to guess candidate endogenous agonist or to 
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design synthetic agonist? 
My approach is based on the engineering of a complete light-activated library of 
chimeric receptor based on bovine rhodopsin with intracellular loops belonging 
to the 65 human Class A oGPCRs identified by the GPRXX nomenclature. This 
synthetic library shares the activation properties of bovine rhodopsin and would 
make possible to screen upon light activation the coupling properties of the 
selected 65 human Class A oGPCRs. A second library of light-activated chimeric 
receptors based on bovine rhodopsin and well-studied GPCRs will give the 
reference controls for light activation and G-Protein coupling of the light-activated 
oGPCRs. 
Historically, the study of the coupling properties of GPCRs was mostly focus on 
the measurement of changes in concentration of second messenger such as 
cAMP, IP3, intracellular Ca2+ upon activation of different G-Proteins. 
An ideal GPCR screening approach should be simple, nonradioactive, with a high 
signal-to-noise ratio, easy to handle (i.e. low number of reagents to add) and 
open for automation (i.e. use of 96/384/1536 well plate-formats). Screening for 
stimulation of cAMP by GPCR activation in generally straightforward229-231 while 
use cAMP screening assay to monitor inhibition of cAMP generally required a 
more complicated approach (i.e. the use of foskolin for maximize the inhibition 
signal requiring preliminary titration experiments). Radiometric cAMP assays 
have been widely used, but are being replaced by fluorescence or luminescence-
based assays. Alternative cAMP assays are based on ELISA (enzyme-linked 
immunoabsorbent assay) and FRET approaches.    Intracellular 
Ca2+   can be monitored using calcium-sensitive fluorescence dyes (such as 
Fura2AM) and automated real time CCD based fluorescence plate readers232,233. 
Screening for G-protein mediated pathways that signal trough different second 
messengers can be as well screen using promiscuous G- proteins36. 
In case of studies based on a few number of GPCRs this approach might be still 
competitive, although its lack in universality. 
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In fact, the measurement of each different second messenger implies the 
development of different reading systems and experimental setups that makes 
difficult if not impossible to compare signal potencies for different G-Proteins 
even for single GPCRs. Screening for changes in the intracellular concentration 
of second messenger is an approach more sensitive to G-Protein mediated 
pathway cross talking, and introduces a not removable source of noise in the 
data. 
The necessity of different experimental setups and analysis for each second 
messenger makes this approach extremely difficult in case of screening of large 
libraries of receptor. My approach is based on the screening of GPCRs coupling 
properties using a reporter gene system. Reporter gene systems are indeed 
more suited for multiple screening of receptors for different reasons. This 
approach is based on the production of a reporter gene response to activation of 
a specific signaling cascade (and relative second messenger). The magnitude of 
the activation can be estimated monitoring the expression levels of the selected 
reporter protein. 
The activation of different subunits of the G-Proteins enhance the production of 
second messengers in the intracellular matrix and activates gene transcription by 
various response elements such as the cAMP response element (CRE), nuclear 
factor of activated T-cells response element (NFAT-RE), serum response 
element (SRE), serum response factor response element (SRF-RE, a mutant 
form of SRE) and several others. 
Reporter genes systems have been used to screen GPCRs signaling properties 
linked to cAMP or Ca2+ signaling due to their stability and sensitivity. Despite the 
concern related to the distance between the activation event and the reporter 
protein expression, reporter gene systems have the clear advantage to share a 
common reading system for all gene activation, considering that the quantity 
measured in this set up is one unique reporter protein. 
The optogenetic stimulation of the 65 light-activated human Class A oGPCRs 
and their screen using gene report systems will allow me to prove functional 
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properties and G-Protein coupling preferences for the selected human oGPCR 
genes and allow the functional dissection of their physiological role, increasing 
the information available in the finding and design of appropriate agonists for 
these genes. 
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3.1 Engineering of human Class A oGPCR light-activated 
chimeras 
3.1.1 Algorithm for the design of chimeric GPCRs 
I adopted as basic principle for the creation of the chimeric GPCRs the domain 
swapping principle. The domain swapping principle is based on the exchange of 
sequences corresponding to the intracellular loops of to the acceptor GPCR with 
the sequences corresponding to the intracellular loops belonging to the donor 
GPCRs genes. The approach I used to create rhodopsin-based light- activated 
chimeric GPCRs was systematically designed in order to be used “off the shelf”, 
i.e. not dependent on the number of genes taken in consideration. 
I chose bovine rhodopsin as the light-activated GPCR template for the creation 
of light-activated human Class A oGPCRs and control GPCRs. I made this choice 
based on previously published work (see Section 1.9.2.2) in which bovine 
rhodopsin was successfully used to engineer light-activated chimeric GPCRs. 
This choice is further supported by the fact that the all the GPCRs for which I 
created light-activated chimeric versions belong to the same GPCRs Class A 
subfamily. Lastly, among all class A GPCRs rhodopsin presents the unique 
feature of having a negligible constitutive activity (or in this case dark activity) 
thanks to the ionic lock between its TM3 and TM6 (see section 1.4.2). One of the 
strengths of the chimeric approach is that there are no limitations on the choice 
of genes to be used as parent GPCRs. In my case the choice of rhodopsin is 
definitely the best option for all previous listed reasons. However, the same 
chimeric algorithm, as well as the cloning and the experimental procedures 
described in the following sections, could be used with a different GPCR as 
acceptor GPCR (i.e. ß2-adrenergic receptor). Of course a different acceptor 
GPCR would change the properties of the chimeric GPCRs, for example 
introducing higher levels of constitutive activity or functional selectivity. 
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I first compared the amino acid and nucleotide sequences of the donor GPCRs 
(oGPCRs and control GPCRs) with the bovine rhodopsin sequence. I assigned 
to each sequence a unique identifier and using Igor Pro the sequences were 
randomized in order and then aligned using MUSCLE algorithm226,227. 
The alignment of the donor GPCR sequences with bovine rhodopsin allowed me 
to identify regions belonging to intracellular loops of the donor receptors. I used 
the works of Korana and Deisseroth groups to select in the rhodopsin amino acid 
sequence: 
 
- The cutting sites belonging to regions at the border of the rhodopsin 
transmembrane domains. 
- The amino acid and nucleotide sequence of intracellular loops both for 
bovine rhodopsin and all donor GPCRs. 
I identified for each donor GPCRs four candidate sequences corresponding to 
the four different intracellular loops (IL1, IL2, IL3, and IL4). I verified the candidate 
sequences for each intracellular loop of each donor gene by comparison with the 
information deposited in the Uniprot database. 
The domain swapping can be achieved in at least two different ways: 
 
 
-  Design in silico of different light-activated chimeric GPCRs for ordering as 
synthetic genes. 
- Design of a common rhodopsin-based plasmid and use high-throughput 
cloning techniques to cut and paste the intracellular loops belonging to the 
donor GPCRs in the acceptor plasmid (mother plasmid). 
In this work I chose to use the second approach for several reasons: 
 
 
- The creation of a mother plasmid allows the further creation of more 
light-activated chimeric receptors. 
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- Currently available gene synthesis techniques are still expensive in 
comparison with the order of a single mother construct plus short gene 
fragments. 
One key requirement was that high-throughput cloning techniques can be 
improved and automatized in such a way to make the creation of large complete 
libraries of synthetic chimeric receptors achievable in reasonably short amount 
of time and limited resources. 
 
3.1.2 High-throughput cloning 
I designed a common mother construct for the cloning of light-activated chimeric 
GCPRs based on the domain swapping principle. This mother construct is mostly 
constituted by the nucleotides sequences belonging to the rhodopsin 
extracellular loops, transmembrane domains and the N - terminus. I inserted at 
the beginning of the mother construct sequences for membrane integration and 
an anti-VSV-G epitope for antibody staining (for the complete sequence of the 
mother construct see Appendix, Figure 6.3). The VSV-G epitope234 represents 
the amino acid sequence YTDIEMNRLGK derived from the Vesicular Stomatitis 
viral glycoprotein. The epitope is located on the extracellular side of the mother 
construct and serves for checking membrane expression through antibody 
staining. In the rhodopsin sequence, in the same positions corresponding to the 
intracellular loops, I designed four artificial loops. 
The artificial loops are designed in order be able to use the mother construct as 
template for the cloning of both the human Class A oGPCRs and the control 
GPCRs libraries. The cloning approach itself is based on the use of TypeIIs 
restriction enzymes and the Golden Gate-cloning technique191. 
TypeIIs restriction enzymes cleave directionally outside of their recognition 
sequence and they recognize sequences that are continuous non-palindromic. 
They are made of two distinct domains, one for DNA binding and the other for 
DNA cleavage235. They are thought to bind to DNA as monomers for the most 
part, but to cleave DNA cooperatively, through dimerization of the cleavage 
domains of adjacent enzyme molecules. For this reason, some TypeIIs 
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enzymes are much more active on DNA molecules that contain multiple 
recognition sites. The Golden Gate cloning technique is a high-throughput 
genetic engineering technique based on the use of Type IIs Restriction 
enzymes236. The presence of Type IIs restriction enzyme recognition sites in the 
DNA sequence that has to be cloned ("insert") in the acceptor plasmids 
implies multiple advantages in the cloning strategy: 
 
 
 No restriction sites in the cloned gene (“seamless” cloning) 
 
 Digestion and ligation happen in the same reaction step without the need 
for gel purification 
 More than one insert can be cloned inside for each cloning step 
The Golden Gate cloning approach had to be tailored to fit my needs. The 
sequence for the bovine rhodopsin-based mother construct was finalize 
considering the proposed cutting sites from Airan et al.220. Those cutting sites 
correspond to the start at the end of the transmembrane domains of bovine 
rhodopsin that enclose the intracellular loops (IL1, IL2, IL3 and IL4). The fake 
intracellular loops shared a common design with some specific difference among 
them in order to perform Golden Gate cloning: 
 
 
- Each fake intracellular loop starts and ends with two sequences that are 
also present on each corresponding control and oGPCRs intracellular loop 
(i.e. every first intracellular loops of the control/orphan receptors will start 
and end with the same sequences present at the start and the end of the 
first fake intracellular loops in the mother construct). 
- The start-end sequences are unique for each non-coding intracellular loop 
of the mother construct and this guarantee the conserved directionality in 
the insertion of the control/oGPCR intracellular loops. 
- Each artificial loop contains a unique pair of TypeIIs restriction enzymes 
sites in opposing direction.  The presence of these sites allow the
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insertion of the control/orphan intracellular loops and does not make 
possible the re-ligation of the fake insert that would be re-digested. 
- An additional and unique analytical enzyme site is present in each fake 
intracellular loop to eliminate the plasmid in which one of more artificial 












I CGTC CTCA GAGACC, GGTCTC - BsaI ACCGGT - AgeI 
II GGTG GCCA GAGACG, CGTCTC - BsmBI GCTAAGC - BlpI 
III CGGA CGCA GTCTTC, GAAGAC - BbsI GATATC - EcoRV 
IV CGC/CGT ACA GAAGAGC, GCTCTTC - SapI GCGGCCGC - NotI 
 
Tab 3.1 Restriction enzymes and relative sequences (different of each of the four fake intracellular loops) 
contained in the rhodopsin-based mother construct 
 
 
I performed the screening of the light-activate oGPCRs and control GPCRs 
libraries in HEK293 (Human Embryonic Kidney) mammalian cell lines. 
Considering the use of a mammalian based screening system, I subcloned when 
necessary control GPCRs (in their full-length and light-activated form) as well as 
the 65 light-activated human Class A oGPCRs in a modified pcDNA3.1(- 
) mammalian expression vector. There are currently no off-the-shelf available 
mammalian expression vectors that are free from endogenous restriction sites 
for TypeIIs enzymes in their sequence. The presence of these endogenous 
cutting site would make the use of TypeIIs restriction enzymes impossible leading 
to unplanned cutting of the plasmid during the cloning process. 
For this reason, I modified pcDNA3.1(-) (from Invitrogen V79020) in its 
nucleotides sequence by site-direct mutagenesis to eliminate any endogenous 
TypeIIs restriction sites. In the original pcDNA3.1(-) sequences six endogenous 
TypeIIs restriction sites are present: 
 
- BsaI (two sites) 
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- BbsI (one site) 
 
- SapI (three sites) 
 




Restriction Enzyme Original Sequence New Sequence 
BsaI gagacc Gagaca 
BbsI gaagac Gaagag 
SapI gaagagc Gaagaac 
SapI gctc  tc gctcc  G 
 




I subcloned the bovine rhodopsin-based mother construct in the modified 
pcDNA3.1 (-) using XhoI and EcoRI restriction sites. The intracellular loops 
belonging to the human Class A oGPCRs and control GPCRs were ordered in 
the form of oligonucleotides (Integrated DNA Technologies) and synthetic genes 
(Epoch Life Science). 
In the case of the intracellular loops ordered as oligonucleotides, each 
intracellular loop came in the form of a forward and reverse oligonucleotide. Prior 
to insertion in the mother construct, I resuspended both oligonucleotides (forward 
and reverse) for each intracellular loop to a final concentration of 5ug/ul. I then 
mixed 0.5ul of each complementary oligonucleotide in 99ul of annealing buffer 
(10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA in distilled water) and I heated 
the solution to 95°C for 15 min. Prior to use, I allowed the solution to slowly cool 
to room temperature. I performed the insertion of the intracellular loops in the 
mother construct using 96 well plates in order to being able to perform each 
cloning step in parallel for all light-activated human Class A oGPCR and control 
GPCRs. I tested different conditions in order to develop the optimal modified 
Golden Gate cloning protocol: 
 
- Variation in the number of intracellular loops inserted for each cloning 
step. 
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- Variation in the number of incubation cycles for each cloning step. 
 
- Variation in the duration of each single incubation cycle. 
 
- Role of the analytical digest in the intracellular loops insertion efficiency. 
 
- Role of the restriction enzymes heat inactivation in the intracellular loops 
insertion efficiency. 
 
In the final set of conditions, I prepared the following mixture with a total reaction 
volume of 20ul for each cloning step (two for a total of four loops exchanged for 
each chimeric GPCR): 
 
1. 100 ng uncut plasmid DNA (i.e. mother construct) 
 
2. 7.8 ng each intracellular loops 
 
3. The ratio between the mother construct plasmid and the intracellular loops 
was approximately 5:1 
4. 1ul T4 DNA ligase 
 
5. 2ul of Promega ligation buffer 
 
6. 5 units of the first TypeIIs restriction enzyme, depending on the 
intracellular loops chosen 
 
I then incubated the mixture in a thermocycler for a first set of heating cycles: 
 
Number of cycles First time step Temperature Second time step Temperature 
11 2 minutes 37 degrees 2 minutes 37 degrees 
 
Table 3.3 First set of thermocycles with duration and temperature of each cycles and total number of cycles 
 
 
At the end of these first set of thermocycles, I added five units of the second 
restriction enzymes (always in accordance with the chosen intracellular loops), 
and started a second set of thermocycles: 
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Number of cycles First time step Temperature Second time step Temperature 
11 2 minutes 37 degrees 1 minute 37 degrees 
 
Table 3.4 Second set of thermocycles with duration and temperature of each cycles and total number of cycles 
 
 
After the second set of thermocycles I heat inactivated the TypeIIs restriction 
enzymes by increasing the mixture temperature to 50°C for 5 min and up to 80°C 
degrees for 10 min. I let cool down the mixtures at room temperature for at least 
half an hour. In order to reduce the amount of clones containing mother construct 
still having the artificial intracellular loops, I digested the PCR products with 5 
units of an additional restriction enzyme (AgeI, BlpI, EcoRV or NotI corresponding 
to IL1, IL2, IL3, IL4). 
I retransformed the digested PCR products into E. coli XL10 gold competent 
cells. In order to keep the 96 well format and the high-throughput approach of the 
cloning technique, I added 50ul E. coli XL10 gold competent cultures to each well 
of a 96 well plate PCR plate. I tested an aliquot of the cells need for each plate 
for competency by retransforming 1ng of pcDNA3.1(-) in 1ul and counting the 
number of colonies. I only continued with cultures/plates that yielded more than 
1000 colonies for transforming the Golden Gate PCR products after storage at -
80°C. I transformed Golden Gate PCR products using the 96 well PCR E. Coli 
XL10 competent cells plates and plated them in six well dishes I previously filled 
with LB media and ampicillin. I used glass beads in order to speed up the plating 
process (~3-4 glass beads for each well of the six well plates). After transforming, 
I miniprepped 2 clones for each Golden Gate PCR products that were verified by 
Sanger sequencing (LGC Genomics). I selected only one positive clone for 
creating the libraries. The modified Golden Gate approach was generally 
extremely stable with an efficiency grated than 80%. The modified Golden Gate 
approach worked for most of the genes. In some specific cases, it was more 
difficult and in some other cases not possible to obtain positive clones using the 
general approach described before. In those cases, I applied modifications to the 
established protocol in order to increase intracellular loops insertion efficiency. 
One first modification I performed was to 
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add two intracellular loops in two different moments: first intracellular loops and 
relative TypeIIs restriction enzyme before the first set of thermocycles and the 
second intracellular loops with relative TypeIIs restriction enzymes before the 
second set of thermocycles. Also, since there are not constrain on the order of 
which intracellular loops can be inserted into the mother construct, I tested all 
possible permutation of two loops insertion. Both previous modifications allowed 
me to increase the number of positive clones obtained for the light- activated 
chimeric libraries. For some of the remaining genes that still presented difficulties 
in cloning, I engineered an alternative modified Golden Gate protocol, based on 
the principle of reducing the percentage of glycerol from the restriction enzymes 
in the total volume of the initial mixture. I set the total reaction volume to 32ul, 
consequently increasing the amount of Promega Ligase buffer to 3.2ul. I kept the 
quantity of mother construct, intracellular loops and relative ratio unmodified. This 
modified protocol allowed to test also the role of the analytical digest in the 
previously described cloning modified Golden Gate cloning protocol. I 
retransformed 1.5ul of the mixture prior digestion and I digested the remaining 
30.5ul using the appropriate analytical enzymes as already described according 
to the standard Golden Gate protocol. The result was not conclusive, but no 
major improvement was reached when the analytical digest was omitted. For a 
few amount of light-activated human Class A oGPCRs both the original and the 
modified Golden Gate protocols did not give positive clones. In this case, in order 
to preserve the completeness of the light- activated orphan library, I ordered the 
corresponding genes were prepared using gene synthesis (Epoch Life Science). 
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3.2 Functional testing of light-activated chimeric GPCRs 
3.2.1 Luciferase-based reporter plasmid for screening G-protein 
mediated signaling pathways 
For the screening of GPCRs I used a gene reporter system based on different 
luciferases. This system has the advantage to be easily identifiable and 
quantifiable using the bioluminescence properties of the enzyme luciferase when 
interacting with the appropriate substrate luciferin. Among luciferases present in 
nature, the luciferase from Photinus pyralis (Firefly luciferase) and from Renilla 
reniformis (Renilla Luciferase) have been widely used in gene reporter systems 
considering the full characterization of their enzymatic reactions237. Luciferase-
based gene reporter systems have the ability to test many signaling events by 
coupling a response element linked to the signal that has to be detected to the 
transcription of the luciferase gene. The intensity of the signal can be measured 
and quantified by bioluminescence. For GPCRs it is known that signal 
transduction mediated by the interaction with different    Gα 
subunits regulate different intracellular second messengers. Increase or 
decrease of intracellular level of these second messengers can up-or down- 
regulate gene transcription. 
More specifically, in case of GPCRs the relation between second messengers 
and gene activation is well known and can be in good approximation described 
as follow238: 
 
- Activity of GPCRs that modulate increase or decrease of intracellular 
concentrations of cAMP can be monitored by coupling luciferase 
transcription to a cAMP responsive element (CRE) 239,240 
- Activity of GPCRs that modulate increase of intracellular concentration of 
calcium trough IP3 (Ca2+) can be monitored by coupling luciferase 
transcription to the transcription factor Nuclear factor of activated T-cells 
(NFAT) 241,242 
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- Activity of GPCRs that interact with RhoGEF and RhoA can be monitored 
by coupling luciferase transcription to a modified serum response factor, 
sensitive only to RhoA activation (SRE.L)243 
- Activity of GPCRs that modulate activation of the ERK1/2 pathway can be 
monitored by coupling luciferase transcription to the serum responsive 
element (SRE)244 
The previous description is limited to the interaction between second messengers 
and transcription factors. To extend this description to the interaction between G-
protein mediated pathways and transcription factors, it has to be taken in account 
the complexity of the G-protein mediated signal transduction. This complexity is 
actually an advantage, because it permits to have different choices of 






Figure 3.1 Mechanism of coupling between G-protein mediated pathways and luciferase gene response systems 




For example, in case of Gα-q coupled GPCRs, their activity can be monitored 
using a NFAT responsive element (that will respond to raise of intracellular Ca2+ 
concentration trough IP3), or using a SRE responsive element (that will respond 
to PKC and consequent ERK1/2 activation). I decided to use three different 
Luciferase based reporter plasmids: 
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1 - A CRE reporter plasmid (Pgl4.29, Promega) sensitive to change in cAMP 








2 - A SRE reporter plasmid (Pgl4.33, Promega) sensitive to activation of 
MAPK trough β-arrestin and PKC and hypothetically related to activation of 








3 - A SRE.L reporter sensitive to RhoA activation and hypothetically related to 






Figure 3.4 Vector map of the luciferase-based SRE.L reporter plasmid 
62  
I also used the CRE reporter to measure decrease in cAMP concentration by 
stimulating cAMP production using endogenously expressed receptors and 
estimate Gα-i/o mediated signaling pathways. All previously described reporter 
plasmids are based on Firefly Luciferase as reporter protein, which expression 
changes only upon activation of one of the previously described G-protein 
mediated signaling pathways. Gene reporter systems based only on a single 
reporter protein (such as Luciferase) might be statistically noisy by not taking in 
account hidden variables such as transfection efficiency (especially when not 
working with stable cell lines) and cell number. To get an estimate of these hidden 
variables, I co-transfected together with the Firefly-based Luciferase reporter 
plasmid a second Luciferase reporter plasmid based on Renilla Luciferase. I 
subcloned the Renilla Luciferase reporter gene in pcDNA3.1(-) (between NheI 
and XbaI sites) and thus it contains the same promoter of the Firefly based 
reporter plasmids, with the difference that is constantly expressed proportionally 
to the number of positively transfected cells and it is not affected by activation of 
any G-protein mediated signaling pathways. 
 
3.2.2 Experimental procedure 
I screened all genes included in this study with one single reporter plasmid at 
time. The total duration of each experiment was 5 days. On DAY 1, I treated 96 
well plates with transparent bottom (Greiner Bio- one) with poly-l-ornithine (PLO) 
in dilution 1: 25 in PBS (final concentration 1mM). I added 70ul of the PLO dilution 
to each 96 well plate, and either incubated at 37° for three hours or stored in the 
fridge overnight. Plates coated with this procedure could be used for as long as 
four weeks keeping their coating properties. Before cell seeding, I washed the 96 
well plates with PBS in order to remove any residual PLO. When removing PLO 
(as well as for any other experimental steps concerning the change of media in 
the 96 well plates) I used a cell culture tip (volume 250ul) attached to a cell culture 
aspiration pump. I used the tip instead of a classic glass pipette for its larger 
sucking section that lower the sucking pressure at the contact between the tip 
and the 
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well plate and reduce both the amount of coating aspirated and the amount of 
cell detached during the different media changes. I seeded four 96 well plates 
with HEK 293 cell at the concentration of 50000 cells for 100ul (well). I cultured 
and seeded HEK293 cells in DMEM supplemented with 10% FBS, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin in a humidified incubator (37 degrees 
Celsius, 5% CO2). 
24 hours after seeding (DAY 2) I changed the media to antibiotics-free DMEM 
supplemented with 5% FBS. The choice of antibiotic free media was due to the 
fact that cells were transfected by lipofection and antibiotics are proved to lower 
transfection efficiency and cell viability. Transfection was performed following a 
template 96 well plate that was applied to all four 96 well plate seeded with 
HEK293 cells. In the template each well corresponds to either: 
 
- A single light-activated human Class A oGPCR 
 
- A single light-activated chimeric control GPCR 
 
- A single full-length agonist activated control GPCRs 
 
Transfection was performed on a 96 well plate using lipofection and 
polyethylenimine solution (PEI, 1mg/ml in H2O; Polysciences) as lipofection 
reagent. I tried different ratios between receptor plasmids, Firefly reporter 
plasmid and Renilla plasmid in order to achieve the best combination in terms of 
transfection and reporter efficiency. For PEI best transfection efficiency was 
reached for 100ng of DNA for 1ul of reagent. 
I also tried different ratio between the receptor plasmids, the Firefly reporter 
plasmid and the Renilla plasmid, leading to the final choice of keeping a constant 
ratio of 1:1 between the receptor plasmid and the Firefly reporter plasmid and a 
10:1 ratio between the Receptor-Firefly reporter plasmids and the Renilla 
plasmid. 
Taking in account the previously described constrains, for each well, I mixed 
75ng of receptor, 75ng of Firefly reporter plasmid and 7.5ng of Renilla plasmid 
with 25ul of Optimem-L and incubate for 5 minutes. In parallel I diluted 1ul of 
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PEI solution (1mg/ml in H2O; Polysciences) in 25 ul Optimem-I (Life Technologies 
519043) for each well. I combined the two solutions, incubated at room 
temperature for 20 min and then added to the cells using a multichannel pipette. 
After six hours, I changed the culture media to starve media (DMEM 
supplemented with 0.5% FBS and antibiotics). 
On DAY 3, I incubated the cells overnight with 10uM of 9-cis retinal (Sigma) 
dissolved in DMEM supplemented with 0.5% FBS and antibiotics. The binding of 
rhodopsin with 11-cis retinal and its isomerization in all-trans form upon 
interaction with a photon is a necessary condition for the activation of the 
rhodopsin signal cascade. It has been shown in literature that HEK 293 cells 
contains the machinery for retinal recycling, but it is not yet clear if the level of 
endogenous 11-cis retinal contained in the HEK293 cells would be sufficient for 
activate light-stimulated chimeric receptors. 9-cis retinal is functionally equivalent   
to   11-cis   retinal   and   allow   rhodopsin   activation   upon    light 
stimulation245. On DAY 4, I performed light and ligand stimulation. Out of the 
four plates prepared and transfected, I chose two plates as light plates and two 
as dark plates. Prior to start light and ligand stimulation, I changed media to CO2 
independent media supplemented with 0.5% FBS and antibiotics. I performed 
ligand-stimulation of control receptors and reporter-only transfected cells right 
before light stimulation with selected agonist and fixed concentrations. I carried 
out ligand and light stimulation in an incubator (Exoterra) modified with 450 light 
emitting diodes (300 LED IP65, SMD3528; 150 LED IP66, SMD5050, 465-470 
nm and 525-530 nm wavelength ranges). The four 96 well plates were ligand and 
light stimulated at 37 degrees Celsius for six hours with blue and green light (400  
W/cm2) or only blue light (280 
W/cm2, for the SRE reporter, in order to avoid endogenous activation of green- 
sensitive opsin expressed in HEK293 cells). I shielded the two dark plates from 
light by wrapping them in aluminum foil. When testing for reduction of intracellular 
cAMP concentration using the CRE reporter plasmid, I stimulated the cells with 
NECA (500 nM) immediately (three to five minutes) before agonist 
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and light stimulation in order to increase intracellular levels of cAMP by 




Receptor(s) Ligand Final concentration 
1AR 
2AR 
Norepinephrine (NOR) 10 M
220
 
FFR3 Propionate (PPA) 10 mM
247
 





Dopamine (DOP) 100 M249,250 
M2R 
M3R 
Muscarine (MUSC) 100 M
251
 




Table 3.5 List of agonist used for the ligand stimulation of endogenously expressed GPCRs and transiently 
transfected full-length control GPCRs 
 
 
After six hours of (ligand and light) stimulation, I developed luminescence 
signals using the Dual-Glo system from Promega. The protocol I used for the 
Dual-Glo Luciferase assay was slightly modified in comparison with the one 
proposed from the manufacturer. Prior to use the Dual-Glo Promega kit, I 
removed the CO2 independent media using the previously described 
procedure; I prepared the first reagent by mixing Firefly Luciferase buffer with 
the relative substrate. This buffer allows cell lysis and furnishes a proper 
substrate for reading Firefly luciferase values. I added 50ul of the Firefly 
substrate plus buffer to each well and I shook the plates manually plates for 10 
minutes (covered with an aluminum foil to protect from light) in order to allow a 
complete lysis of the cells. I read Firefly values in a microplate reader (Biotech 
Synergy H1) using a luminescence fiber; intensity was integrated for 1 s for 
each measurement and I used an artificial software gain of 135 for every 
measurement. 
After the Firefly measurement, I prepared the second reagent by mixing the 
Promega Stop&GLO substrate and buffer. 50ul of the mixture were added 
directly in the original 50ul of Firefly mixture. The STOP&GLO buffer has the 
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property to quench the Firefly luciferase and to act as a buffer for the Renilla 
luciferase. I shook again the plates for 10 minutes and I read Renilla values using 
a microplate reader with the same setting already described for the Firefly 
measurements. 
 
3.3 Data Analysis for the luciferase-based screening 
platform 
For the analysis of the luciferase assays, I normalized all Firefly values by the 
Renilla values for each well of the 96 well plates to take in account variations 
coming from cell number and transfection efficiency253. For each of the 96 well 
plates, I normalized the Firefly/Renilla values of each well with the average value 
of the non-agonist-stimulated control wells to consider the    intrinsic 
variation of each plate and being able to compare between different plates. 
I repeated each experiment three to five times. For each experiment, every 96 
well plate was validated by first looking at the ratio of the agonist-stimulated 
control GPCRs versus the not agonist-stimulated control GPCRs. These controls 
were included on each plate and used as validation: if agonist control receptor 
did not show the expect induction between agonist and not agonist stimulation, 
the single plate was not taken in account in the overall experimental analysis for 
the specific reporter gene. 
I used induction values calculated for light-activated control receptor as validation 
for the light-stimulation procedure. Average values were calculated for light-
activated control GPCRs on both light plates (N=2) and dark plates (N=2). If light-
activated control GPCRs did not show the expect induction between light state 
and dark state, the experiment was consider as not validated and not included in 
the overall average for the specific reporter plasmid. 
I calculated averages of Firefly/Renilla ratios for each well on the total number of 
experiments for each different G-protein coupled pathway reporter plasmid. I 
used these values to identify orphan genes for which light activation was 
considered significant by calculating induction values defined as the ratio 
between Firefly/Renilla in light condition over dark condition. 
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I considered oGPCRs genes for which induction values were bigger than 2.5- 
fold as active (for CRE, SRE and SRE.L reporter plasmids), while for the NECA- 
stimulated CRE reporter plasmid significant light dependent induction was 
considered for genes in which values were lower than 0.7-fold. 
 
3.4 Antibody staining of the light-activated chimeric oGPCRs 
For antibody staining, I used a 96 well plates format following a similar procedure 
as described already in the previous section for the Luciferase assays. On DAY 
1, I coated and seeded cells into a 96 well according to the protocol for the 
Luciferase functional assays. One DAY 2, I transfected all 65 light-activated 
Human Class A oGPCRs constructs plus rhodopsin as positive staining control 
following the procedure already described in the previous section. I considered 
not transfected cells plus primary antibody as negative staining control. 
On DAY 3, cells were washed with DPBS (LifeTechnologies Inc.) two times for 
three minutes to remove any residual media and to decrease the chances of 
detach them in the following washing steps. I prepared 4% PFA solution from 
95% PFA powder (Sigma) in PBS, and I used it to fix cells for 15 minutes at room 
temperature. PFA was used as fixation agent in order to not permeabilize the cell 
membrane; the not permeabilization of the cell membrane together with the 
location of the VSV-G epitope on the extracellular side of the mother construct 
allowed me to stain chimeric receptor that are expressed at the cell membrane. 
After fixation, I washed the cells four times for five minutes with DPBS; cells were 
later incubated 30 minutes in blocking buffer (1% BSA in DPBS, 50 ul/well) prior 
the incubation with primary antibodies (clone P5D4, Sigma, 1 hours at RT, 1:250 
final dilutions in blocking buffer). I washed again the cells 3 times for 5 minutes’ 
prior incubation with 30ul/well of anti-polyvalent biotinylated antibody for 10 
minutes at RT. 
After another washing step (2 times for 3 minutes with DPBS) I incubated cells 
with horse-radish peroxidase secondary antibody for 10 minutes at RT. I 
prepared a DAB mixture by adding 30 ul of DAB (Sigma, D6065) in 1 ml of DAB 
substrate (Sigma, D6190). After washing with DPBS (2 times for 3 minutes), I 
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added 40ul/well of DAB mixture and let incubate for 3 minutes at RT. I stopped 
the reaction adding 70ul/well of distilled water and I measured absorbance values 
at 450nm using a Synergy H1 plate reader for each well. 
 
3.5 Bioinformatics tools for GPCRs-G-protein coupling 
prediction 
At the moment in which this thesis is written, these are the algorithm published 
that claim to be able to decipher G-protein coupling for GPCRs: 
 
- Cao, 2002: A Naïve Bayes model254 
 
- Sreekumar, 2004: hidden Markov model 255 
 
- Yabuki, 2005: hidden Markov model plus support vector machine 256 
 




- Sgourakis, 2005: refined hidden Markov model258 
 
- Ono, 2006: hidden Markov model259 
 
- Guo,2006: Autocross-Covariance Transform 260 
 
Some of these algorithms are available online, for the ones not published on 
public servers the authors were contacted in order to retrieve the original source 
code. The algorithms retrieved and used for this current work are: 













These algorithms are based on Hidden Markov Models. In order to have an 
estimate of how good these algorithms perform on data set of well-known GPCRs 
there are two main parameters to take in account: the sensitivity of the algorithm 
and the specificity. Sensitivity is defined as the number of positive results 
confirmed as positive from experimental data, specificity is the number of 
negative results confirmed as negative by experimental data. In the case of 
GPCRs coupling, sensitivity is the ability to predict a G-protein coupled pathway 
for a GPCR that has been confirmed by experimental approaches, specificity take 
in account the number of predicted G-protein coupled pathways that are not 
verified in experimental data. 
For the chosen algorithms: 
 
 
- The Griffin algorithm is trained on a set of 682 GPCRs (of which 394 are 
olfactory receptors) and has a claimed sensitivity and specificity of on 
average more than 85 % on the training set 
- The Predcouple algorithm is trained on 282 GPCRs and a “correct 
classification rate” of 91 %, predicting 6 out of 24 experimental verified 
promiscuous GPCRs coupling 
- The Predcouple2 algorithm is trained on 226 GPCRs with a claimed 
sensitivity of 100% and specificity of 92 % on the training dataset. 
For all these algorithms, two different data set were prepared: 
- One dataset containing well-studied GPCRs (overlapping with the training 
dataset of each algorithms) and the original sequences of the 65 chosen 
oGPCRs 
- One dataset containing the sequences of the 65 light-activated Human 
Class A oGPCRs 
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I collected data for each of the dataset. For each control and oGPCR for which 
the algorithms were run I considered each pathway with a probability of coupling 
higher than 50 % as predicted coupling. 
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4.1 Human Class A oGPCR gene s e l e c t i o n  
94 genes in the human genome are currently listed and classified as human 
Class A oGPCRs. For all class 94 human Class A oGPCRs I retrieved both amino 
acid sequences and nucleotide sequences from the Uniprot database 
(http://www.uniprot.org). For GPR79 it was not possible to retrieve a deposited 
nucleotide sequence and it was excluded from the study. For a limited amount of 
genes, the nucleotide sequences were adapted to match the deposited protein 
sequence. I did not include 29 human oGPCR genes in this study either because 
they are currently considered as opsins (OPN3, OPN5) or because classified in 
one of the GPCRs subfamilies. 
In this study I selected 65 genes for engineering of bovine rhodopsin-based 
chimeric receptors. These genes correspond to the human Class A oGPCRs 
genes currently identified by the GPRXX nomenclature according to the IUPHAR 
(I first checked the list in April 2011 and verified it again in April 2015 to keep 
track of any changes). 
Using the algorithm described in the section 3.1, I designed and cloned for all 
selected 65 human Class A oGPCRs their respective light-activated chimeras 
based on bovine rhodopsin. 
For one gene, GPR101, I was not able to retrieve a meaningful chimeric 
sequence and therefore this gene was excluded from the functional screening. 
 
 
Identifier Gene name SwissProt/Uniprot ID 
MO3 GPR1 P46091 
MO4 GPR3 P46089 
MO5 GPR4 P46093 
MO6 GPR6 P46095 
MO7 GPR12 P47775 
MO8 GPR15 P49685 
MO9 GPR17 Q13304 
MO10 GPR18 Q14330 
MO11 GPR19 Q15760 
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MO12 GPR20 Q99678 
MO13 GPR21 Q99679 
MO14 GPR22 Q99680 
MO15 GPR25 O00155 
MO16 GPR26 Q8NDV2 
MO17 GPR27 Q9NS67 
MO18 GPR31 O00270 
MO19 GPR32 O75388 
MO20 GPR33 Q49SQ1 
MO21 GPR34 Q9UPC5 
MO22 GPR35 Q9HC97 
MO23 GPR37 O15354 
MO24 GPR37L1 O60883 
MO25 GPR39 O43194 
MO26 GPR42 O15529 
MO27 GPR45 Q9Y5Y3 
MO28 GPR50 Q13585 
MO29 GPR52 Q9Y2T5 
MO30 GPR55 Q9Y2T6 
MO31 GPR61 Q9BZJ8 
MO32 GPR62 Q9BZJ7 
MO33 GPR63 Q9BZJ6 
MO34 GPR65 Q8IYL9 
MO35 GPR68 Q15743 
MO36 GPR75 O95800 
MO37 GPR78 Q96P69 
MO39 GPR82 Q96P67 
MO40 GPR83 Q9NYM4 
MO41 GPR84 Q9NQS5 
MO42 GPR85 P60893 
MO43 GPR87 Q9BY21 
MO44 GPR88 Q9GZN0 
MO45 GPR101 Q96P66 
MO46 GPR119 Q8TDV5 
MO47 GPR120 Q5NUL3 
MO4 GPR132 Q9UNW8 
MO49 GPR135 Q8IZ08 
MO50 GPR139 Q6DWJ6 
MO51 GPR141 Q7Z602 
MO52 GPR142 Q7Z601 
MO53 GPR146 Q96CH1 
MO54 GPR148 Q8TDV2 
MO55 GPR149 Q86SP6 
MO56 GPR150 Q8NGU9 
MO57 GPR151 Q8TDV0 
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MO58 GPR152 Q8TDT2 
MO59 GPR153 Q6NV75 
MO60 GPR160 Q9UJ42 
MO61 GPR161 Q8N6U8 
MO62 GPR162 Q16538 
MO63 GPR171 O14626 
MO64 GPR173 Q9NS66 
MO65 GPR174 Q9BXC1 
MO66 GPR176 Q14439 
MO67 GPR182 O15218 
MO68 GPR183 P32249 
 
Table 4.1 List of oGPCRs selected for the luciferase-based functional screening with relative identifiers and 
SwissProt/Uniprot reference numbers 
 
 
4.2 Control GPCR gene selection 
There are currently several GPCRs for which both several agonists and G-
Protein mediated activated signaling pathways are known. I chose a subset of 
control GPCRs taking in account coupling properties and available information in 
literature on their use in a chimeric form. I chose nine different well studied 
GPCRs as candidate genes for the creation of light-activated control chimeric 
GPCRs. 
These genes were also used in their agonist-activated form to estimate the 
efficiency of their respective light-activated chimeras and to prove the 
preservation of coupling properties between agonist and light-activated control 
GPCRs. 
The genes I selected as full-length control GPCRs (defining as full-length 
receptors being able to be chemically stimulated by their proper agonists) belong 
almost entirely to the human genome, with the only exception of the α1 
adrenergic receptor (α1AR) whose original species is rat. 
 
 
Receptor Species Predom. G coupling Expr. Vector Source 
2-adrenergic receptor 
(2AR) 
Human Gα-s pcDNA3 Robert Lefkowitz 






Rat Gα-q pCMV5 Robert Lefkowitz 




Free fatty acid 
receptor 3 
(FFR3) 
Human Gα-i/o pcDNA3 Graeme Milligan 




Human Gα-s endogenous Atwood 2011 
Dopamine receptor D1 
(D1R) 
Human Gα-s pcDNA3.1(-) MGC (MHS6278- 
202856822) 
Dopamine receptor D2 
(D2R) 






Human Gα-q and Gα-s pcDNA3.1(-) Klaus Groschner 











Human Gα-q endogenous Atwood 2011 
 
Table 4.2 List of control GPCRs used in agonist and light-activated chimeric forms form with their specie of 
provenience, expression vector and origin information 
 
 
Only two full-length control GPCRs are endogenously expressed in HEK293 cells 
according to Atwood et al.248, while all other full-length control GPCRs were 
transiently transfected using the mammalian expression pcDNA3.1(-), or 
equivalent mammalian expression vectors having a CMV promoter, in order to 
guarantee comparable expression efficiency (Table 4.2). 
 
4.3 Validation of the luciferase-based reporter   plasmids 
I chose HEK293 cells to build the oGPCRs screening platform for the luciferase-
based assays. According to Atwood et al., HEK293 cells should theoretically 
express sufficient levels of G-Protein related proteins to activate G-Protein 
mediated intracellular cascades. 
For each luciferase-based reporter plasmid I performed three different sets of 
experiments to validate the screening assay: 
 
- I first agonist-stimulated HEK293 cells transfected with only the different 
luciferase-based reporter plasmids chosen for the screening of the G- 
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Protein mediated pathway and the Renilla plasmid. The set of agonists 
used was the same chosen for the stimulation of the ligand-activated 
control GPCRs. With this experiment I wanted to estimate efficiency of the 
reporter plasmids and the contribution of HEK293 cells endogenous 
GPCRs to background signals. 
- Then, I stimulated HEK293 cells transiently transfected with the ligand- 
activated control GPCRs plus the Luciferase based reporter plasmid and 
the Renilla plasmid to estimate sensitivity and specificity of each reporter 
in recording increase in the Firefly/Renilla ratio due to agonist stimulation. 
- Last, I light-stimulated the light-activated version of the control GPCRs to 
estimate the efficiency of the light stimulation experimental apparatus and 
the specificity and sensitivity of each reporter plasmid in recording light 
induced increase in the Firefly/Renilla ratios. 
4.3.1 CRE reporter plasmid 
I performed the validation of the CRE luciferase-based reporter plasmid 
performing the three different sets of experiments described in the previous 
section. The luciferase-based CRE reporter plasmid is supposed to be sensitive 
to rising in intracellular level of cAMP upon receptor activation. When not stated 
differently, HEK293 cells have always been transfected with the Renilla luciferase 
plasmid for all the experiments performed. 
 
4.3.1.1 Agonist stimulation of endogenously expressed GPCRs 
In a first set of experiments I stimulated endogenously expressed GPCRs in 
HEK293 cells transfected with the luciferase-based CRE reporter plasmid. I 
stimulated HEK293 cells using the set of agonists described in section 3.2.1 of 
the Material and Methods. 
I performed these experiments to measure the response of HEK293 
endogenously expressed GPCRs able to stimulate the CRE transcription factor. 
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Figure 4.1 Agonist-stimulation of endogenously expressed GPCRs in HEK293 cells monitored using the 
luciferase-based CRE reporter plasmid 
 
 
Only HEK293 cells stimulated with NECA showed a Firefly/Renilla ratio 
significantly higher in comparison with unstimulated cells. All other agonist shows 
Firefly/Renilla ratios not significantly higher of the ones recorded unstimulated 
cells. 
The activation of the CRE reporter plasmid upon NECA stimulation is due to the 
stimulation of endogenously expressed GPCRs adenosine receptors A2A and 
A2B, as expected from literature. 
Data represented in Figure 4.1 prove that: 
 
 
- HEK293 cells levels of expression of G-Protein related proteins are 
sufficient to stimulate the CRE the reporter plasmid. 
- The CRE reporter plasmid used is sensitive enough to detect signal coming 
from agonist stimulation of endogenously expressed GPCRs. 
- The only significant signal background for the luciferase-based CRE 
reporter plasmid is due to NECA stimulation of endogenously expressed 
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adenosine receptors (A2A, A2B), while no significant background signal is 
recorded for any of the other agonist used. 
4.3.1.2 Agonist stimulation of transiently transfected full-length control GPCRs 
I agonist-stimulated HEK293 cells transiently transfected with the full-length 
control GPCRs listed in Table 4.2 in order to estimate the sensitivity and 
specificity of the luciferase-based CRE reporter plasmid in detecting signals 





Figure 4.2 Agonist-stimulation of transiently transfected full-length control GPCRs in HEK293 cells monitored 
using the luciferase-based CRE reporter plasmid 
 
 
HEK293 cells transiently transfected with full-length 2-adrenergic receptor 
(B2AR) and Dopamine 1 (DR1) show a significant increase in the Firefly/Renilla 
ratio upon Norepinephrine (B2AR) and Dopamine (DR1) stimulation. Considering 
the results in Figure 4.1, the signals recorded from Norepinephrine and 
Dopamine stimulation are dependent only on the activation of transiently 
transfected B2AR and DR1 and have are not dependent on endogenously 
expressed GPCRs. HEK293 cells stimulated with NECA showed an activation 
comparable with the one shown in Figure 4.1. 
HEK293 cells transfected with Muscarinic 1 receptor (M1R) showed a weak 
increase in the Firefly/Renilla ratio upon stimulation with Muscarine. All other 
HEK293 cells transiently transfected with full-length control GPCRs showed no 
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significant increase in the Firefly/Renilla ratio upon agonist stimulation in 
comparison with unstimulated cells. 
Data shown in Figure 4.2 prove that the luciferase-based CRE reporter plasmid 
is enough sensitive to discriminate signal coming from transiently transfected 
agonist stimulated full-length control GPCRs. Also, the CRE reporter plasmid is 
activated only through agonist stimulation of GPCRs (transiently transfected and 
endogenously expressed) for which ability to increase intracellular level of cAMP 
has been previously proved. 
 
4.3.1.3 Light-stimulation of transiently transfected light-activated control GPCRs 
I light-stimulated HEK293 cells transiently transfected with light-activated control 
GPCRs (Table 4.2) following the light-stimulation procedure described in section 





Figure 4.3 Light-stimulation of transiently transfected light-activated control GPCRs in HEK293 cells monitored 
using the luciferase-based CRE reporter plasmid 
 
I considered the Firefly/Renilla ratio values in dark and light conditions for 
HEK293 cells transfected with rhodopsin (“RHO” column, Figure 4.3) as negative 
control, not expecting stimulation of the CRE transcription factor from the 
activation of Gα-t1/2. 
Light-activated control GPCRs show an activation pattern comparable with the 
agonist stimulation of their respective full-length genes (Figure 4.3 vs Figure 
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4.2). Light-activated B2AR, DR1 and A2A showed a significant increase in the 
Firefly/Renilla ratio values upon light-stimulation. 
Light-activated M1R present a light-dependent CRE stimulation significantly 
higher in comparison with the one recorded from the agonist stimulation of the 
full-length M1R (Figure 4.2). 
I stimulated HEK293 cells transiently transfected with the full- length M1R with 
CCH (Carbachol, not selective agonist) and VU357017 (selective M1R agonist) 
in order to prove that the light induced response in the light-activated M1R is 
neither an artifact created by the assay or an artificial coupling created by the 
chimeric M1R. HEK293 cells transfected only the luciferase-based CRE reporter 
plasmid were as well stimulated using CCH and VU357017 and considered as 
negative control. 
 
Figure 4.4 CCH stimulation of full-length M1R transiently transfected in HEK293 cells monitored using the 
luciferase-based CRE reporter plasmid 
 
 
Figure 4.5 VU357017 stimulation of full-length M1R transiently transfected HEK293 cells monitored with the 
luciferase-based CRE reporter 
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HEK293 cells transiently transfected with the full-length M1R and stimulated with 
different concentrations of CCH shown Firefly/Renilla values significantly higher 
in comparison with HEK293 cells containing only the luciferase-based CRE 
reporter plasmid (Figure 4.4). 
HEK293 cells transiently transfected with the full-length M1R and stimulated with 
different concentrations of VU35017 show no significant difference in the 
Firefly/Renilla ratio values in comparison with HEK293 cells only transfected with 
the luciferase-based CRE reporter plasmid (Figure 4.5). 
The data represented in Figure 4.3, 4.4 and 4.5 suggest that the removal of the 
M1R ligand dependency in the light-activated M1R preserve the ability of the 
M1R intracellular loops to couple to Gα-s subunits, increase intracellular levels 
of cAMP and subsequently activate the CRE transcription factor. 
Data shown in Figure 4.3 prove that: 
 
 
- The light stimulation procedure described in section 3.3 is sufficient to 
stimulate light-activated control GPCRs. 
- The CRE reporter plasmid is sensitive enough to record light-dependent 
CRE activation by transiently transfected light-activated control GPCRs. 
- The light-activated control GPCRs showed a light-dependent CRE 
activation pattern (Figure 4.5) comparable with the activation pattern of 
their respective full-length genes. 
4.3.2 SRE.L reporter plasmid 
I performed the same three sets of experiments describe in section 3.1 to validate 
the luciferase-based SRE.L reporter plasmid. This reporter plasmid is supposed 
to be sensitive to RhoA activation. Except for when stated differently, in the 
following experiments HEK293 cells were always transfected with the Renilla 
luciferase plasmid. 
4.3.2.1 Agonist stimulation of endogenously expressed GPCRs 
I agonist-stimulated HEK293 cells transfected with the luciferase-based SRE.L 
reporter plasmid in order to measure activation coming from agonist stimulation 
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Figure 4.6 Agonist-stimulation of endogenously expressed GPCRs in HEK293 cells monitored using the 
luciferase-based CRE reporter plasmid 
 
HEK293 cells stimulated with Muscarine show Firefly/Renilla ratio values 
significantly higher in comparison with same values measured for unstimulated 
cells, while all other agonists show values comparable with unstimulated cells. 
According to the literature, HEK293 cells endogenously express a significant 
amount of Muscarine 3 receptor (M3R) supposed to be able to activate RhoA 
and consequently stimulate the SRE.L transcription factor. 
Data shown in Figure 4.6 prove that the SRE.L reporter plasmid is sensitive 
enough to record signals coming from agonist stimulation of endogenously 
expressed GPCRs. Also, only Muscarine stimulated HEK293 cells show 
significant background signal coming from the activation of endogenously 
expressed M3R, while all other agonist shows comparable activation with 
unstimulated cells. 
 
4.3.2.2 Agonist stimulation of transiently transfected full-length control GPCRs 
I agonist-stimulated HEK293 cells transiently transfected with full-length control 
GPCRs and SRE.L reporter plasmid. 
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Figure 4.7 Agonist-stimulation of transiently transfected full-length control GPCRs in HEK293 monitored using 
the luciferase-based SRE.L reporter 
 
 
HEK293 cells transiently transfected with α1-adrenergic receptor (A1AR), free- 
fatty acid 3 receptor (FFAR3), Muscarinic 1 (M1R) and Muscarinic 2 (M2R) show 
significant increase in Firefly/Renilla ratio values upon agonist stimulation. All 
other transiently transfected full-length controls show Firefly/Renilla ratio values 
comparable between stimulated and unstimulated states. While the induction 
recorded for the A1AR and FFAR3 can be exclusively related to the activation of 
the transiently transfected full-length control GPCRs, the M1R and M2R induction 
need further analysis. The M1R is known to be Gα-q coupled while the M2R is 
known to be Gα-i/o coupled. The data for agonist stimulation of HEK293 cells 
only SRE.L reporter transfected (Figure 4.6) show that Muscarine is able to 
activate the endogenously expressed M3R in HEK293 cells. This suggests that 
the M1R and M2R responses upon Muscarine stimulation (Figure 4.7) might not 
be dependent on the agonist stimulation of transiently transfected M1R and M2R, 
but on the endogenous response of M3R. 
 
4.3.2.3 Light stimulation of transiently transfected light-activated control GPCRs 
I light-stimulated HEK293 cells transfected with light-activated control GPCRs 
following the procedure explained in section 3.2. 
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No dark activity is recorded in HEK293 cells transiently transfected with light- 
activated control GPCRs. Firefly/Renilla values for rhodopsin are comparable 
under dark vs. light condition. 
Light stimulation conserves the activation pattern of the agonist stimulation for 
the A1AR and FFAR3 receptors, while light-activated M1R and M2R shown no 





Figure 4.8 Light-stimulation of transiently transfected light-activated control GPCRs in HEK293 cells monitored 
using the luciferase-based SRE.L reporter plasmid 
 
 
The absence of light-dependent stimulation of the SRE.L reporter plasmid by the 
light-activated M1R and M2R is in accordance with the hypothesis that the 
agonist dependent stimulation shown in Figure 4.6 for the M1R and M2R is due 
to the activation of endogenously expressed M3R, whose RhoA coupling and 
consecutive activation of the SRE.L responsive element is also confirmed by light 
activation of its corresponding light-activated chimera shown in Figure 4.10. 
 
4.3.3 SRE reporter plasmid 
To validated the luciferase-based SRE reporter plasmid I performed three sets 
of experiments described in section 4.1. The SRE reporter plasmid is supposed 
to be sensitive to MAPK and PKC activation. When not stated differently, HEK293 
cells have to been considered always transfected with the Renilla plasmid. 
4.3.3.1 Agonist stimulation of endogenously expressed GPCRs 
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I agonist-stimulated HEK293 cells transfected with the SRE reporter plasmid in 
order to record activity from stimulation of endogenously expressed GPCRs and 
estimate background signals for this reporter assay. 
 
 
Figure 4.9 Agonist-stimulation of endogenously expressed GPCRs in HEK293 cells monitored using the 
luciferase-based SRE reporter 
 
 
HEK293 cells stimulated with Muscarine show significant increase in the 
Firefly/Renilla ratio values in comparison with unstimulated cells, while all other 
agonist show Firefly/Renilla ratio values comparable with unstimulated cells. 
The activation by Muscarine of SRE reporter plasmid can be explained by the 
activation of the endogenously expressed M3R, like already shown in Figure 
4.6 for HEK293 cells transfected with the SRE.L reporter plasmid. 
 
 
4.3.3.2 Agonist stimulation of transiently transfected full-length control GPCRs 
I agonist stimulated HEK293 cells transiently transfected with full-length control 
GPCRs. Agonist-stimulated HEK293 cells transiently transfected with A1AR, 
FFAR3, M1R and M2R full-length control GPCRs show significant increase in the 
Firefly/Renilla ratio upon agonist stimulation in comparison with unstimulated 
cells. In the case of the A1AR and FFAR3 the increase in the Firefly/Renilla ratio 
values in the stimulated states is due only to the activation of the transiently 





Figure 4.10 Agonist-stimulation of transiently transfected full-length control GPCRs in HEK293 cells monitored 
using the luciferase-based SRE reporter plasmid 
 
 
The response of the M1R can be justified by agonist stimulation of the transiently 
transfected M1R receptor and the endogenously expressed M3R, while the 
response of the M2R receptor is entirely derived from the agonist stimulation of 
endogenously expressed M3R, as supported also by the results of the equivalent 
experiment performed using the SRE.L reporter plasmid (Figure 4.7) 
 
4.3.3.3 Light stimulation of transiently transfected light-activated control GPCRs 
I light-stimulated HEK293 cells transiently transfected with light-activated control 
GPCRs following the procedure described in section 3.1 of the Material and 
Methods. 
Light-stimulated HEK293 cells transiently transfected with light-stimulated control 
GPCRs shown an activation pattern (Figure 4.11) comparable with the agonist-
induced activation pattern of the respective full-length control genes (Figure 4.10) 
in the case of the A1AR, FFAR3 and M1R receptors. 
The absence of signal from the light-activated M2R control GPCRs validate as 
M3R dependent the ligand induced activation shown in Figure 4.10. The agonist-
induced response for cells transiently transfected with the M1R (Figure 4.10) can 
be considered as the sum of the endogenous stimulation of the M3R plus the 
stimulation of the transiently transfected M1R. 
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Figure 4.11 Light-stimulation of transiently transfected light-activated control GPCRs monitored using the 
luciferase-based SRE reporter 
 
 
Figure 4.11 and 4.10 show that the SRE Luciferase reporter plasmid can be used 
to screen PKC and MAPK dependent G-Protein mediated pathways in the 
functional assay for the light-activated oGPCRs. 
 
4.3.4 CRE reporter plasmid to monitor cAMP depletion 
The luciferase-based CRE reporter plasmid can be used to screen for reduction 
of intracellular level of cAMP upon receptor activation. HEK293 cells can be pre-
stimulated in order to increase intracellular levels of cAMP. 
In theory pre-stimulated cells expressing receptor known to be Gα-i/o couple will 
have at the end of the screening assay lower Firefly/Renilla ratio values in 
comparison with the other pre-stimulated cells. 
In order to verify this hypothesis, I performed the three sets of experiments 
already performed for the other luciferase-based reporter plasmids, plus an 
additional experiment to estimate the right concentration of agonist to use for 
HEK293 pre-stimulation. 
 
4.3.4.1 NECA dose response curve for pre-stimulation of HEK293 cells 
As already shown for the validation of the luciferase-based CRE reporter plasmid 
HEK293 cells endogenously express a sufficient amount of adenosine receptors 
to stimulate production of cAMP upon NECA stimulation. 
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In a first set of experiments I tested different concentrations of NECA to stimulate 
endogenously expressed adenosine receptors A2A and A2B in HEK293 cells to 
increase the amount of intracellular cAMP levels. 
 
 




Using different concentrations of NECA I was able to calculate a dose response 
curve for stimulation of endogenously expressed GPCRs in HEK293 cells 
transfected with the luciferase-based CRE reporter plasmid. 
I chose 500nM as final concentration for HEK293 pre-stimulation with NECA 
considering this values as close to the NECA EC50. 
 
4.3.4.2 Agonist stimulation of endogenously expressed GPCRs 
I pre-stimulated HEK293 cells transfected with the luciferase-based CRE reporter 
plasmid with 500nm of NECA for five minutes (see section 3.2) prior agonist 
stimulation (following the same procedure used for previous luciferase- based 
reporter plasmids validations). 
In this assay the values of the Firefly/Renilla ratios for control GPCRs that are 
known to decrease intracellular cAMP levels by coupling with Gα-i/o subunits are 
supposed to be lower in the case of the ligand/light stimulated state in 









All agonist stimulated HEK293 cells show Firefly/Renilla ratio values comparable 
with the values of HEK293 cells only pre-stimulated with 500 nm of NECA (Figure 
4.15). No further CRE stimulation is recorded for any of the agonist-stimulated 
HEK293 cells, suggesting that HEK293 do not endogenously express sufficient 
levels of any Gα-i/o coupled GPCRs. 
 
4.3.4.3 Agonist stimulation of transiently transfected full-length control GPCRs 
I agonist-stimulated HEK293 transiently transfected with full-length control 




Figure 4.14 Agonist-stimulation of transiently transfected full-length control GPCRs in prestimulated HEK293 
cells monitored using the luciferase-based CRE reporter plasmid 
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FFAR3, DR2 and M2R show lower values of Firefly/Renilla ratios in the agonist- 
stimulated state in comparison with the unstimulated state. These receptors tare 
known by literature to be able to lower the amount of intracellular cAMP levels 
upon agonist stimulation. The FFAR3 receptor shows a strong reduction in cAMP 
levels that is in accordance with previously published work. All other control 
receptors show Firefly/Renilla ratio values comparable with the values of NECA 
pre-stimulated HEK293 cells. 
Data shown in Figure 4.14 suggest that NECA pre-stimulation of HEK293 cells 
transfected with the luciferase-based CRE reporter plasmid is a valid approach 
to screen for decrease of intracellular level of cAMP upon agonist-stimulation of 
transiently transfected control GPCRs. 
 
4.3.3.4 Light stimulation of transiently transfected light-activated control GPCRs 
I light stimulated pre-stimulated HEK293 cells transiently transfected with light- 
activated control GPCRs. 
The light-activated control GPCRs show a light-activation pattern in accordance 





Figure 4.15 Light-stimulation of transiently transfected light-activated control GPCRs in prestimulated HEK293 
cells using the luciferase-based CRE reporter 
 
 
Light-activated FFAR3, D2R and M2R show a significant reduction in 
Firefly/Renilla ratios in the light-activated states in comparison with dark values, 
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while all other light-activated control GPCRs show Firefly/Renilla ratio values 
comparable for the in the dark and light state. 
The data presented in Figure 4.14 and 4.15 show that is possible to record 
reduction of intracellular level of cAMP upon light-stimulation of light-sensitive 
control GPCRs Gα-i/o coupled using HEK293 cells transfected with the 
luciferase-based CRE reporter plasmid and pre-stimulated with 500nM of NECA. 
 
4.4 Functional screening of light-activated human Class A 
oGPCRs 
The luciferase based reporter plasmid previously described for which I performed 
a full validation using both transiently transfected full-length and light-activated 
control GPCRs were used to set up the screening platform for all the selected 64 
light-activated human Class A oGPCRs using HEK293 cells. The screening 
platform and the data analysis were set up following the procedure described in 
sections 4.2 and 4.3 of the Material and Methods. Only when not stated 
differently, HEK293 cells were always transfected with the Renilla plasmid for all 
the following described experiments. 
 
4.4.1 CRE reporter 
I transfected HEK293 cells with all 64 light-activated human Class A oGPCRs, 
CRE reporter. HEK293 cells were light stimulated according to procedure 
described in the section 3.1.1. 
None of the 64 light-activated human Class A oGPCRs screened used the 
luciferase-based CRE reporter plasmid shows significant activity in the dark, with 
Firefly/Renilla ratios comparable to the ratios under dark condition of light- 




Figure 4.16 Light-stimulation of transiently transfected light-activated human Class A oGPCRs in HEK293 cells 





Figure 4.17 Induction values for light-stimulated human Class A oGPCRs calculated on the data collected using 
the luciferase-based CRE reporter 
 
 
I calculated induction values from the data represented in Figure 4.16 (Figure 
4.17) for all 64 light-activated human Class A oGPCRs by dividing Firefly/Renilla 
values after light stimulation with dark values. I set as threshold to identify strong 
activation from light-activated human Class A oGPCRs an induction value higher 
or equal to 2.5 (that implies more than a two-fold increase in the Firefly/Renilla 
ratio between light and dark conditions). 




Identifier Gene Name Induction value 
MO3 Opto-GPR1 5.87 
MO13 Opto-GPR21 28.55 
MO19 Opto-GPR32 23.07 
MO26 Opto-GPR42 3.45 
MO31 Opto-GPR61 9.78 
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MO49 Opto-GPR135 11.89 
 
Table 4.8 Orphan genes for which significant light-dependent induction was measured using the luciferase- 
based CRE reporter 
 
 
4.4.2 SRE.L reporter 
I light-stimulated HEK293 cells transiently transfected with all 64 light-activated 
human Class A   oGPCRs and the luciferase-based SRE.L reporter plasmid. 
 
 
Figure 4.18 Light-stimulation of transiently transfected light-activated human Class A oGPCRs in HEK293 cells 
monitored using the luciferase-based SRE.L reporter 
 
 
Figure 4.19 Induction values for light-stimulated human Class A oGPCRs calculated on the data collected using 
the luciferase-based SRE.L reporter 
 
 
No light-activated human Class A oGPCRs shows significant activity in the dark, 
with Firefly/Renilla ratios comparable to the ratios under dark condition of light - 
activated control receptors and rhodopsin shown in Figure 4.7 and Figure 4.8. 
I calculated induction values from the data represented in Figure 4.20 for all 64 
light-activated human Class A oGPCRs. I set as threshold to identify strong 
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activation from light-activated human Class A oGPCRs an induction value higher 
or equal to 2.5 
Two light-activated human Class A oGPCRs show an induction value above the 
defined threshold, while the remaining 62 receptors do not show any significant 
light dependent activation: 
Identifier Gene Name Induction value 
MO20 Opto-GPR33 49.1 
MO37 Opto-GPR78 64.5 
 




4.4.3 SRE reporter 
I transfected HEK293 cells with all 64 light-activated human Class A oGPCRs, 
SRE reporter and Renilla luciferase plasmid. Cells were light stimulated following 
the procedure describe in section 3.2.1. 
 
 
Figure 4.20 Light-stimulation of transiently transfected light-activated human Class A oGPCRs in HEK293 cells 
monitored using the luciferase-based SRE reporter 
 
 
No light-activated chimeric orphan receptor shows significant activity in the dark, 
with Firefly/Renilla ratios comparable to the ratios under dark condition of light-
activated control receptors and rhodopsin as shown in Figures 4.14   and 




Figure 4.21 Induction values for light-stimulated human Class A oGPCRs calculated on the data collected using 
the luciferase-based SRE.L reporter 
 
 
I calculated induction values from the data represented in Figure 4.20 (Figure 
4.21) for all 64 light-activated chimeric Class A oGPCRs. I set as threshold to 
identify strong activation from light-activated Class A oGPCRs an induction value 
higher or equal to 2.5 
Six light-activated human Class A oGPCRs show an induction value above the 




Identifier Gene Name Induction value 
MO4 Opto-GPR3 5.32 
MO10 Opto-GPR18 2.49 
MO20 Opto-GPR33 2.69 
MO35 Opto-GPR68 3.45 
MO37 Opto-GPR78 5.05 
MO44 Opto-GPR88 3.41 
 




4.4.4 CRE reporter plasmid and NECA prestimulation 
I transfected HEK293 cells with all 64 light-activated human Class A oGPCRs. 
Cells were prestimulated with 500nm of NECA and then light-stimulated 




Figure 4.22 Light-stimulation of transiently transfected light-activated human Class A oGPCRs in prestimulated 




Figure 4.23 Induction values for light-stimulated human Class A oGPCRs calculated on the data collected using 
the luciferase-based CRE reporter after HEK293 NECA prestimulation 
 
 
I calculated induction values from the data represented in Figure 4.22 for all 64 
light-activated chimeric Class A oGPCRs (Figure 4.23). For this functional 
screening it is not possible to use the same induction threshold used for the 
previously described reporter plasmids. In this experimental setup, using the 
CRE reporter plasmid with NECA pre-stimulation, I expect a reduction in the 
Firefly/Renilla ratio values under light conditions in comparison with the dark 
values. I defined as new threshold a value of “reverse” induction (still calculated 
as Firefly/Renilla ratio value under light conditions divided for the same ratio 
under dark conditions) 0.7, which implies a minimum of 30% reduction between 
light and dark Firefly/Renilla ratios. 
Six light-activated human Class A oGPCR show an induction value below the 
fixed threshold, while all the others 58 GPCRs do not show any significant light 
dependent decrease for intracellular cAMP levels: 
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Identifier Gene Name Induction value 
MO5 Opto-GPR4 0.53 
MO19 Opto-GPR32 0.63 
MO20 Opto-GPR33 0.67 
MO30 Opto-GPR55 0.67 
MO33 Opto-GPR63 0.63 
MO56 Opto-GPR150 0.64 
Table 3.11 Orphan genes for which significant light dependent induction was measured in NECA prestimulated 
CRE reporter based screening assays 
 
 




Figure 4.24 Absorbance normalized by the value of Rhodopsin (MO101) for the 64 light-activated Class A oGPCRs 
I transfected HEK293 cells with all 64 light-activated human Class A oGPCRs 
and bovine rhodopsin. Cells were light stimulated and later stained with an anti- 
VSVG antibody (see section 3.1) following the procedure described in section 
3.3. 
Absorbance values normalized for Rhodopsin (indicated with MO101 in Figure 
4.24) for all 64 light-activated human Class A oGPCRs show significant transient 
expression in light stimulated HEK293 cells The fixation technique used allows 
me to consider the absorbance values show in figure 4.24 for all 64 light-activated 
human Class A oGPCRs has to be related mostly to expression of the light-
activated human Class A oGPCRs on the cell membrane. 
All 64 light-activated human chimeric human Class A oGPCRs show significant 
level   of   membrane   expression   in   comparison   with   the   positive control 
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rhodopsin, with the exception of Opto-GPR12 and Opto-GPR15 that show a 
lower but yet still significant expression level in comparison with expression level 
of rhodopsin and the negative control. 
 
4.6 Validation of G-Protein coupling prediction algorithms 
I used the PREDCOUPLE, PREDCOUPLE2 and GRIFFIN prediction algorithms 
to study in silico the predicted coupling of 64 light-activated human Class A 
oGPCRs chosen for this study, their corresponding complete orphan sequences 
and ligand and light-activated control GPCRs. 
The first criterion I adopted to validate each single algorithm was the agreement 
between the predicted coupling for the control GPCRs and the coupling reporter 
by literature and the experiment I performed using Luciferase based reporter 
plasmids. 
Secondly, I considered the agreement between the predicted couplings for the 
full-length 64 human Class A oGPCRs I selected for this work and their 
respective light-activated chimeric genes. According to the hypothesis on which 
my screening using chimeric receptor is based and according to the data shown 
for control GPCRs, the coupling between full-length GPCRs and their respective 
chimeric receptor has to be the same. 
As third criterion I consider the overall agreement between the three different 
algorithms I used to study the coupling of orphan and control GPCRs. Although 
based on different mathematical and statistical approaches, the outcome for the 
predicted coupling for control GPCRs and oGPCRs in both their ligand and light-
activated form should be algorithm independent. 
 
4.6.1 Validation of the GRIFFIN algorithm 
4.6.1.1 Full-length control GPCRs 
I run the Griffin algorithm with the sequence of the full-length control GPCRs 
described in table 4.6 in order to estimate the algorithm performance with GPCRs 
for which coupling properties are already known. 
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2 adrenergic receptor 
(2AR) 
Gα-s Gα-s 
1 adrenergic receptor 
(1AR) 
Gα-q Gα-q 
Free fatty acid 





Dopamine receptor D1 
(D1R) 
Gα-s Gα-s 




















The Griffin algorithm scored a 9/9 of correct predictions when analyzing 
sequences of full-length control GPCRs, showing that is able to predict correct 
coupling when analyzing entire sequences of GPCRs genes. 
 
4.6.1.2 Light-activated control GPCRs 
I run the GRIFFIN algorithm on the sequences of the light-activated control 
GPCRs to check if the algorithm is able to predict the correct coupling of chimeric 
GPCRs for which I have proved preservation of coupling properties in the 





Predominant G coupling 
(experimental) 
Predicted G. Coupling 
2 adrenergic receptor 
(2AR) 
Gα-s Gα-t1/2 
1 adrenergic receptor 
(1AR) 
Gα-q Gα-t1/2 




Adenosine A2A receptor 
(A2AR) 
Gα-s Gα-t1/2 
Dopamine receptor D1 (D1R) Gα-s Gα-t1/2 
Dopamine receptor D2 (D2R) Gα-i/o Gα-t1/2 
Muscarinic acetylcholine 
receptor M1 (M1R) 
Gα-q and Gα-s Gα-t1/2 
Muscarinic acetylcholine 
receptor M2 (M2R) 
Gα-i/o Gα-t1/2 
Muscarinic acetylcholine 
receptor M3 (M3R) 
Gα-q Gα-t1/2 
 




The Griffin algorithm scored a 0/9 of positive result when predicting G-Protein 
coupling for light-activated control GPCRs. All light-activated control GPCRS are 
predicted to be coupled to Gα-t1/2 that is the G-Protein mediated pathway 
activated by rhodopsin. 
This result suggests that the GRIFFIN algorithm is not able to distinguish 
between bovine rhodopsin and chimeric receptor for which bovine rhodopsin 
constitute the majority of their sequences. 
 
4.6.1.3 Human Class A oGPCRs 
I run the GRIFFIN algorithm on all 64 Human Class A oGPCRs both on their full 








































































































































Table 4.14 Coupling prediction for 64 human Class A oGPCRs in their full-length and light-activated forms 




Figure 4.25 Predicted G-Protein coupling for 64 full-length and relative light-activated human Class A oGPCRs 
according to the Griffin Algorithm. 
 
 
The GRIFFIN algorithm is able to predict a possible coupling for all 64 full- length 
human Class A oGPCRs sequences, while all respective light-activated version 
is predicted to be Gα-t1/2 coupled, as already shown in the previous section for 
light-activated control GPCRs. 
This result confirm that the GRIFFIN algorithm is not sensitive enough to predict 
a reasonable coupling for light-activated chimeric receptor for which has been 
shown conservation of coupling properties (like in the case of light-activated 
control GPCRs) and to distinguish between rhodopsin based chimeric receptor 
and rhodopsin itself. 
 
4.6.2 Validation of the PREDCOUPLE algorithm 
4.6.2.1 Full-length control GPCRs 
I run the PREDCOUPLE algorithm with the sequences of the full-length control 
GPCRs described in Table 3.6 in order to estimate the algorithm performance 
with full-length GPCRs for which coupling properties are already known. 
 
Control Receptor Predominant G-coupling 
(Experimental) 
Predicted G-Coupling 
2 adrenergic receptor 
(2AR) 
Gα-s Gα-s 
1 adrenergic receptor 
(1AR) 
Gα-q Gα-q 
Free fatty acid receptor 3 
(FFR3) 
Gα-i/o Gα-i/o 
Adenosine A2A receptor Gα-s Gα-s 
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(A2AR)   
Dopamine receptor D1 
(D1R) 
Gα-s Gα-s 




receptor M1 (M1R) 
Gα-q and Gα-s Gα-q 
Muscarinic acetylcholine 
receptor M2 (M2R) 
Gα-i/o Gα-i/o 
Muscarinic acetylcholine 




Table 4.14 Predicted G-Protein coupling for full-length control GPCRs according to the PREDCOUPLE algorithm 
 
Figure 4.26 Predicted G-Protein coupling for 64 full-length and relative light-activated human Class A oGPCRs 
according to the PREDCOUPLE Algorithm. 
 
 
The PREDCOUPLE algorithm scored a 9/9 of correct predictions when analyzing 
sequences of full-length control GPCRs, showing that is able to predict correct 
coupling when analyzing entire sequences of GPCRs genes. 
 
4.6.2.2 Light-activated control GPCRs 
I run the PREDCOUPLE algorithm on the sequences of the light-activated control 
GPCRs to check if the algorithm is able to predict the correct coupling of chimeric 
GPCRs for which I have proved preservation of coupling properties in the 
experiment described in section 4.3 
Light-activated control Receptor Predominant G coupling 
(experimental) 
Predicted G. Coupling 




1 adrenergic receptor 
(1AR) 
Gα q Gα-q 
Free fatty acid receptor 3 
(FFR3) 
Gα-i/o Gα-i/o 
Adenosine A2A receptor 
(A2AR) 
Gα-s Gα-s 
Dopamine receptor D1 ( 
D1R) 
Gs Gα-s 
Dopamine receptor D2 
(D2R) 
Gα-i/o Gα-i/o 
Muscarinic acetylcholine receptor 
M1 
(M1R) 
Gα-q and Gα-s Gα-q 









Table 4.15 Predicted G-Protein coupling for full-length control GPCRs according to the PREDCOUPLE algorithm 
 
 
The PREDCOUPLE algorithm scored a 9/9 of positive result when predicting G- 
Protein coupling for light-activated control GPCRs. All light-activated control 
GPCRS are predicted to be coupled equivalently to their full-length respective 
genes and in accordance to what I proved with the experiment described in 
section 
This result prove that the PREDCOUPLE algorithm is able to predict correctly 
coupling of light-activated control GPCRs and therefore to distinguish such 
receptor from bovine rhodopsin. 
 
4.6.2.3 Human Class A oGPCRs 
I run the PREDCOUPLE algorithm on all 64 human Class A oGPCRs both on 
their full sequences and their respective light-activated version 
 
 
Gene name Identifier Full-length predicted coupling Light-activated predicted 
coupling 
GPR1 MO3 no match Gα-i/o 
GPR3 MO4 Gα-i/o Gα-i/o 
GPR4 MO5 Gα-i/o Gα-i/o 
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GPR6 MO6 Gα-i/o Gα-i/o 
GPR12 MO7 Gα-i/o Gα-i/o 
GPR15 MO8 Gα-i/o Gα-i/o 
GPR17 MO9 Gα-i/o Gα-i/o 
GPR18 MO10 Gα-i/o Gα-i/o 
GPR19 MO11 Gα-i/o Gα-i/o 
GPR20 MO12 Gα-i/o Gα-i/o 
GPR21 MO13 Gα-s Gα-i/o, Gα-q 
GPR22 MO14 Gα-i/o Gα-i/o 
GPR25 MO15 Gα-i/o Gα-i/o 
GPR26 MO16 Gα-i/o Gα-i/o 
GPR27 MO17 Gα-i/o Gα-i/o 
GPR31 MO18 Gα-i/o Gα-i/o 
GPR32 MO19 Gα-i/o Gα-i/o 
GPR33 MO20 Gα-i/o Gα-i/o 
GPR34 MO21 Gα-i/o Gα-i/o 
GPR35 MO22 Gα-i/o Gα-i/o, Gα-q 
GPR37 MO23 Gα-i/o Gα-i/o 
GPR37L1 MO24 Gα-i/o Gα-i/o 
GPR39 MO25 Gα-i/o Gα-i/o 
GPR42 MO26 Gα-i/o Gα-i/o 
GPR45 MO27 Gα-i/o Gα-i/o 
GPR50 MO28 Gα-q, Gio, Gα-s Gα-q 
GPR52 MO29 Gα-i/o Gα-i/o 
GPR55 MO30 Gα-i/o Gα-i/o 
GPR61 MO31 Gα-i/o Gα-i/o 
GPR62 MO32 Gα-i/o Gα-i/o 
GPR63 MO33 Gα-i/o Gα-i/o 
GPR65 MO34 Gα-i/o Gα-i/o 
GPR68 MO35 Gα-i/o Gα-i/o 
GPR75 MO36 no match Gα-i/o 
GPR78 MO37 Gα-i/o Gα-i/o 
GPR82 MO39 Gα-i/o Gα-i/o 
GPR83 MO40 Gα-i/o, Gα-q Gα-i/o 
GPR84 MO41 Gα-i/o Gα-i/o 
GPR85 MO42 Gα-s Gα-i/o 
GPR87 MO43 Gα-i/o Gα-i/o 
GPR88 MO44 Gα-i/o Gα-i/o 
GPR101 MO45 Gα-i/o Gα-i/o 
GPR119 MO46 Gα-i/o Gα-i/o 
GPR120 MO47 Gα-i/o Gα-i/o 
GPR132 MO4 Gα-i/o Gα-i/o 
GPR135 MO49 Gα-q Gα-i/o, Gα-q 
GPR139 MO50 Gα-i/o Gα-i/o 
GPR141 MO51 Gα-q, Gα-i/o Gα-i/o, Gα-q 
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GPR142 MO52 no match Gα-i/o 
GPR146 MO53 no match Gα-i/o 
GPR148 MO54 no match Gα-i/o 
GPR149 MO55 Gα-i/o Gα-i/o 
GPR150 MO56 Gα-i/o Gα-i/o 
GPR151 MO57 no match found Gα-i/o 
GPR152 MO58 Gα-i/o Gα-i/o 
GPR153 MO59 probable no gpcr Gα-i/o 
GPR160 MO60 Gα-i/o Gα-i/o 
GPR161 MO61 no match Gα-i/o 
GPR162 MO62 no match Gα-i/o 
GPR171 MO63 Gα-i/o Gα-i/o 
GPR173 MO64 Gα-i/o Gα-i/o 
GPR174 MO65 Gα-i/o Gα-i/o 
GPR176 MO66 Gα-i/o Gα-i/o 
GPR182 MO67 Gq Gα-i/o 
GPR183 MO68 no match Gα-i/o 
 
Table 4.16 Predicted G-Protein coupling for full-length control GPCRs according to the PREDCOUPLE algorithm 
 
 
The PREDCOUPLE algorithm is not able to predict a possible G-Protein coupling 
for 8 out of 64 for full-length human Class A oGPCRs, while a possible coupling 
is always predicted for all 64 light-activated oGPCRs. 
Out of 64 human Class A oGPCRs genes, the PREDCOUPLE algorithm show 
no agreement between the predicted coupling for full-length oGPCR and light- 
activated oGPCR genes in 14 cases. 
The agreement between the full-length and light-activated oGPCRs genes 
predicted coupling can be explained by noticing that most of the genes are in 
both cases predicted to couple one single G-protein mediated pathways, Gα-i/o. 
 
4.6.3 Validation of the PREDCOUPLE2 a l g o r i t h m  
4.6.3.1 Full-length control GPCRs 
I run the PREDCOUPLE2 algorithm with the sequences of the full-length control 
GPCRs described in table 3.6 in order to estimate the algorithm performance with 
full-length GPCRs for which coupling properties are already known. 
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Control Receptor Predominant G-coupling 
(Experimental) 
Predicted G-Coupling 
2 adrenergic receptor (2AR) Gα-s Gα-s 
1 adrenergic receptor (1AR) Gα-q Gα-q 
Free fatty acid receptor 3 (FFR3) Gα-i/o Gα-i/o 
Adenosine A2A receptor (A2AR) Gα-s Gα-s 
Dopamine receptor D1 (D1R) Gα-s Gα-s 
Dopamine receptor D2 (D2R) Gα-i/o Gα-i/o 
Muscarinic acetylcholine receptor 
M1 (M1R) 
Gα-q and Gα-s Gα-q 
Muscarinic acetylcholine receptor 
M2 (M2R) 
Gα-i/o Gα-i/o 




Table 4.17 Predicted G-Protein coupling for full-length control GPCRs according to the PREDCOUPLE2 algorithm 
 
 
The PREDCOUPLE2 algorithm scored a 9/9 of correct predictions when 
analyzing sequences of full-length control GPCRs, showing that is able to predict 
correct coupling when analyzing entire sequences of GPCRs genes. 
 
4.6.3.2 Light-activated control GPCRs 
I run the PREDCOUPLE2 algorithm on the sequences of the light-activated 
control GPCRs to check if the algorithm is able to predict the correct coupling of 
chimeric GPCRs for which I have proved preservation of coupling properties in 
the experiment described in section 4.3. 
 
 
Light-activated control Receptor Predominant G-coupling 
(Experimental) 
Predicted G-Coupling 
2 adrenergic receptor (2AR) Gα-s Gα-s 
1 adrenergic receptor (1AR) Gα-q Gα-q 
Free fatty acid receptor 3 (FFR3) Gα-i/o Gα-i/o 
Adenosine A2A receptor (A2AR) Gα-s Gα-s 
Dopamine receptor D1 (D1R) Gα-s Gα-s 
Dopamine receptor D2 (D2R) Gα-i/o Gα-i/o 
Muscarinic acetylcholine receptor 
M1 (M1R) 
Gα-q and Gα-s Gα-q 
Muscarinic acetylcholine receptor Gα-i/o Gα-i/o 
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M2 (M2R)   




Table 4.18 Predicted G-Protein coupling for full-length control GPCRs according to the PREDCOUPLE2 algorithm 
 
 
The PREDCOUPLE2 algorithm scored a 9/9 of positive result when predicting G-
Protein coupling for light-activated control GPCRs. All light-activated control 
GPCRS are predicted to be coupled equivalently to their full-length respective 
genes and in accordance to what I proved with the experiment described in 
section 4.3. 
This result prove that the PREDCOUPLE2 algorithm is able to predict correctly 
coupling of light-activated control GPCRs and therefore to distinguish such 
receptor from bovine rhodopsin. 
 
4.6.3.3 Human Class A oGPCRs 
I run the PREDCOUPLE2 algorithm on all 64 human Class A oGPCRs both on 




Gene name Identifier Full-length predicted coupling Light-activated predicted 
coupling 
GPR1 MO3 Gα-q, Gα-i/o Gio, Gα-q 
GPR3 MO4 Gα-s, Gio Gα-q, Gio 
GPR4 MO5 Gio Gio 
GPR6 MO6 Gα-s Gio, Gα-q, Gα-s 
GPR12 MO7 Gα-s, Gio Gα-q, Gio, Gα-s 
GPR15 MO8 Gio, Gα-q, Gα-12/13 Gio, Gα-q, Gα-12/13 
GPR17 MO9 Gio Gio 
GPR18 MO10 Gio Gα-q, Gio 
GPR19 MO11 Gα-q, Gio Gα-q, Gio 
GPR20 MO12 Gα-q, Gα-12/13, Gs Gα-s, Gio 
GPR21 MO13 Gio, Gα-s Gio 
GPR22 MO14 Gio, Gα-s, Gα-12/13 Gio 
GPR25 MO15 Gio, Gα-12/13 Gio 
GPR26 MO16 Gio, Gα-q Gio, Gα-s 
GPR27 MO17 Gio, Gα-q Gio, Gα-q 
GPR31 MO18 Gio Gio 
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GPR32 MO19 Gio, Gα-q Gio, Gα-q 
GPR33 MO20 Gα-q Gα-q, Gio 
GPR34 MO21 Gio, Gα-q Gio 
GPR35 MO22 Gα-q, Gα-12/13, Gio Gα-q, Gα-12/13, Gio 
GPR37 MO23 Gα-q, Gαio, Gαs Gα-q, Gαio 
GPR37L1 MO24 Gio, Gα-s Gio, Gα-q 
GPR39 MO25 Gα-q Gio, Gα-q 
GPR42 MO26 Gio, Gα-q Gio 
GPR45 MO27 Gio Gio, Gα-q 
GPR50 MO28 Gio, Gα-s Gio, Gα-s 
GPR52 MO29 Gio, Gα-q Gio 
GPR55 MO30 Gio, Gα-q Gio, Gα-q 
GPR61 MO31 Gα-s,Gio Gα-s, Gio 
GPR62 MO32 Gα-s, Gα-q, Gα-12/13 Gio, Gα-s 
GPR63 MO33 Gio, Gα-q Gα-q, Gio 
GPR65 MO34 Gio, Gα-q Gα-q, Gio 
GPR68 MO35 Gio Gio 
GPR75 MO36 Gio Gio 
GPR78 MO37 Gα-s, Gα-q Gio, Gα-s 
GPR82 MO39 Gα-q,Gio, Gα-12/13 Gα-q, Gio 
GPR83 MO40 Gio, Gα-q Gio, Gα-q 
GPR84 MO41 Gio, Gα-s, Gα-12/13 Gio 
GPR85 MO42 Gio, Gα-q Gio 
GPR87 MO43 Gio, Gα-q Gio, Gα-q 
GPR88 MO44 Gα-s, Gio Gio, Gα-s 
GPR119 MO46 Gio, Gα-q Gio, Gα-q, Gα-12/13 
GPR120 MO47 Gα-q, Gα-12/13, Gα-s, Gio all - nothing 
GPR132 MO4 Gio, Gq Gα-q, Gio, Gα-s 
GPR135 MO49 Gα-io, Gα-q Gα-q, Gio 
GPR139 MO50 no match Gα-q, Gio 
GPR141 MO51 Gα-q, Gio Gio, Gα-q, Gα-12/13 
GPR142 MO52 Gα-q, Gio, Gα-12/13, Gα-s Gio 
GPR146 MO53 Gio, Gα-q, Gα-12/13 Gα-q, Gio 
GPR148 MO54 Gio Gio 
GPR149 MO55 Gio Gio, Gα-q 
GPR150 MO56 Gio, Gα-q, Gα-s Gio 
GPR151 MO57 Gio Gio, Gα-s 
GPR152 MO58 Gio Gio 
GPR153 MO59 probable no gpcr Gio, Gα-q 
GPR160 MO60 Gio, Gα-q Gio 
GPR161 MO61 Gio Gio 
GPR162 MO62 Gα-q, Gio Gα-q, Gio 
GPR171 MO63 Gα-q, Gio, Gα-12/13 Gio, Gα-q, Gα-12/13 
GPR173 MO64 Gα-q, Gio, Gα-s Gα-q, Gio 
GPR174 MO65 Gio, Gα-q Gio, Gα-q 
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GPR176 MO66 Gα-s Gio, Gα-q, Gα-s 
GPR182 MO67 Gα-q, Gio, Gα-12/13 Gα-q, Gio, Gα-12/13 
GPR183 MO68 Gα-q, Gio Gio, Gα-q 
 
Table 4.19 Predicted G-Protein coupling for 64 human Class A human oGPCRs in their full-length and light- 
activated form according to the PREDCOUPLE2 algorithm 
 
 
The PREDCOUPLE2 algorithm is able to predict a possible G-Protein coupling 
for all 64 full-length and light-activated orphan GPCRs. 
Out of 64 human Class A oGPCRs genes, the PREDCOUPLE algorithm show 
no agreement between the predicted coupling for full-length oGPCR and light- 
activated oGPCR genes in 11 cases. 
The agreement between the full-length and light-activated oGPCRs genes 
predicted coupling is helped by the ability of the PREDCOUPLE2 algorithm to 
propose more than one single possible pathways. 
 
 
Figure 4.27 Predicted G-Protein coupling for 64 full-length and relative light-activated human Class A oGPCRs 
according to the Predcouple2 Algorithm 
 
 
4.6.4 Comparison between the different a l g o r i t h m s  
I defined for each control and oGPCRs in both full-length and light-activated 
chimeric form the agreement between the predicted couplings between different 
algorithms as the superposition between the predicted couplings for the two most 
probable pathways. 
In the case of full-length control GPCRs, there is full agreement both considering 
only the most probable pathways and the two most   probable 
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pathways considering PREDCOUPLE vs GRIFFIN and PREDCOUPLE2 vs 
GRIFFIN. 
In the case of the light-activated control GPCRs, there is no agreement between 
the PREDCOUPLE, PREDCOUPLE 2 and GRIFFIN, and this due to the fact that 
for the GRIFFIN algorithm all light-activated chimeric receptors (control and 
oGPCRs) are considered to conserve the coupling properties of rhodopsin. 
I did not perform the agreement analysis between the PREDCOUPLE and the 
PREDCOUPLE 2 being two different version of the same algorithm, and thus a 
strong agreement between the predicted couplings of these two algorithm would 
be less significant. 
In Figure 4.27 and 4.28 the number of positive coupling (superposition between 
the different algorithms) considering only the main predicted pathways and 
negative coupling (no superposition between the different algorithms) are shown 
for PREDCOUPLE vs GRIFFIN and PREDCOUPLE2 vs. GRIFFIN for the full-
length 64 human Class A oGPCRs. 
In the case of PREDCOUPLE vs GRIFFIN there is high disagreement between 
the predicted couplings for full-length oGPCRs both considering only the main 
predicted pathways or the two most probable. This disagreement is present also 
when comparing PREDCOUPLE2 vs GRIFFIN, although in the case of the 
PREDCOUPLE vs GRIFFIN, I got more positive than negative coupling. 
 
 
Figure 4.28 Number of positive and negative matches between the Predcouple and Griffin Algorithms for 
principal and first two principal predicted G-Protein coupling for 64 full-length and relative light-activated human 






Fig 4.29 Number of positive and negative matches between the Predcouple and Griffin Algorithms for principal 
and first two principal predicted G-Protein coupling for 65 full-length and relative light-activated chimeric Class 
A oGPCRs 
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Orphan GPCRs (oGPCRs) represent a valuable target in drug discovery due to 
their proven and potential role in many diseases. Till now, exploiting of oGPCRs 
in drug development was limited by the insufficient amount of information about 
these receptors, including limited knowledge about their signaling and structural 
properties. 
Notably, in some cases non signaling functions or ligand independent functions 
have been proposed for oGPCRs, but it still remains a question about if and what 
signaling cascades these receptors activate once stimulated by an agonist. 
I have shown that the chimeric approach is a new approach to increase the 
amount of information available about the functional and signaling properties of 
orphan GPCRs and guide drug discovery into exploring new possible therapeutic 
approaches. 
Although the design of chimeric GPCRs has been largely focused in the last 15 
years on the study their molecular functions, this approach has been limited by 
the lack of a systematic protocol in order to design, clone and test large libraries 
of chimeric receptors. Also, the limited amount of data about the functionality of 
chimeric GPCRs has brought doubts about the validity of the domain swapping 
dogma and more generally on the idea that GPCRs can be considered as 
receptors in which the ligand interaction and the signal transduction are two 
related independent processes. Also, for the large number of chimeric GPCRs 
engineered in the past, a platform for a complete screening of all G-Protein 
mediated signaling pathways was missing, leaving the concern that functional 
chimeric GPCRs might show original unwanted coupling properties in 
comparison with their full-length receptors. In this work I demonstrated that such 
a systematic approach to the design, clone and screen large libraries of chimeric 
receptors is possible. 
114  
Indeed, the “chimeric algorithm” described in this thesis allows creating libraries 
of chimeric GPCRs in a step-by-step process from sequence retrieval till the 
generation of the synthetic genes. 
The gene reporter system based on the use of luciferase-based reporter plasmids 
allowed screening for several G-Protein mediated pathways for a large number 
of chimeric receptor at the same time. For all G-Protein mediated pathways 
different methods are currently available. However, they have the inconvenient of 
being based on different readouts. This implies that, while screening for activation 
of different G-Protein pathways, results coming from different assays cannot be 
easily compared. 
The testing platform build on the use of luciferase based gene reporter plasmids 
has the unique advantage of unifying in one single output signals coming from 
different signaling pathways. In fact, one of the main problems when screening 
large libraries of receptors that can activate different signaling pathways, such as 
GPCRs, is comparing results coming from different screening systems. 
The reliability of the luciferase-based assays is testified by the results on ligand- 
activated control GPCRs, which show activation pattern in accordance with 
previously available data, implying that the platform is able to correctly detect and 
distinguish G-Protein mediated signaling pathways. 
The reliability of the “chimeric algorithm” is testified by the results achieved with 
the testing of the light-activated control GPCRs library. 
Light-activated version of full-length control GPCRs designed following the 
“chimeric algorithm” show intact functionality and specificity, excluding most of 
the concern regarding the generation of chimeric GPCRs such as loss of 
functionality or creation/deletion of signaling cascades. 
The cloning approach based on the design of a common mother construct for the 
creation of all genes of a synthetic library can be translated for application with 
any other GPCRs, such as GPCRs or light sensitive opsin that might present 
more convenient properties. Bi stable opsins as well as protein that present a 
close life cycle can be used following the same approach to create libraries of 
light-activated receptors tuned to fit to different experimental 
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settings. One of the biggest concerns at the beginning of this work was to develop 
a screening platform that allows me to overcome the issue of not having a proper 
positive control while testing the light-activated human Class A oGPCRs. The 
coherence between the screening data belonging to full-length control GPCRs 
and their relative light-activated chimeric versions allow me to propose that the 
signaling data collected from the light-activated human Class A oGPCRs reflect 
the signaling properties of their relative full-length genes. 
Out of the 64 light-activated human Class A oGPCRs tested for G-Protein 
mediated pathways, I observed in total 19 receptor-pathway couplings in the 
HEK293 cell line. Considering that G-Protein coupling properties can be cell- type 
dependent, these results strongly suggested that human Class A oGPCRs might 
still conserve intact functional properties and are able to signal trough G- Protein 
mediated pathways even if I was not able to detect a significant activation in 
HEK293 cells. Fourteen different light-activated human Class A oGPCRs 
designed according the chimeric algorithm show significant activation of one or 
more luciferase-based reporter plasmids. 
 
 
Light-activated human Class A 
oGPCR 
Luciferase-based reporter plasmid 
activated 
Possible second messengers 
activated 
Opto-GPR1 CRE cAMP é 
Opto-GPR3 SRE PKC and MAPK/ERK 
Opto-GPR4 CRE + NECA cAMP ê 
Opto-GPR18 SRE PKC and MAPK/ERK 
Opto-GPR21 CRE cAMP é 
Opto-GPR32 CRE cAMP é 
Opto-GPR33 SRE.L, SRE, CRE + NECA RhoA, PKC and MAPK/ERK, cAMP ê 
Opto-GPR42 CRE cAMP é 
Opto-GPR55 CRE + NECA cAMP ê 
Opto-GPR63 CRE + NECA cAMP ê 
Opto-GPR68 SRE PKC and MAPK/ERK 
Opto-GPR78 SRE PKC and MAPK/ERK 
Opto-GPR88 SRE PKC and MAPK/ERK 
Opto-GPR135 CRE cAMP é 
 
Table 5.1 List of light-activated human Class A oGPCRs with significant activation of one or more luciferase- 
based reporter plasmid upon light stimulation. 
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The functional data I collected can be compared to the already available 
information for the receptors listed in table 4.1. Constitute activity and intensity 
and localization of oGPCR expression are important factors in order to estimate 
oGPCR possible physiological roles. Information coming from knockout and 
knockdown studies are as well fundamental. 
Especially taking in account the importance of GPCRs in drug discovery, the 
availability of murine knockout models is extremely important in understanding 
the physiological functional roles of GPCRs and oGPCRs and to observe 
disease-related phenotypes. 
In the following table are collected the available KO murine models (in the form 
of Embryonic Steam (ES) cells or stable murine strains) with relative phenotype 
(when observed). In Appendix II, references reporting phenotypes are collected 




 Gene ES Mice Phenotype Phenotype description 
1 





YES Under Production YES Behavior, Immune response, Growth 
3 
GPR3 YES Under Production YES Behavior, Metabolism 
 
4 
GPR4 YES Under Production Proposed Cardiovascular system, 
Homeostasis, Aging, Respiration 
5 















GPR17 YES YES Proposed Behavior, Immune system, Aging, 
Nervous system 
9 
GPR18 YES Under Production NO NO 
10 
GPR19 YES YES Proposed Behavior 
 
11 




GPR21 YES Under Production Proposed Behavior, Growth, Metabolism, 
Immune system 
13 






YES YES Proposed Embryogenesis, Growth, Immune 






YES NO Proposed Behavior, cardiovascular system, 
growth, nervous system 
16 
GPR26 YES Under Production Proposed Behavior, Metabolism, Growth 
17 
GPR27 NO Under Production NO NO 
 
18 
GPR30 YES Under Production YES Cardiovascular system, Growth, 
Immune system, Biliary system 
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19 
GPR31b YES Under Production NO NO 
20 
GPR33 YES YES YES Nervous system (abnormal gait) 
 
21 
GPR34 YES YES YES Immune system, Nervous system, 
Vision 
22 
GPR35 YES YES NO NO 
23 
GPR37 YES Under Production Proposed Behavior, Growth, Nervous system 
24 
GPR37l1 YES Under Production Proposed Behavior, Nervous system, Vision 
25 





YES YES YES Behavior, Metabolism, Biliary 





YES NO Proposed Cardiovascular system, Growth, 





YES YES Proposed Digestive system, Growth, 





YES NO Proposed Hematopoietic system, Metabolism, 
Immune system 
30 







YES NO Proposed Digestive system, Embryogenesis, 
Growth, Metabolism, Immune 







YES Under Production Proposed Behavior, Digestive system, Growth, 
Metabolism, Aging, 
33 





NO YES Proposed Behavior, Growth, Metabolism, 
Aging, nervous system 
35 GPR54 
(Kiss1r) 
YES YES YES Behavior, Growth, Digestive system, 















YES YES NO NO 
39 
GPR61 NO YES Proposed Metabolism (aldosterone) 
40 
GPR62 YES Under Production NO NO 
41 





YES Under Production Proposed Metabolism, Reproduction 
 
43 






YES YES YES Metabolism 
 
45 
GPR68 NO Under Production Proposed Hematopoietic system, Metabolism, 




























YES YES Proposed Behavior, Growth, Metabolism, 
Aging, Nervous system, 
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51 
GPR74 NO Under Production Proposed Nervous system 
52 

















YES NO Proposed Metabolism 
 
56 





GPR84 YES YES Proposed Hematopoietic system, Immune 
system 
58 





YES YES Proposed Digestive system, Metabolism, Biliary 
system, Skeleton 
60 
GPR87 YES YES Proposed Limbs, Digits, Tail, Skeleton 
61 




GPR89 YES Under Production Proposed Growth, Metabolism, Immune 











YES Under Production Proposed Hematopoietic system, Immune 





YES YES YES Behavior, Nervous system 
66 





YES YES YES Behavior, Hearing system, Aging, 





YES YES YES Behavior, Growth 
69 










YES YES YES Reproduction, Skeleton 
 
72 
GPR107 YES YES YES Hematopoietic system, Metabolism, 
Aging 
73 































YES YES YES Growth, Hematopoietic system, 
Metabolism, Immune system, Aging, 
Respiratory system 
80 








YES YES Proposed Growth, Metabolism, Biliary system, 










GPR124 NO YES Proposed Cardiovascular system, Digestive 
system, Growth, Aging, Nervous 










YES NO Proposed Behavior, Growth, Metabolism, 
Aging, Nervous system 
86 














GPR132 YES Under Production Proposed Growth, Hematopoietic system, 
Immune system, Respiratory System 
90 





NO Under Production NO NO 
92 
GPR137 YES Under Production NO NO 
93 
GPR137b YES YES NO NO 
94 
GPR137c YES NO NO NO 
95 
GPR139 YES YES NO NO 
96 
GPR142 YES YES NO NO 
 
97 
GPR143 YES NO Proposed Nervous system, Pigmentation, 
Vision 
98 
GPR146 YES NO NO NO 
99 
GPR149 YES Under Production Proposed Behavior, Reproduction 
100 
GPR150 YES NO NO NO 
101 
GPR152 YES YES NO NO 
102 





YES YES Proposed Metabolism, Respiration 
104 




GPR156 YES YES NO NO 
106 
GPR157 YES NO NO NO 
107 
GPR158 YES YES NO NO 
108 
GPR160 YES NO NO NO 
 
109 
GPR161 YES NO Proposed Behavior, Embryogenesis, Aging, 
Nervous system, Vision 
110 
GPR162 YES YES NO NO 
111 
GPR165 NO Under Production NO NO 
112 





YES YES NO NO 
114 
GPR175) YES YES NO NO 
115 
GPR176 YES YES NO NO 
116 
GPR178 YES YES NO NO 
117 
GRP179 YES Under Production Proposed Vision 
118 
GPR180 YES Under Production Proposed Cardiovascular system, Metabolism 
119 
GPR182 YES YES NO NO 
120  
120 




GRM1 NO Under Production YES Behavior, Growth, Hearing, 




GRM2 YES Under Production YES Behavior, Metabolism, Nervous 
system 
123 
GRM3 YES YES YES Behavior, Nervous system 
124 
GRM4 NO Under Production Proposed Behavior, Nervous system 
125 
GRM5 NO Under Production YES Behavior, Growth, Nervous system 
126 
GRM6 YES YES YES Nervous system, Vision 
 
127 









GPRC2a YES YES YES Behavior, Growth, Metabolism, 
Immune system, Aging Vision 
 
130 
GPRC5a YES NO YES Immune system, Respiration, 
Tumorigenesis 
131 
GPRC5b YES YES YES Behavior, Aging 
 
Table 5.2 List of GPCRs (including oGPCRs) belonging to different subfamilies (Class A, Adhesion and Class 
C) for which at least one KO model is available or under development. 
 
 
The data in table 4.2 show that for the moment a consistent amount of murine 
KO models are currently available for GPCRs. This might change in the future 
thanks to the CRISP/CAS9 technique that shortens both costs and time of 
development of stable KO strains261,262. For the oGPCRs for which I detected a 
significant stimulation of one or more luciferase-based reporter plasmids the 
previously mentioned information is also available. For some specific cases 
possible agonist and related activated second messengers are proposed in 
single studies, explaining why these genes are still formally considered as 
oGPCRs (see table 5.3 for genes and references). 
In the following paragraphs, for each oGPCRs for which I detected at least one 
possible G-Protein coupling, I will summarize what is known and what my result 
add to it. 
GPR1 is currently considered a chemerin receptor, although an agreement on 
this is still missing. Chemerin is a chemoattractant protein that plays an active 
role in recruitment of dendritic cells and macrophages to inflammation sites. A 
chemerin-dependent activation of RhoA has been reported for GPR1, not 
recorded in my assays. However, the light-activated GPR1 showed    significant 
activation   of   the   CRE   luciferase-based   plasmid, suggesting   that GPR1 
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increases intracellular levels of cAMP. Modifications of intracellular level of cAMP 
are required for regulation of actin based cell migration and chemotaxis. Thus 
activation of the CRE luciferase-based reporter plasmid is in agreement with the 
hypothesis of the involvement of this receptor in inflammation and migration-
related biological processes. GPR3 is expressed in oocytes and it is supposed 
to play a role in the communication between oocytes and the surrounding stromal 
tissue. It has been proved its ability to increase cAMP in oocytes without the 
interaction with a ligand (constitutive activity), although Sphingosine 1-phosphate 
(S1P) has been proposed as putative ligand. Recently, it has been suggested 
that GPR3 might play a role in the Alzheimer’s disease263. It has been determined 
that the absence of GPR3 alleviated the cognitive deficits and reduced amyloid 
pathology in four different d i s e a s e s - 
relevant mouse models of Alzheimer. Furthermore, GPR3 was found to be 
elevated in postmortem brain tissue from a subset of patient suffering of 
Alzheimer264. The activation of the CRE luciferase-based reporter system by the 
light-activated GPR3 supports the hypothesis that this receptor might modify 
intracellular level of cAMP, not only in oocytes. For this receptor, as well as   for 
all other oGPCRs involved in diseases, the conservation of the activated pathway 
in literature and in my screening assay open to different considerations. The look 
for a possible agonist or antagonist for GPR3 could be direct to ensemble of 
molecules that have been proved to act as ligand for similar GPCR that modify 
as well intracellular level of cAMP. The screening could be limited even more by 
considering only molecules present in the native tissue of GPR3 or similar 
GPCRs, conserving the approach of the already described orphan strategy. On 
the other hand, both the information coming from my screening assay and 
confirm by literature might move the therapeutic approach from GPR3 through 
the pathway activated by the receptor itself. My results suggest that the role of 
cAMP regulation in Alzheimer disease should be further investigate and that this 
second messenger could be considered at therapeutic target. 
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GPR4 is considered to be a proton-sensing GPCR. This class of GPCRs is 
supposed to be activated usually upon pH drops to values between 6.2-6.8. The 
study of proton-sensing GPCRs is still challenging (although different knockout 
murine models are available, see table 5.2) for the redundancy of this class of 
receptors that usually call for multiple gene deletions. Previous studies proved 
the ability of GPR4 to activate different G-protein mediated pathways, while in 
my screening assay the light-activated GPR4 is proved to lower significantly 
intracellular level of cAMP. pH modification is involved in inflammatory 
processes. The light-activated GPR4 would allow investigating further the role of 
this specific proton-sensing GPCR in tissue where different other proton- sensing 
GPCRs are simultaneously expressed. It is interesting to notice that this receptor, 
being involved in pH sensing and (directly to indirectly) to inflammatory states 
shown ability to modify intracellular level of cAMP in my screening assay, raising 
considerations similar to the ones related to GPR3. GPR18 is supposed to be 
able increase intracellular level of cAMP upon activation with lipoamino acids and 
cannabinoids. The hypothesis that GPR18 upon stimulation with different ligands 
might be able to modify cAMP intracellular levels fit with the available data 
about its possible physiological 
roles. GPR18 is considered involved in cell migration280, macrophage apoptosis 
281 and it has been proposed a role in controlling the reconstitution of the mouse 
small intestine intraepithelial lymphocytes 282. 
I found activation of the SRE reporter by the Opto-GPR18, while no signal was 
detected in experiments with the CRE luciferase-based reporter plasmid. Indeed, 
activation of the ERK1/2 pathway by GPR18 has been reported in the control of 
hypotension in rats. Also, the MAPK/ERK1/2 pathway is involved in cell 
proliferation and cell death, and as previously described GPR18 might be linked 














Gene Tissue Localization KO (ES or mice) Phenotype Possible agonists Second messengers 
GPR1 Ubiquitous YES YES Chemerin RhoA, ROCK
265
 
GPR3 Ubiquitous YES Not confirmed S1-P cAMP
266
 
GPR4 Ubiquitous YES Not confirmed Protons cAMP, RhoA, PKC
267,  268,269
 
GPR18 Ubiquitous YES Not confirmed Lipoamino acids cAMP270, 271 
GPR21 Ubiquitous YES Not confirmed No information available PKC272 
GPR32 Arterial/venous tissue No  No information available No information available 
GPR33 Thyroid, lung, spleen, thymus YES YES No information available cAMP
273
 
GPR42 No signal in human tissue No  Propionate cAMP
274
 
GPR55 Brain and digestive system YES YES Cannabinoid ligands PKC and MAPK/ERK1
275
 
GPR61 CNS and testes YES Not confirmed No information available cAMP
155
 
GPR63 Ubiquitous YES No Sphingosine 1-phosphate No Information available 
GPR68 Ubiquitous YES YES Sphingosylphosphorylcholin, 
Benzodiazepine, Protons 
cAMP, PKC 276,277, 278 
GPR78 Brain and placenta NO  Constitute activity cAMP
279
 
GPR88 Central Nervous System and 
trachea 
YES YES No information available No information available 
GPR135 Ubiquitous, but especially CNS No  No Information available No information available 
GPR150 Mainly CNS YES Not confirmed No Information available No information available 
 
Table 5.3 List of human class A oGPCRs that show significant activation of one or more luciferase-based reporter plasmid including information about tissue expression, presence of 
a murine knockout with significant phenotype, list of possible candidate agonists and G-protein mediated pathway for which coupling was demonstrated using different assays. 
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I found a significant number of light-activated human Class A oGPCRs able to 
activate directly or inversely the CRE reporter plasmid, implying their ability to 
modify intracellular cAMP levels, fundamental in regulating actin based cell 
migration, chemotaxis and in general important for the control of inflammatory 
processes. 
GPR32 and GPR33 belong to this group of light-activated oGPCRs that activate 
the CRE reporter plasmid. 
GPR32 has been proposed to be sensitive to resolvins, a family of lipid mediators 
involved in temper the inflammatory response. More specifically, GPR32 seems 
to be involved in inflammatory processes localized in the lungs, such as 
inflammatory signaling in human airway epithelial cells and in the TGF- β1 
induced epithelial mesenchymal transition of lung cancer cells. 
GPR33, although still classified as an oGPCRs, is considered by sequence 
homology as a chemoattractant receptor; its inactivation in humans, different 
great apes and rodent species as well as the presence of an intact allele in 
geographically restricted human populations suggest that this gene was 
undergoing positive selection in the last million years273. 
Our data proves signaling functions for the intact light-activated GPR33 both in 
cAMP and internalization related G-Protein mediated pathways, strengthening 
the hypothesis of an active role of GPR33 in leucocyte chemotaxis and pathogen 
entry, like similar chemoattractant receptors, although further internalization 
studies might be needed in order to verify this hypothesis. 
GPR42 can be considered the oGPCRs included in my screening with the most 
limited amount of information available. Expression data for this oGPCR are not 
available as well as KO models. It has been suggested its ability to increase 
levels of intracellular cAMP after stimulation with Propionate, ability recorded also 
in my data for the Opto-GPR42283. 
Unlike GPR42, GPR55 is an oGPCR for which the available information justifies 
its involvement in several different physiological roles. It has been shown for 
GPR55 the ability to activate PKC and MAPK mediated pathways. These 
pathways are involved in cell proliferation:  indeed, for GPR55 it has been 
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proposed a role in neuronal growth as well as in angiogenesis. In my screening 
Opto-GPR55 reversely activates the CRE luciferase-based reporter plasmid, the 
ability of GPR55 to modify intracellular level of cAMP might strengthen the 
hypothesis that this oGPCRs is involved in the inflammatory response and 
migration-related molecular processes. In fact, it has been shown that GPR55 is 
involved in intestinal inflammation, in lipid accumulation and consequent rise of 
inflammatory states and in the process of cancer angiogenesis in ovarian 
carcinoma. Actually, the role of GPR55 is not limited to the angiogenic process, 
but it has been shown that GPR55 promotes cancel cell proliferation, metastasis 
formation in colon cancer and in general GPR55 is considered a novel 
tumorigenic target284. All previous considerations suggest that GPR55 might be 
able to activate different G-protein mediated pathways and play a 
relevant role in different physiological processes. 
GPR61 is known to be constitutive active and to have the ability to increase 
intracellular levels of cAMP. Opto-GPR61 significantly activate the CRE 
luciferase-reporter plasmid, confirming the coupling properties of this oGPCR. 
From a functional point of view, little is known about GPR61; the current 
hypothesis suggests a role of GPR61 in metabolism and in the regulation of 
aldosterone secretion. 
Although for GPR63 candidate agonists were identified263, limited amount of 
information is available on its involvement in any relevant physiological 
processes. Opto-GPR63 was able to significantly reduce the amount of 
intracellular cAMP, suggesting that this oGPCR might possible be involved in 
inflammatory processes or, in general, in biological processes involving cell 
migration. 
For GPR68 new information about possible agonist was recently retrieved using 
approaches based on homology models, leading to the identification of 
benzodiazepine as novel not-selective agonist. GPR68 is considered to be a 
proton-sensing GPCR (like the previously described GPR4) involved in different 
physiological processes related to acidosis, such as inflammation and the 
regulatory processes of the acidic tumor microenvironment.        Dendritic cells 
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expressing GPR68 show inhibited migration properties in acidic environments. 
GPR68 controls the activity of proton transport proteins in epithelial cells and 
plays a specific role in asthma, regulating the contraction of airways in respect to 
change in pH285. For GPR68 example of cAMP and PKC mediated pathway 
activation are present in literature. In my screening the Opto-GPR68    activated 
the SRE luciferase-based reporter plasmid, while no significant activation was 
measured for the CRE luciferase-based reporter. The data of my screening 
compared with previously known data about GPR68 suggest that the ability of 
GPR68 to activate different G-protein mediated pathway might be related not 
only on the ligand and tissue dependency, but also on the difference between 
homeostatic and inflammatory conditions. 
GPR78 presents a unique feature among the oGPCRs for which I recorded a 
significant light-dependent activation in my screening. In fact, it is the only gene 
expressed in humans, but not in mice. GPR78 has been suggested to be 
constitutive active in HEK293 cells, increasing the amount of intracellular cAMP 
levels. In my screening actually two different reporter plasmid were significantly 
activated by the Opto-GPR78, the SRE and the SRE.L luciferase-based reporter 
plasmid, while no significant activation was measured for the luciferase-based 
CRE reporter plasmid. This suggest that possibly the increase of cAMP level 
related to constitutive activity of GPR78 might not be related to this receptor 
function. 
Most of the oGPCRs positive in my screening were found to have either 
inflammation-cAMP related signaling functions or cell growth-apoptosis related 
functions. Actually, oGPCRs were believed to be involved in high-order brain 
functions both taking in account the difficulties in finding both proper candidate 
agonists and, as shown in table 4.2, clear phenotypes in mouse KO studies. In 
the case of GPR88, the hypothesis of its implication in high-order brain function, 
more specifically disease models, is still valid. Mice lacking GPR88 exhibit a 
lower basal level of dopamine, which is a fundamental regulator of brain 
activity137,138. GPR88 is supposed to be involved in disorders of the CNS such as 
the bipolar disorder (BD) and schizophrenia139. Relation between GPR88 
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and these mental illnesses were found in different human populations where the 
relation was analyzed in triads formed by parents and child. In my screening, 
opto-GPR88 activates the SRE luciferase-based reporter plasmid, indicating the 
ability of GPR88 to activate either PKC or MAPK mediated pathways. However, 
how the activation of these specific pathways might lead to the development of 
sever physiological disease is difficult to estimate. 
GPR135 and GPR150 can be considered a similar case to GPR42. Also for this 
oGPCR very little is known apart from its expression pattern in human. No 
possible candidate agonist is available, as well as hypothesis about their 
physiological role. Opto-GPR135 activates the CRE reporter plasmid, implying 
the ability of GPR135 to increase intracellular level of cAMP. The Opto-GPR150 
decreased the CRE luciferase-based signal of NECA pre-stimulated cells, 
implying the ability of GPR150 to decrease intracellular level of cAMP. The 
absence of KO models as well as putative agonists makes the light-activated 
version of these oGPCRs a promising approach to dissect their physiological 
roles in the native tissues. 
What implications does this research result have? For the light-activated human 
Class A oGPCRs for which I did not detect functional coupling a conserved 
functionality cannot be excluded. Being the G-Protein coupling dependent on the 
intracellular concentration of G-Protein related proteins, those light-activated 
human oGPCRs for which no significant coupling was detected in HEK293 cells 
could still activate canonical and non-canonical pathways in other cell types and 
tissues. 
This data inspire further experiments in which light-activated Class A human 
oGPCRs can be tested in native tissue/organs, allowing to dissect their 
physiological roles. In fact, the light-activated oGPCRs may for the first time allow 
to test in vitro and in vivo the functional properties of this class of GPCRs using 
all advantages the Optogenetic approaches. 
The data I collected allow to prioritize the study of oGPCRs in specific disease 
models by knowing their signaling properties before elucidating their activation 
mechanism and identifying proper agonists. 
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More generally, the approach described in this work permits to further elucidate 
the role of G-Protein dependent specific signaling pathways and second 
messenger. The creation of light-activated versions of known GPCRs will allow 
establishing a technique in which these pathways can be turned ON and OFF. 
This might allow in further studies to relate specific phenotypes to signaling 
pathways. 
Finally, the rhodopsin-based library of chimeric GPCRs I designed may allow 
investigating structure properties of GPCRs for which current structure 
knowledge is limited; in fact, the techniques and the results achieved in 
crystallization of rhodopsin in its active and inactive form, as well as a coupled 
taste with the G-Protein can be as well used to obtain structural information about 
orphan GPCRs and verified their coupling properties by crystallization studies. 
In summary, the chimeric algorithm as well as the luciferase-based platform 
represent a new approach for elucidating functional properties for oGPCRs for 
which little is knew besides sequences and expression pattern. 
The alternative approach based on the study of gene sequences using 
bioinformatics tools such as G-Protein prediction algorithms based on different 
mathematical and statistical tools in order to predict G-Protein coupling is far from 
being able to substitute functional testing. In fact, the algorithms tested in this 
work, when they do not fail in distinguish full-length GPCRs from their respective 
light-activated chimeric receptors, give not coherent results, showing a prediction 
pattern dependent on the mathematical or statistical approaches used to 
calculate the prediction. Also, these algorithms do not take in account differences 
in the topological localization of specific sequences when predicting G-Protein 
coupling, and approximate properties with a degree of detail not sufficient for 
elaborate proper predictions. 
The main aim of this work was to answer three questions: 
 
 
- Are orphan GPCRs functional at all? 
 
- If yes, which signaling pathways do they activate? 
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- It is possible to retrieve a possible ligand for the receptors still 
consider as orphan? 
 
 
My results show that some Class A oGPCRs are functional and able to activate 
G-Protein mediated pathways in light-activated chimeras. The stability and 
reliability of both the chimeric algorithm and the assay strongly suggest that the 
signaling properties recorded for the light-activated human Class A oGPCRs 
reflect the signaling properties of their respective full-length genes. My results 
suggest that further investigation is needed for those light-activated human Class 
A oGPCRs for which no significant G-Protein coupling was recorded, with 
necessary testing in native tissues. The chimeric approach and my library of light-
activated Class A human oGPCRs allow to overcome the necessity for 
information about activation properties and agonist for oGPCRs by creating a 
class of signaling-equivalent synthetic receptor that can be used in vitro and in 
vivo to elucidate signaling properties and physiological roles of this fundamental 
class of receptors. 
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Figure 6.1 Vector map of pcDNA3.1(-) constructed from its original sequence, including endogenous TypeIIs 





Figure 6.2 Vector map of pcDNA3.1(-) used for the cloning of the light-activated control GPCRs and light- 
















































































































































































































































































































































































































































































































































































































































































Table 6.1 Amino acid sequences of all light-activated human Class A oGPCRs created using the chimeric 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.2 Nucleotide sequences of all light-activated human Class A oGPCRs created using the chimeric 





























































































































Table 6.3 Amino acid sequences of all light-activated control GPCRs created using the chimeric algorithm 
























































































































































































































































































































Table 6.4 Nucleotide sequences of all light-activated control GPCRs created using the chimeric algorithm 
described in section 3.1 
 
 
 CRE SRE SRE.L CRE+stim. 
Gene name Dark Light Dark Light Dark Light Dark Light 
Opto-GPR1 1.52 ± 0.42 8.94 ± 3 52 0 52 ± 0.17 0.61 ± 0 22 0.74 ± 0.25 0 57 ± 0.20 1.39 ± 0.12 1.45 ± 0.26 
Opto-GPR3 0.45 ± 0.16 0.33 ± 0 07 0 68 ± 0.23 3.63 ± 2 95 0 63 ± 0.19 0.44 ± 0.17 1.03 ± 0.13 0 92 ± 0.18 
Opto-GPR4 0.47 ± 0.18 0 294 ± 0.07 1 61 ± 1.00 1.84 ± 1 36 0 67 ± 0.25 0 50 ± 0.38 0.60 ± 0.12 0 36 ± 0.11 
Opto-GPR6 0.49 ± 0.26 0.25 ± 0 08 1 26 ± 0.84 1.09 ± 0.46 0 69 ± 0.21 0 51 ± 0.20 1.02 ± 0 08 0.83 ± 0 2 
Opto-GPR12 0.19 ± 0.08 0.2 ± 0.06 1.17 ± 0.58 0.76 ± 0 30 0.8 ± 0.28 0 58 ± 0.27 1.14 ± 0.19 0 95 ± 0.15 
Opto-GPR15 0.26 ± 0.14 0.21 ± 0 07 0 54 ± 0.29 0.65 ± 0 31 0.77 ± 0.25 0.73 ± 0.32 1.02 ± 0.13 0.77 ± 0.13 
Opto-GPR17 0.32 ± 0.10 0.27 ± 0 08 0.49 ± 0.25 0.6 ± 0.24 0 87 ± 0.34 0 54 ± 0.17 1 ± 0.08 0 83 ± 0.15 
Opto-GPR18 0.19 ± 0.06 0.22 ± 0 06 0 32 ± 0.07 0.8 ± 0.49 0 87 ± 0.28 0 56 ± 0.21 1 ± 0.12 1.14 ± 0.33 
Opto-GPR19 0.21 ± 0.08 0.24 ± 0 09 0.46 ± 0.23 0.55 ± 0 25 0.73 ± 0.22 0 63 ± 0.28 1.03 ± 0.14 0.9 ± 0.21 
Opto-GPR20 0.23 ± 0.03 0.49 ± 0 20 0.49 ± 0.20 0.86 ± 0 29 0 59 ± 0.15 0 64 ± 0.24 0.88 ± 0.10 0.74 ± 0.19 
Opto-GPR21 0.36 ± 0.07 10.36 ± 5.73 1 66 ± 1.36 0.57 ± 0 22 0 62 ± 0.19 0 64 ± 0.22 0.86 ± 0 08 0 99 ± 0.31 
Opto-GPR22 0.27 ± 0.09 0.41 ± 0.12 1.41 ± 0.74 1.27 ± 0 59 0 69 ± 0.18 0 86 ± 0.31 1.05 ± 0 29 2.45 ± 1.34 
Opto-GPR25 0.29 ± 0.08 0.4 ± 0.08 0 97 ± 0.61 1.44 ± 1 03 0 64 ± 0.22 0.45 ± 0.15 1.29 ± 0.17 0 98 ± 0.19 
Opto-GPR26 0.36 ± 0.10 0.41 ± 0 09 1.2 ± 0.84 0.54 ± 0.14 0 53 ± 0.17 0.44 ± 0.15 1.15 ± 0.11 0 86 ± 0.15 
Opto-GPR27 0.32 ± 0.10 0.23 ± 0 04 0 56 ± 0.20 0.59 ± 0 21 0 58 ± 0.17 0.41 ± 0.15 1.01 ± 0 06 0 89 ± 0.14 
Opto-GPR31 0.27 ± 0.11 0.57 ± 0 27 0 56 ± 0.19 0.79 ± 0 38 0 57 ± 0.21 0 51 ± 0.17 1.02 ± 0.10 0.8 ± 0.15 
Opto-GPR32 0.21 ± 0.07 4.89 ± 2 32 0 81 ± 0.38 0.67 ± 0 36 0 54 ± 0.16 0.44 ± 0.13 1.04 ± 0 09 0 66 ± 0.15 
Opto-GPR33 0.31 ± 0.14 0.46 ± 0.10 0.3 ± 0.07 2.45 ± 1 33 0 62 ± 0.16 
30.56 ± 10.2 
3 
0.97 ± 0 09 0 65 ± 0.13 
Opto-GPR34 0 3 ± 0.11 0.3 ± 0.09 0.49 ± 0.16 0.5 ± 0.14 0 61 ± 0.27 0 65 ± 0.16 0.95 ± 0 09 0 81 ± 0.09 
Opto-GPR35 0.32 ± 0.11 0.22 ± 0 04 0 33 ± 0.08 0.47 ± 0.16 0 63 ± 0.16 0 64 ± 0.21 1.03 ± 0.10 0.74 ± 0.12 
Opto-GPR37 0 3 ± 0 08 0.25 ± 0 07 0.5 ± 0.11 0.41 ± 0.13 0 53 ± 0.12 0.47 ± 0.16 0.91 ± 0 08 0 91 ± 0.15 
Opto-GPR37L1 0.25 ± 0.08 0.31 ± 0 09 0 33 ± 0.11 0.33 ± 0 08 0.49 ± 0.13 0.5 ± 0.19 0.89 ± 0.11 1 06 ± 0.20 
152  
Opto-GPR39 0.39 ± 0.19 0.51 ± 0 21 0 67 ± 0.21 0.35 ± 0.10 0 52 ± 0.15 0 63 ± 0.19 0.87 ± 0 05 0.92 ± 0.21 
Opto-GPR42 0 3 ± 0.14 1.05 ± 0 68 0 59 ± 0.21 0.49 ± 0.18 0 61 ± 0.15 0.6 ± 0.20 0.88 ± 0 05 1.22 ± 0.46 
Opto-GPR45 0.43 ± 0.16 0.56 ± 0.12 1 38 ± 0.60 0.71 ± 0 24 0 53 ± 0.13 0.48 ± 0.15 1.16 ± 0.18 0.85 ± 0.07 
Opto-GPR50 0.4 ± 0.16 0.43 ± 0 06 0 81 ± 0.20 0.86 ± 0 28 0 51 ± 0.15 0 34 ± 0.12 1.07 ± 0.19 1.07 ± 0.13 
Opto-GPR52 0.26 ± 0.09 0.3 ± 0.07 0 93 ± 0.49 0.65 ± 0 24 0 54 ± 0.15 0.45 ± 0.17 0.99 ± 0 07 0.88 ± 0.11 
Opto-GPR55 0.32 ± 0.12 0.46 ± 0 09 0.74 ± 0 2 0.66 ± 0 20 0.5 ± 0.15 0.4 ± 0.10 1.12 ± 0.10 0.75 ± 0.15 
Opto-GPR61 0.62 ± 0.17 6.11 ± 3.10 0.58 ± 0 2 0.66 ± 0 29 0 51 ± 0.15 0 62 ± 0.18 1.07 ± 0.12 0.82 ± 0.12 
Opto-GPR62 0.32 ± 0.09 0.51 ± 0.14 0 57 ± 0.22 0.77 ± 0 22 0 55 ± 0.16 0.6 ± 0.11 0.89 ± 0 04 0.83 ± 0.15 
Opto-GPR63 0.37 ± 0.11 0.51 ± 0.13 0.42 ± 0.12 0.44 ± 0.16 0 53 ± 0.18 0.78 ± 0.16 1.16 ± 0 28 0.74 ± 0.15 
Opto-GPR65 0.39 ± 0.15 0.53 ± 0 21 0 59 ± 0.19 0.67 ± 0 26 0 54 ± 0.14 0 58 ± 0.16 1.02 ± 0 05 0 8 ± 0 08 
Opto-GPR68 0.81 ± 0.45 0.78 ± 0 31 0 97 ± 0.27 2.61 ± 0.76 0 52 ± 0.15 0 58 ± 0.17 0.84 ± 0 05 1.02 ± 0.09 
Opto-GPR75 0.33 ± 0.14 0.30 ± 0 08 0 99 ± 0.45 1.28 ± 0 93 0 61 ± 0.18 0 62 ± 0.15 0.89 ± 0 09 0.86 ± 0.13 
Opto-GPR78 0.29 ± 0.05 0.65 ± 0 24 1 ± 0.34 5.05 ± 2 87 0 54 ± 0.12 35.1 ± 11.47 0.96 ± 0.13 1.38 ± 0.32 
Opto-GPR82 0.28 ± 0.07 0.50 ± 0.14 0 59 ± 0.19 0.54 ± 0 21 0 68 ± 0.17 0.71 ± 0.15 0.93 ± 0.14 1.31 ± 0.43 
Opto-GPR83 0.81 ± 0.18 0.67 ± 0.14 0 95 ± 0.19 0.86 ± 0 25 0 56 ± 0.22 0 51 ± 0.16 1.23 ± 0 26 1.09 ± 0.17 
Opto-GPR84 0.47 ± 0.09 1.02 ± 0 27 0.75 ± 0.23 0.67 ± 0.19 0.49 ± 0.16 0.45 ± 0.13 1.03 ± 0.14 1.04 ± 0.12 
Opto-GPR85 0.55 ± 0.15 1.10 ± 0 38 0 54 ± 0.16 0.43 ± 0.10 0 39 ± 0.10 0.49 ± 0.15 0.97 ± 0.13 0.72 ± 0.15 
Opto-GPR87 0.44 ± 0.09 0.53 ± 0 09 0 59 ± 0.18 0.66 ± 0.18 0.44 ± 0.12 0.45 ± 0.13 1.06 ± 0 05 1 ± 0.24 
Opto-GPR88 0.52 ± 0.08 0.44 ± 0 04 0 55 ± 0.17 1.88 ± 0 92 0.48 ± 0.15 0 55 ± 0.19 1.04 ± 0 06 1.02 ± 0.12 
Opto-GPR119 1.27 ± 0.45 0.87 ± 0 23 0 64 ± 0.17 0.67 ± 0.14 0.47 ± 0.09 0 52 ± 0.10 1.06 ± 0.14 0 9 ± 0.10 
Opto-GPR120 0.69 ± 0.18 0,48 ± 0,20 1,78 ± 0,79 1,59 ± 1,02 1,22 ± 0,54 0,80 ± 0,64 0,65 ± 0,24 0,77 ± 0,19 
Opto-GPR132 1.33 ± 0.43 0.66 ± 0 20 0 57 ± 0.18 0.55 ± 0.15 0.5 ± 0.11 0 69 ± 0.17 0.96 ± 0 09 0.89 ± 0.07 
Opto-GPR135 0.57 ± 0.12 6.78 ± 3 09 0 64 ± 0.09 1.11 ± 0.45 0 58 ± 0.14 0 55 ± 0.14 1.07 ± 0.10 1.09 ± 0.23 
Opto-GPR139 0.42 ± 0.09 0.43 ± 0.11 0.41 ± 0.08 0.53 ± 0.11 0.46 ± 0.11 0 55 ± 0.12 0.8 ± 0.03 1.18 ± 0.41 
Opto-GPR141 0.55 ± 0.13 0.37 ± 0 08 0 58 ± 0.15 0.45 ± 0.12 0 63 ± 0.16 0 68 ± 0.20 0.93 ± 0 08 1.28 ± 0.41 
Opto-GPR142 0.33 ± 0.12 0.3 ± 0.05 0 67 ± 0.29 0.46 ± 0.14 0.7 ± 0.17 0 91 ± 0.19 0.76 ± 0 04 0.95 ± 0.23 
Opto-GPR146 0.65 ± 0.15 1.06 ± 0.43 0 96 ± 0.21 1.62 ± 0 89 0.6 ± 0.17 0 58 ± 0.12 1.5 ± 0.45 1.09 ± 0.24 
Opto-GPR148 0.55 ± 0.13 0.78 ± 0 39 1 05 ± 0.29 0.68 ± 0 25 0.81 ± 0.4 0 58 ± 0.16 1.09 ± 0 07 0.95 ± 0.13 
Opto-GPR149 0.46 ± 0.10 1.01 ± 0 39 0.88 ± 0 3 0.69 ± 0.17 0 66 ± 0.28 0 54 ± 0.18 1.21 ± 0.15 0.91 ± 0.19 
Opto-GPR150 0.74 ± 0.26 1.05 ± 0 32 1.43 ± 0.31 1.26 ± 0 33 0.48 ± 0.12 0.7 ± 0.23 1.15 ± 0.10 0.73 ± 0.14 
Opto-GPR151 0.52 ± 0.09 0.75 ± 0.18 0 65 ± 0.17 1.17 ± 0 25 0 87 ± 0.49 0.49 ± 0.12 0.83 ± 0 06 0 9 ± 0 09 
Opto-GPR152 0.42 ± 0.08 0.48 ± 0.10 0 56 ± 0.17 0.74 ± 0 26 0 52 ± 0.10 0 68 ± 0.16 0.87 ± 0.13 0.88 ± 0.17 
Opto-GPR153 0.67 ± 0.15 0.67 ± 0 09 0 66 ± 0.21 0.69 ± 0.18 0 54 ± 0.12 0.75 ± 0.19 0.93 ± 0.10 1.1 ± 0.16 
Opto-GPR160 0.44 ± 0.04 0.58 ± 0.15 0 67 ± 0.26 0.86 ± 0 51 0 87 ± 0.13 0 83 ± 0.13 1.13 ± 0.12 1.02 ± 0.15 
Opto-GPR161 0.57 ± 0.08 0.67 ± 0.13 0 66 ± 0.21 0.65 ± 0 21 0.7 ± 0.18 0.74 ± 0.20 0.88 ± 0.11 1.04 ± 0.25 
Opto-GPR162 0 39 ± 0.1 0.57 ± 0 08 0 61 ± 0.13 0.88 ± 0 34 0.73 ± 0.14 0 95 ± 0.24 0.98 ± 0 06 1.68 ± 0.79 
Opto-GPR171 0.54 ± 0.09 0.54 ± 0.11 0.70 ± 0.10 0.73 ± 0 21 0 63 ± 0.12 0.74 ± 0.13 1.08 ± 0 06 2.19 ± 1.20 
Opto-GPR173 0.37 ± 0.09 0.38 ± 0 09 0 59 ± 0.14 0.57 ± 0.13 1 98 ± 1.18 0.8 ± 0.11 1.1 ± 0.06 1.46 ± 0.27 
Opto-GPR174 1.01 ± 0.23 0.87 ± 0.19 1 28 ± 0.69 0.68 ± 0.16 0 55 ± 0.17 0.74 ± 0.09 1.14 ± 0 26 1.02 ± 0.23 
Opto-GPR176 0.53 ± 0.12 0.64 ± 0.12 0.96 ± 0 2 0.72 ± 0.13 0 67 ± 0.22 0 65 ± 0.14 0.91 ± 0 06 1.02 ± 0.12 
153  
Opto-GPR182 0.71 ± 0.18 0.75 ± 0 32 0.7 ± 0.11 1.72 ± 0 96 0 52 ± 0.15 0 56 ± 0.11 0.98 ± 0 07 1.13 ± 0.12 
Opto-GPR183 0.43 ± 0.09 0.65 ± 0 07 0 88 ± 0.16 2.02 ± 1 01 0.76 ± 0.23 0 68 ± 0.18 0.96 ± 0 08 0 91 ± 0.11 
 
Table 6.2 Mean induction values for each light-activated human Class A oGPCRs for the different 
luciferase-based gene reporters used for the functional screening (section 4.2, 4.3) 
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